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ABSTRACT 
Many pathogens evade complement recognition by binding to complement regulatory 
proteins, such as factor H (FH), that protect host cells from complement attack. 
Asexual Plasmodium falciparum stages evade complement destruction by capturing 
FH on their surface. An initial study identified Pf92 as the only protein that interacts 
with FH; however, the Pf92 knockout transgenic parasites did not wholly abolish FH 
recruitment to the merozoite. Thus, I hypothesized that potentially, more merozoite 
proteins are involved in complement evasion. 
 
I used a combination of modified ELISA binding assay and surface plasmon resonance 
and tested a library of 110 recombinant merozoite proteins for interaction with FH. 
Protein microarray was used to measure antibody responses to the merozoite antigens 
that interacted with FH in a malaria longitudinal cohort of children. Additionally, I tested 
whether circulating levels of FH and the Y402H variant in the FH gene influence 
malaria severity. 
 
In addition to Pf92, I found seven additional merozoite proteins that interact with the 
FH, i.e. PF3D7_1105800, PF3D7_0206200, RH5, P12, PF3D7_1252300, 
PF3D7_0629500 (SEG) and P12p. Majority of the proteins bound to complement 
control protein modules (CCP) 5-7 of FH. Antibody responses against a combination 
of some of these merozoite FH receptor antigens were found to be associated with 
protective immunity. Children with severe malaria (SM) had markedly lower circulating 
FH levels compared to uncomplicated malaria (UM) controls (median: SM=269 ug/ml, 
UM=378 ug/ml, P=<0.0001). Besides, children homozygous for the Y402H variant had 
a slightly increased risk of severe malaria (OR 1.08 95% CI: 0.46-2.58 P=0.854) while 
those who were heterozygous had reduced risk (OR 0.62 95% CI: 0.30-1.28 P=0.195) 
when compared with normal individuals. 
 ii 
These findings suggest that the Plasmodium falciparum parasite uses many proteins 
to interact with FH to avoid complement destruction and that FH protein, could be a 
vital host determinant for malaria severity. This study offers insights into the 
mechanisms of malaria parasite complement immune evasion and provides a rationale 
for future studies to evaluate stage-specific parasite proteins for interaction with 
complement regulatory proteins. 
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THESIS OUTLINE 
I start in chapter one by giving a broad introduction to malaria, its epidemiology and 
control strategies. I then briefly discuss malaria vaccine development and innate 
immunity to malaria. Thereafter, I introduce the complement system, mechanisms that 
pathogen use to evade complement activation and the role of complement in immunity 
to malaria. I close the discussion on complement by focusing how it contributes to the 
development of severe malaria. 
 
In chapter two I comprehensively describe the malaria longitudinal cohort of children 
and the hospital case control study whose samples I used. I then provide detailed 
explanations for the experimental procedures that I conducted. 
 
In chapter three I test the hypothesis that many merozoite proteins interact with 
complement regulatory protein FH in order to facilitate immune evasion. I began by 
expressing a library of recombinant merozoite antigens. I then used a combination of 
ELISA binding assay and surface plasmon resonance to narrow down the merozoite 
antigens that bind to FH. I observed that, contrary to what is known that only one 
merozoite antigen binds to FH, many more proteins are involved.  
 
In chapter four I explore whether antibody responses to merozoite proteins that bind 
FH (merozoite FH receptor proteins) are associated with protection. In the longitudinal 
cohort I observe that children, who make antibody responses to a combination of these 
proteins, have some protective immunity.  
 
In chapter five I determine, whether variation in FH levels within individuals influence 
malaria susceptibility and severity. In the longitudinal cohort there was a five-fold range 
in FH levels. This variation did not statistically influence the prospective risk of 
 xvii 
developing malaria. Using the case-control study, there was a marked difference in FH 
levels in children with severe malaria compared to the uncomplicated malaria controls. 
Children, who had the CC AMD risk allele of the Y402H variant of FH had a slightly, 
but not significantly, increased risk of having severe malaria than those who are 
normal, TT.  In addition, children, who were CC homozygotes had reduced FH levels 
compared to the TT homozygote children.  
 
Chapter six summarizes key finding and offers recommendation for future studies  
 
 
 1 
CHAPTER ONE 
1 Introduction 
1.1 Summary and aims 
This introductory chapter provides background information to the thesis project. It is 
split into two parts. In the first section, I discuss the public health significance of 
malaria, control strategies, innate immunity to malaria, and parasite immune evasion 
mechanisms. In the second section, I review the complement system and its role in 
disease pathogenesis with a focus on infectious diseases.   
 
1.2 Malaria is a global health problem 
The global burden of malaria is massive. In 2017 alone, an estimated 219 million cases 
occurred globally. Approximately 92% of these cases occurred in Africa, followed by 
Southeast Asia with 5% and Eastern Mediterranean with 2%. There were 435,000 
deaths reported, 61% occurred in children under the age of five years. Sub-Saharan 
Africa accounted for 93% of all malaria deaths (WHO 2018b). Of note, between 2010 
and 2017, malaria incidence declined by 18% from 72 to 59 cases per 1000 population 
at risk. However, the number of cases per 1000 population has remained at 59 for the 
last three years indicating that much more remains to be done, if the goal of moving 
towards malaria elimination is to be achieved. Furthermore, with many countries still 
having ongoing malaria transmission Figure 1.1 (WHO 2018b), new tools are urgently 
needed to contribute to malaria prevention and control. 
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Figure 1.1: A global map of countries with ongoing malaria transmission.  
Countries with indigenous malaria cases in 2000 and their status as of 2017. Countries with zero 
indigenous cases over at least the past three consecutive years are considered to be malaria free. 
Figure from (WHO 2018b). 
 
1.3 Five species of Plasmodium infect humans 
Malaria in humans is caused by five species of Plasmodium: P. falciparum, P. vivax, P. 
malariae, P. ovale and P. knowlesi. The current distribution of Plasmodium species 
shows the preponderance of P. falciparum in tropical parts of Africa, while P. vivax is 
common in tropical areas outside Africa. Most Africans lack the Duffy blood group 
antigen that is expressed on the surface of erythrocytes (Howes et al. 2011), and is 
considered as an essential receptor for P. vivax invasion (Miller et al. 1976). However, 
this long held-notion is being challenged by more recent evidence that suggests that 
P. vivax can infect, and cause disease in some Duffy-negative individuals (Menard et 
al. 2010; Mendes et al. 2011). This suggests that the parasite can invade erythrocytes 
using other receptors. However, it remains to be determined, whether these are true 
P. vivax or variants. Both P. falciparum and P. vivax are prevalent in Southeast Asia 
and the Western Pacific. Infections with P. vivax were rarely thought to lead to death 
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in contrast to those with  P. falciparum (Baird 2007). On the contrary, it has now been 
demonstrated that infections with P. vivax could be associated with severe and fatal 
illness (Kochar et al. 2005; Genton et al. 2008; Tjitra et al. 2008). Although P. 
malariae can occur in all malaria areas, its prevalence as a mono-infection or co-
infection with other plasmodia is generally low. In tropical Africa, P. falciparum and P. 
malariae co-infections are sometimes encountered. Unlike P. malariae, P. ovale is 
more widespread primarily in tropical Africa whereas human  P. knowlesi infections 
have been reported in Southeast Asia (Cox-Singh et al. 2008; Autino et al. 2012).  
 
1.4 Plasmodium spp. have a complex life cycle 
The life cycle of Plasmodium parasites is complex. It requires an anopheline mosquito 
vector and a vertebrate host Figure 1.2 (White et al. 2014). In the human host, infection 
begins with the bite of an infected Anopheles mosquito that inoculates the individual 
with sporozoites (Greenwood et al. 2008). It is estimated that one mosquito can inject 
up to 10-100 sporozoites per bite (Vanderberg and Frevert 2004; Gueirard et al. 2010). 
The sporozoites migrate to the capillaries, then travel via the bloodstream to drain into 
the liver, where they invade hepatocytes and initiate the pre-erythrocytic cycle (Jones 
and Good 2006). The pre-erythrocytic phase of infection is clinically silent, and lasts 
approximately 5-14 days depending on the Plasmodium spp. involved (Antinori et al. 
2012). Upon invasion of hepatocytes, sporozoites transform inside a parasite-induced 
cellular compartment (also called the parasitophorous vacuole), where they undergo 
replication, also called schizogony, at the end of which thousands of daughter cells are 
formed. These cells differentiate into invasive blood stage parasites called merozoites 
that are released in ‘batches’ into the bloodstream within membranous remnants of 
their host cells (merosomes). The transformation from sporozoites to merozoites is 
driven by the expression of a discrete set of genes (Sturm et al. 2006; Bijker et al. 
2015).  
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In the bloodstream, the merozoites quickly invade red blood cells (RBCs) to initiate the 
pathogenic erythrocytic stage of the parasite life cycle, also called asexual cycle. To 
achieve this, the merozoite makes initial contact with the red blood cell and reorients 
to bring its apical tip close to the cell surface. Parasite proteins in the apical prominence 
bind to red blood cell proteins, triggering commitment to entry (Gilson and Crabb 
2009). Subsequently, a tight junction forms between parasite and red blood cell 
membranes, propelling the parasite into the cell (Dvorak et al., 1975). Within the RBCs, 
the merozoites mature to form rings, then trophozoites and eventually schizonts that 
burst to release a new generation of merozoites thereby starting the process of 
invading new RBCs. Asexual P. falciparum blood stage parasites produce 8-20 new 
merozoites every 48 hrs (72 hrs for P. malariae), causing parasite numbers to rapidly 
rise to levels as high as 1013 per host (Greenwood et al. 2008). 
 
A variety of parasite products are released upon lysis of infected red blood cells 
(iRBCs) that correlate with the onset of malaria symptoms including headaches, fever, 
and lethargy (Crompton et al. 2014). The asexual life cycle is accompanied by 
gametocytogenesis, whereby a fraction of merozoites differentiate into male and 
female gametocytes that are taken up during a mosquito’s blood meal. In the mosquito 
midgut, male and female gametes fuse to form ookinetes that cross the midgut 
epithelium, where they develop into oocysts, which ultimately differentiate into 
sporozoites that invade the mosquito’s salivary glands (Crompton et al. 2014). 
Depending on the external temperatures, the mosquito becomes infectious to its next 
susceptible host approximately two weeks after ingesting gametes. Of note is that P. 
vivax can develop within the mosquito at lower temperatures than P. falciparum, 
explaining the preponderance of P. vivax infections outside tropical and subtropical 
regions (Greenwood et al. 2008). 
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Figure 1.2 Plasmodium falciparum life cycle in the human host and the anopheline mosquito 
The cycle starts when a mosquito injects of sporozoites into the dermis of the human host during a 
blood meal (A), the sporozoites then travel to the liver (B), where they invade the hepatocytes and 
then multiply. After about one week, the liver schizonts burst releasing merozoites into the 
bloodstream that invade red blood cells to begin the asexual cycle (C), also called the blood stage. 
Some parasites can develop into sexual forms (gametocytes). Gametocytes are taken up by a blood-
feeding anopheline mosquito (D) where they reproduce sexually, forming an ookinete and then an 
oocyst within the mosquito mid-gut. The oocyst bursts to release sporozoites, which migrate to the 
salivary glands awaiting inoculation during the next blood meal. The entire cycle can take 
approximately one month. Estimated numbers of parasites are shown in the boxes. Figure from 
(White et al. 2014).  
1.5 Clinical presentation of malaria 
When an individual gets infected with Plasmodium falciparum malaria parasites, a 
variety of clinical manifestations may follow. Depending on the host innate or acquired 
immunity, these range from asymptomatic parasitemia to uncomplicated malaria, 
which can lead to severe malaria and ultimately death. Uncomplicated malaria usually 
presents with fever and other nonspecific symptoms such as vomiting and diarrhoea. 
In adults, severe malaria can sometimes lead to complications including acute 
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pulmonary oedema, jaundice, and renal failure. Such complications are not common 
in young children with severe malaria, who mostly present with prostration, respiratory 
distress, severe anaemia, or cerebral malaria (White et al. 2014). Coma which is as a 
result of cerebral malaria and acidosis, occurs in all age groups Figure 1.3 
(Greenwood et al. 2008). Age is closely linked to the manifestations of severe malaria 
(Dondorp et al. 2008). Severe anaemia tends to occurs in children in areas of high 
transmission and is usually a result of repeated infections, whereas cerebral malaria 
is common in older children in low transmission areas (Calis et al. 2008; White, 2014a; 
Snow et al. 1994) 
 
 
 
Figure 1.3 Manifestations of severe Plasmodium falciparum malaria by age.  
Severe malaria anaemia and coma affect mostly young children, while jaundice and renal failure 
occur in adults. Figure from (White et al. 2014).  
 
 
The most commonly encountered clinical syndromes that define severe malaria in 
children fall into three main categories: severe anaemia, cerebral malaria/ impaired 
consciousness and metabolic acidosis/respiratory distress. These syndromes may 
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occur separately or in any combination Figure 1.4 (Marsh et al., 1995). Although 
syndromes of malaria are known, and their age distribution have been described, it 
remains unclear why some individuals develop an asymptomatic infection while others 
proceed to severe malaria. However, it has been shown that genetic factors 
(Kwiatkowski 2005), and both the age of the patient and the intensity of transmission 
influence susceptibility to severe anaemia and cerebral malaria (Snow et al. 1997; 
Reyburn et al. 2005)- 
 
 
Figure 1.4 Prevalence overlap and mortality for major subgroups of 1844 Kenyan children 
with severe malaria.  
Total numbers are given in parenthesis, and mortality is given in percentages, mean age of the 
children was 2.2 years. Figure from (Marsh et al., 1995). 
 
 
1.6 Epidemiology of malaria   
Infections with Plasmodium falciparum are limited primarily to the tropics (WHO 
2018b). In sub-Saharan Africa, malaria transmission can occur either throughout the 
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year (perennial) or can be highly seasonal, but primarily confined to the 3-4 month-
long rainy season Figure 1.5 below (Autino et al. 2012). 
 
Definition of malaria transmission. Malaria transmission can be classified as either 
stable or unstable, which is also closely related to endemicity levels. The stable-
unstable classification was first proposed by Sir Ronald Ross and adapted by George 
Macdonald for the measurement of malaria endemicity. Stability was defined 
quantitatively by the average number of feeds that a mosquito takes on a man during 
its lifetime (Macdonald 1957). The limitation of Macdonald’s stability index 
measurement was that it required detailed entomological data that is rarely available 
(Snow et al. 2012). Constant, frequent, year-round infection was termed as stable 
transmission, whereas in areas where transmission is low, erratic or focal is termed as 
unstable transmission. Another metric used to define malaria transmission relies on 
using parasite prevalence in the 2-10 year-olds (PfPP 2-10) (Hay et al. 2008). Based on 
this metric, four different endemicity areas can be distinguished: holoendemic, when 
transmission occurs all year round; hyperendemic, where intense transmission occurs 
but with periods of remission during the dry season; mesoendemic indicating regular 
seasonal transmission; and hypoendemic with very intermittent transmission.  
 
Presentation of malaria in areas of stable/unstable transmission: In stable malaria 
transmission areas, anaemia and childhood mortality are common, parasitemia is high 
in children aged 6-15 years, and adults often carry asymptomatic infections (Griffin et 
al. 2015). In areas where transmission is low/unstable, protective immunity preventing 
malaria symptoms is not acquired, but the symptomatic disease affects all ages. In 
such regions, changes in environmental, economic, or social conditions can result in 
an epidemic, with substantial mortality in all age groups (White et al. 2014). While 
these are general considerations, there are special groups of people for whom the 
normal patterns are not observed e.g., pregnant women.  
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Pregnant women remain at increased risk whether residing in stable or unstable 
transmission areas. In stable transmission areas, where adult women are considered 
to have developed acquired immunity due to continuous exposure, P. 
falciparum infection during pregnancy does not cause symptomatic malaria, but it may 
lead to placental malaria infection and low birth weight (LBW) in newborns (Steketee 
et al. 2001; Parise et al. 1998). In these areas, primigravidae and, to a lesser extent, 
secundigravidae are at highest risk for malaria infection and LBW (Jelliffe 1968; Brabin 
1983; McGregor et al. 1983; Steketee et al. 1988). In unstable transmission areas, 
women do not acquire substantial antimalarial immunity hence infection with P. 
falciparum can lead to clinical illness in the woman, and this has been linked to anemia 
in the women and low birth weight (McCormick 1985).  
 
 
 Figure 1.5 Illustration showing the start/end of transmission season on the Africa continent 
over a year.  
While few countries have all year transmission, most countries have two rainy seasons that lead to 
fluctuations in malaria incidence according to seasonality. Figure from (Autino et al. 2012). 
 
 
1.7 Malaria control efforts 
Historical perspectives The first malaria control efforts date back to 1942-1951. 
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During this period household spraying of the residual insecticide dichloro-diphenyl-
trichloroethane (DDT) led to the elimination of malaria in the south eastern states of 
America (Zucker 1996). After that, the WHO launched an ambitious Global Malaria 
Eradication Programme in 1955 that aimed to use chloroquine for malaria treatment 
and prevention and DDT for vector control. This programme achieved some success 
as it led to a reduction of malaria in low transmission areas but suffered lack of 
sustained political good will. This  was later compounded by emergence of 
chloroquine-resistant Plasmodium parasites and DDT-resistant Anopheles 
mosquitoes (Greenwood et al. 2008; WHO 2013). Furthermore, the campaign did not 
attempt to eradicate malaria in many parts of Africa, where transmission is intense. In 
1998, WHO launched yet another large-scale attempt to fight malaria, called the Roll 
Back Malaria Initiative, with a focus on the African continent. The goal of the 
programme was to ensure that at least 60% of the continent’s at-risk population were 
protected or treated with appropriate methods (Snow and Marsh 2010).  
 
Current perspectives At present, substantial resources have been mobilized for 
malaria control with many programs working towards the ambitious goal of malaria 
elimination. For instance, in 2017 an estimated US$ 3.1 billion was invested in malaria 
control and elimination efforts globally by governments of malaria-endemic countries 
and international partners (WHO 2018b), although mostly contributed by the latter. The 
modern control tools to which these resources are being channeled to include: i) vector 
control, ii) chemoprevention and iii) rapid diagnosis, testing, and treatment. 
 
1.7.1 Vector Control 
Vector control involves stopping mosquitoes from biting human beings. The most 
commonly used methods for prevention of  mosquito bites are insecticide-treated bed 
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nets (ITNs) and indoor residual spraying (IRS) (World Health Organization 2016). 
Pyrethroids are by far the most commonly used insecticides for IRS and are the only 
ones currently recommended by the WHO for treatment of bed nets (World Health 
Organization 2016). Three other classes of WHO-recommended adulticides 
(organophosphates, carbamates, and organochlorines) are also used in IRS to 
differing extents throughout Africa (Knox et al. 2014). The evidence suggests that in 
areas with a stable transmission, ITNs reduce the incidence of uncomplicated malarial 
episodes by 50% compared to no nets at all, and by 39% when compared to untreated 
nets. In areas of unstable transmission, the equivalent reduction in uncomplicated 
malaria was 62% compared to no nets and 43% compared to untreated nets (Lengeler 
2004).  
 
Indoor residual spraying has been shown to reduce the incidence of malaria in 
unstable malaria settings in randomized clinical trials. However, similar data from 
settings with stable malaria transmission are scanty. A limited amount of data suggests 
that ITNs provide better protection than IRS in unstable areas. However, more trials 
are needed to compare the effects of ITNs with IRS, as well as to quantify their 
combined effects (Pluess et al. 2010). For both ITNs and IRS, insecticide resistance 
in countries with ongoing malaria transmission is concerning (WHO 2018a).  
 
1.7.2 Chemoprevention 
The WHO defines seasonal malaria chemoprevention (SMC), (previously referred to 
as Intermittent Preventive Treatment in children (IPTc)), as the periodic administration 
of full treatment courses of an effective antimalarial medicine during the malaria 
season to prevent malarial illness. The objective is to maintain a therapeutic 
antimalarial drug concentration in the blood throughout the time of greatest malarial 
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risk. The recommended medicines are sulfadoxine pyrimethamine (SP) and 
amodiaquine (AQ), which should be administered if the parasite is sensitive to them 
(WHO 2012). This recommendation is based on a previous clinical trial, which 
suggested that SMC was highly effective, reducing the incidence of malaria by 82% 
and also contributing to a reduction in childhood deaths (Wilson and IPTc Taskforce 
2011). Slightly reduced estimates of the degree of protection provided by SMC were 
reported in a Cochrane review of the efficacy of SMC (Meremikwu et al. 2012). 
Although SMC is beneficial and is highly recommended by the WHO, it has not been 
fully implemented due to its associated high costs and logistical challenges. It requires 
twelve contacts per year between child and health care provider so that each dose of 
anti-malarial is given under direct observation, which is rarely practicable and, if this is 
not done, there is a danger that children may not get a full course (Greenwood et al. 
2017).  
 
A potential future threat to the implementation of SMC is the observation of an increase 
in the proportion of malaria-causing parasites carrying markers of resistance to SP at 
the end of the malaria transmission season in some early trials (Wilson and IPTc 
Taskforce 2011; Cissé et al. 2016). Except for dihydroartemisinin-piperaquine there is 
currently no agreed drug combination that can be used in place of  SP and AQ in the 
areas where SMC is being delivered (Zongo et al. 2015). The option of using 
artemisinin-based combination (ACT) therapy widely for chemoprevention in Africa 
would be controversial given the threat of the emergence of parasite resistance to 
ACTs (Takala-Harrison et al. 2015; Talundzic et al. 2015; Wang et al. 2015; 
Greenwood et al. 2017).  
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1.7.3 Rapid malaria diagnosis  
Prompt detection and treatment of malaria patients has been argued to be the most 
effective intervention to ensure that a mild case of malaria does not develop into severe 
disease. High levels of access for effective malaria case management may also help 
to reduce the pool of individuals who contribute to onward transmission (WHO 2010). 
Malaria diagnosis involves identifying malaria parasites, antigens or their products in 
patient blood. Although this may seem relatively simple, the diagnostic efficacy of any 
tool may be affected by multiple factors such as: the different malaria species; the 
different stages of the parasite, the endemicity of different species, parasitemia levels, 
immunity, and the use of chemoprophylaxis. All of these factors can influence parasite 
identification and interpretation of malaria diagnostics (Tangpukdee et al. 2009). 
Malaria diagnosis combines both clinical and laboratory components.  
 
A clinical diagnosis of malaria is based on the patient’s symptoms and physical findings 
at examination. However, the considerable overlap of malaria symptoms with other 
febrile diseases makes accurate clinical diagnosis challenging. For example, initial 
symptoms of malaria (fever, chills, sweats, headaches, muscle pains, nausea and 
vomiting) are often non-specific and are also shared by many infectious diseases. 
Likewise, the physical findings are often not specific (elevated temperature, 
perspiration, tiredness). This overlap of malaria symptoms with those commonly 
present in other tropical diseases impedes diagnostic specificity, which can promote 
the indiscriminate use of anti-malarial.  It can also compromise the quality of care for 
patients with non-malarial fevers in endemic areas (Reyburn et al. 2004; Mwangi et al. 
2005a; McMorrow et al. 2008). However, it’s worthwhile to note that in severe malaria 
(caused by Plasmodium falciparum), clinical findings (confusion, coma, neurologic 
focal signs, severe anaemia, respiratory difficulties) are more striking and may 
increase the index of suspicion for malaria. 
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Malaria diagnosis in the laboratory is achieved using different techniques. These 
include: microscopy (Ngasala et al. 2008), quantitative buffy coat (QBC) method 
(Bhandari et al. 2008), rapid diagnostics tests such as optiMAL (Tagbor et al. 2008; 
Zerpa et al. 2008), paraScreen (Endeshaw et al. 2008), and molecular techniques such 
as polymerase chain reaction (PCR) (Holland and Kiechle 2005; Vo et al. 2007). Some 
advantages and disadvantages of these methods relate to sensitivity, specificity, 
accuracy, precision, the time consumed, cost-effectiveness, the need for highly skilled 
microscopists (Tangpukdee et al. 2009). There are also indirect serological 
techniques. Serological kits detect antibodies against malaria parasites, using either 
indirect immunofluorescence (IFA) or enzyme-linked immunosorbent assay (ELISA) 
approaches. In endemic areas, these serological techniques are used mostly for 
epidemiological surveillance and vaccine research. Moreover, in non-endemic areas, 
such as in Europe, antibody detection is used mostly for diagnosis and for checking 
the safety of blood transfusion. However, the detection of antibodies is not suitable for 
the diagnosis of acute malaria  
(https://www.cdc.gov/malaria/diagnosis_treatment/diagnosis.html). The gold standard 
for malaria diagnosis is microscopy using either thin or thick blood smears, and RDTs 
where laboratory facitilies are unavailable (WHO 2014).  
 
1.7.4 Treatment for malaria 
The WHO recommends treatment of uncomplicated malaria using artemisinin-based 
combination treatments (ACTs) which are a combination of artemisinin derivatives and 
other structurally unrelated and more slowly eliminated antimalarials. The most 
commonly used ACTs are artemether-lumefantrine, artesunate-amodiaquine, 
dihydroartemisinin-piperaquine, artesunate-mefloquine, and artesunate plus 
sulfadoxine-pyrimethamine (WHO 2018b). Although highly effective, their continued 
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usage is threatened by reports of the emergence of resistance to artemisinin. 
Artemisinin resistance is characterized by slow parasite clearance in vivo without 
corresponding reductions in conventional in vitro susceptibility (Dondorp et al. 2009). 
The resistance is linked to mutations in the “propeller” region of the P. falciparum Kelch 
protein (Ariey et al. 2014). Emergence of clinical resistance to artemisinin was first 
reported in Cambodia (Denis et al. 2006; Noedl et al. 2008; Dondorp et al. 2009) but 
has now spread across Southeast Asia and South China (Ashley et al. 2014; Huang 
et al. 2015; Ménard et al. 2016). So far there is no reported evidence that artemisin 
resistance has spread to Africa (WWARN K13 Genotype-Phenotype Study Group 
2019). Nevertheless, continuous spread of artemisinin resistance as currently reported 
would have dramatic consequences since replacement therapies are currently limited 
(Ménard et al. 2016).  
  
1.8 Malaria vaccines in clinical trials 
The development of an efficacious vaccine against Plasmodium falciparum malaria 
remains a key research priority. Malaria vaccine development has primarily focused 
on pre-erythrocytic, blood-stage or transmission-blocking vaccine targets (Ouattara 
and Laurens 2015). An ideal pre-erythrocytic vaccine would have to aim at either 
preventing sporozoites from reaching the liver or prevent maturation of liver stage 
parasites and hence prevent clinical disease as well as transmission (Riley and 
Stewart 2013). Blood stage vaccines would aim to reduce the severity of the disease. 
The scientific rationale supporting the development of asexual blood-stage vaccines is 
rooted in the observation that naturally acquired immunity can be passively transferred 
to susceptible individuals (Cohen et al. 1961). Finally, the transmission-blocking 
vaccines aim to target sexual stages, thereby preventing parasite development within 
the mosquito and subsequent transmission to the human host (Birkett 2016). 
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1.8.1 Pre-erythrocytic vaccines 
Pre-erythrocytic vaccine targets include the circumsporozoite protein(CSP), a protein 
expressed on the surface of sporozoites (Kappe et al. 2004). The most advanced CSP-
based vaccine is RTS, S. It is comprised of hepatitis B surface antigen (HBsAg) 
particles fused to the P. falciparum CSP central repeat and thrombospondin domains 
formulated in the adjuvant ASO1 (Ouattara and Laurens 2014). Among the numerous 
vaccines thus far tested, RTS, S was the first one to undergo evaluation in a phase 3 
clinical trial involving 15,460 children at 11 sites in 7 African countries (Agnandji et al. 
2011; Leach et al. 2011). During the first 18 months of follow-up, three doses of RTS, 
S/AS01 induced protective efficacy against clinical malaria of 46% in 5–17 month old 
children, and 27% in 6–12 week old infants (RTS,S Clinical Trials Partnership 2014). 
This protective efficacy declined during the 38–48 month follow up period and at the 
end of the trial was 28.3% and 18.3% for the children and infants, respectively. Other 
pre-erythrocytic vaccine candidates include those that achieve protective immunity 
through irradiated/chemo-attenuated P. falciparum sporozoites, e.g. PfSPZ vaccines 
(Seder et al. 2013; Mordmüller et al. 2017) and the next-generation RTS, S-like 
vaccine, R21 (Collins et al. 2017).  
 
1.8.2 Asexual stage vaccines 
Asexual blood-stage antigen-based vaccines are aimed to stop parasite invasion of 
the red blood cells and hopefully translate to offering protection against clinical 
disease. At present several blood-stage antigens have or are being tried and these 
include apical membrane antigen 1 (AMA1), erythrocyte-binding antigen175 (EBA-
175), glutamate-rich protein (GLURP), merozoite surface protein (MSP) 1, MSP2 and 
MSP3 and serine repeat antigen 5 (SERA5) (Ellis et al. 2010; Ntege et al. 2017). So 
far most of these vaccines have shown limited efficacy and this has been thought to 
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be due to antigenic variation, extensive polymorphism, conformation-dependence, and 
in some instances safety concerns (Schwartz et al. 2012; Ntege et al. 2017). To 
overcome some of these challenges various approaches have been tried including: i) 
incorporation of multiple alleles of same antigens into one vaccines such as the 
example of PfAMA1-DiCo (Sirima et al. 2017) and  ii) use of relatively conserved 
regions of antigens targets such as BK-SE36 vaccine (Palacpac et al. 2013). However, 
none of these vaccines has reached advanced stages. 
  
1.8.3 Transmission blocking vaccines 
Transmission blocking vaccines (TBVs) are designed using antigens expressed by the 
transmissible sexual-stages of the parasite, as well as those expressed by the 
mosquito, and aim to prevent sporozoite development and onward transmission 
(Carter et al. 2000). Notably, while TBV would not directly offer protection to an 
individual, it could have a substantial impact: in an endemic population of 
asymptomatic or submicroscopic carriers, a TBV will serve to arrest onward 
transmission and thus provide protection to the community through herd immunity 
(Draper et al. 2018). Transmission-blocking immunity is thought to be mediated by 
antibodies against surface protein antigens of sexual stages and acting within the 
midgut of a blood-fed mosquito (Carter 2001). A number of different potential antigenic 
targets of transmission immunity have been investigated. Other antigens that have 
been tested as potential TBVs include Pfs47 that is involved in parasite immune 
evasion in the mosquito vector (Molina-Cruz et al. 2013),  PfHAP2 that is expressed 
on the male gametocyte and microgamete (Angrisano et al. 2017) and Pfs25 which is 
expressed during macro-gametogenesis within the mosquito midgut and persists 
throughout zygote, ookinete and early oocyst development (Wu et al. 2008).  
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1.8.4 Multi-stage, multi-component vaccines 
Historically, vaccine development has focused on a small number of antigens. Thus 
far, of the more than 5000 parasite proteins, approximately 20 or so have reached 
preclinical development (Riley and Stewart 2013). It is now believed that it may be 
necessary to combine parasite antigens from the same stage (Osier et al., 2014) or 
those selected from different stages of malaria parasites to achieve synergistic effects. 
For example, partially effective pre-erythrocytic and blood-stage components might 
allow the development of a multicomponent vaccine that can reduce malaria 
transmission as well as provide protection against malaria (malERA Consultative 
Group on Vaccines 2011). Nevertheless, a previous attempt to use multistage antigens 
did not give encouraging results. For example, the NYVAC-PF7 attenuated vaccine 
containing candidates from various stages: pre-erythrocytic (CSP, SSP, and LSA1), 
blood stage (MSP1, AMA1, and SERA), and mosquito-stage (Pfs25) antigens only 
showed modest results (Ockenhouse et al. 1998).  
 
Another example that has been tested is PEV3A containing peptides from both the 
pre-erythrocytic (circumsporozoite protein) and the blood- stage antigen (AMA-1). 
Although the vaccine did not induce sterile protection, lower rates of parasite growth 
were observed in volunteers compared to unvaccinated controls (Thompson et al. 
2008). There have also been attempts to design a cocktail of multistage and 
multicomponent vaccines (Boes et al. 2015) although this is yet to move to advanced 
stages of vaccine testing.  
 
1.9 Malaria vaccine development: challenges and opportunities 
Effective vaccines constitute one of the greatest success stories within the public 
health sector. The most notable examples include the eradication of smallpox and the 
virtual elimination of polio (Hussein et al., 2015). For malaria, many factors have 
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hindered the development of a highly efficacious vaccine for widespread use. First, 
there is a lack of reliable correlates of protection. It has been known that antibodies 
play a crucial role in acquired immunity to malaria (Cohen et al. 1961); however, there 
has been inconsistency in the literature as to the precise antigens that induce 
protective immunity (Tuju et al. 2017). Second, it is the complex biology of the life cycle 
of the parasite, which exists in different forms (and each form with a different pattern 
of antigen expression) in different tissues of the body and the mosquito. It has been 
shown that the parasite has well over 5, 000 genes (Gardner et al. 2002) and it remains 
unclear which of the respective proteins should be selected for vaccine development 
(Tuju et al. 2017). Lastly, among other factors, antigenic variation and polymorphism, 
have rendered subunit vaccine development challenging, especially given that many 
of the sequence alterations in malaria proteins occur in regions that appear to be 
crucial to immunity (Good 2001). Nevertheless, these challenges also provide 
opportunities to find new ways to interrupt the parasite life cycle and potentially 
contribute to the design of a next-generation malaria vaccine. 
 
1.10 Immunity to malaria 
Epidemiological observations suggest that in areas where there is continuous 
exposure to malaria, children become susceptible to clinical episodes of malaria 
including severe malaria. However, the incidence of severe malaria declines with age 
becoming rare in children over five year of age.This indicates that immunity to this life-
threatening illness can be acquired relatively early in life (Baird JK and Baird 1995). In 
contrast, adults carry parasites but remain asymptomatic and rarely experience severe 
disease (Marsh and Kinyanjui 2006).  Sterile immunity to infection with parasites is 
rarely achieved. In the subsequent few sections below, I discuss specific aspects of 
immunity to malaria in more depth including innate immunity, genetically based 
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resistance, naturally acquired immunity (NAI) and antibodies as mediators of NAI. The 
discussion focuses on blood stage immunity. 
 
1.10.1 Innate immunity to malaria 
Unlike other infections with intracellular pathogens, such as viruses, bacteria and some 
protozoan parasites, in which the role of the innate immune responses has been well 
investigated (Scharton-Kersten et al. 1995; Biron 1997; Scharton-Kersten and Sher 
1997; Unanue 1997) relatively few studies have examined the role of innate immunity 
to malaria. In these studies, the focus has been on macrophages, dendritic cells, gd T 
cells and natural killer cells (NK). 
 
Macrophages. Studies in humans and mouse models have shown that macrophages 
function as antigen-presenting cells and can also phagocytose infected erythrocytes 
(Serghides et al. 2003). Following chronic or acute infections in semi-immune 
individuals, proteins on the surface of iRBCs induce the development of malaria-
specific antibodies (Bull et al. 1998) leading to Fc-receptor-mediated uptake of blood-
stage parasites by phagocytic cells. However, during acute infection in non-immune 
hosts, antigen-specific antibody responses are not yet developed, and effector cells 
must rely on alternative mechanisms to recognize and clear iRBCs. Monocytes or 
macrophages often use pattern recognition receptors (PRRs), including scavenger 
receptors such as CD36, to recognize and phagocytose invading microbes before a 
pathogen-specific immune response has been generated (Peiser et al. 2002). In vitro, 
studies have pointed out the importance of CD36-iRBCs interaction in malaria. 
Macrophages from CD36 knockout mice phagocytosed significantly less iRBCs (2.9%) 
compared to macrophages from CD36 wild type (WT) mice (19.3%) (Patel et al. 2004). 
Moreover, macrophages can also mediate antibody-dependent cellular inhibition or the 
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production of anti-parasite molecules, such as nitric oxide, after their activation by 
CD4+ T-cell-derived INF-g (Good and Doolan 1999; Good 2001).  
 
Dendritic cells. DCs form a distinct lineage of mononuclear phagocytic cells specialized 
in antigen presentation. They have a unique ability to capture, process, and present 
antigens to T cells (Nussenzweig and Steinman 1980), directly activate B cells (Avery 
et al. 2003) and are also involved in the activation NK cells (Ferlazzo et al. 2002). 
Additionally, DCs are involved in tolerance development in the thymus by negative 
selection of autoreactive lymphocytes (Brocker et al. 1997) and in the periphery, where 
they present self-antigens in the absence of inflammation (Steinman and Nussenzweig 
2002). This entire range of DC functions have been associated with their capacity to 
recognize pathogen- or damage-associated molecular patterns (PAMPs or DAMPs, 
respectively) through pattern recognition receptors (PRRs) (Iwasaki and Medzhitov 
2015).  
 
Evidence that malaria parasites interact with DCs to promote inflammatory responses 
is limited and controversial. Urban and colleagues showed that intact malaria-infected 
erythrocytes; specifically, PfEMP1(discussed in the immune evasion section) adhere 
to dendritic cells via CD36 or CD51, inhibit the maturation of dendritic cells and 
subsequently reduce their capacity to stimulate T cells (Urban et al. 1999). Conversely, 
Elliot and colleagues showed that DC modulation does not require CD36 binding, 
PfEMP1, or contact between DCs and infected RBCs but depends on the iRBC dose. 
The iRBCs expressing a PfEMP1 variant that binds chondroitin sulfate A (CSA) but not 
CD36 were phagocytosed. In addition there was inhibition of lipopolysaccharide (LPS)-
induced phenotypic maturation and cytokine secretion, and abrogation of the ability of 
DCs to stimulate allogeneic T-cell proliferation (Elliott et al. 2007). The possible 
reasons for such contradictions could include the use of different parasite species and 
stages, and also differences in the DC activation status (Amorim et al. 2016).  
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gd T cells. Human T cells express two different types of antigen T-cell receptors (TCRs) 
in a molecular complex with CD3 (Brenner et al. 1986). Most mature T cells express 
the ab TCR, which recognizes antigens in association with major histocompatibility 
complex antigens (Davis and Bjorkman 1988) and is responsible for both regulatory 
functions and cell-mediated immune responses. A small subpopulation of T cells 
expresses the gd TCR, which can recognize an antigen in an MHC-restricted or non-
MHC-restricted manner (Meuer et al. 1983). In healthy human adults, the majority of 
γδ T cells in peripheral blood are Vγ9V δ2+ T cells, representing between 1-10% of 
circulating lymphocytes. These cells can be found as the minority in the gut, liver and 
other peripheral tissues, whereas V δ1+ γ δ cells are present at higher frequencies at 
these sites (Pang et al. 2012). Until recently, it was thought that γδ T cells were simply 
innate immune T cells with limited or somewhat redundant functions. The current view 
is that these cells complement many different arms of the innate immune system 
(Hayday and Pennington 2007) and, it is becoming clear that they are heterogeneous 
populations of cells with important unique roles in many infections, autoimmune 
diseases, allergies and in immunoregulation (Deroost and Langhorne 2018). To date, 
several studies have investigated the role of these cells during malaria infections. 
These studies, done both in vivo and in vitro, suggest that activation of γδ T cells during 
malaria infection contributes to parasite clearance while others argue that they could 
be responsible for immune-mediated pathology Table 1.1 (Deroost and Langhorne 
2018). 
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Table 1.1 γδ T cells in human and mouse malaria 
 Human Mouse 
Known γδ T subsets expanded during Plasmodium infection in 
Skin (sporozoites entry) Not known Not known 
Liver (liver stage 
infection) 
Not known Not known 
Peripheral blood and 
lymphoid organs (blood-
stage infection) 
Vγ9Vδ2 (Ho et al. 1994; 
Roussilhon et al. 1994; 
Schwartz et al. 1996)  
Vγ1 (Mamedov et al. 
2018), Vγ2, Vγ4 
(Taniguchi et al. 2007) 
γδ T cell expanded by 
Irradiated / Live 
sporozoites 
Yes (Seder et al. 2013) 
(Zaidi et al. 2017) 
Yes (Zaidi et al. 2017) 
Liver-stage parasites Not known Not known 
Blood-stage parasites Yes- in vitro by P. 
falciparum (Goodier et al. 
1995) 
Yes- in vivo (Inoue et al. 
2017) 
Potential effector functions against 
Sporozoites Not known Not known 
Liver-stages Not known Not known 
Blood-stages Vδ1, Vγ9Vδ2: 
degranulation and 
granulysin decrease P. 
falciparum replication in 
vitro (Costa et al. 2011) 
IFNγ- production during 
blood stage infection 
(Seixas and Langhorne 
1999) 
Protective against infection by 
Sporozoites Vγ9V δ2 cell expansion 
associated with protection 
in irradiated sporozoite 
vaccination (Seder et al. 
2013) 
Yes – by recruitment of  
CD8a+ dendritic cells 
which cross-present to 
effector CD8+ T cells 
(Zaidi et al. 2017) 
Blood stage Not known  Vγ1 γδ T cells and M-
CSF protect against 
chronic P. chabaudi 
(Mamedov et al. 2018) 
 Table modified from (Deroost and Langhorne 2018) 
 
 
Natural Killer cells. NK cells represent an early source of IFN-γ during primary murine 
malaria infections and NK depletion using an anti-NK1.1 monoclonal antibody leads to 
higher parasitemia and mortality (Kitaguchi et al. 1996).  In vitro, human NK cells form 
stable conjugates with iRBCs but not with uninfected RBCs and the induction of IFN-γ 
synthesis is dependent on direct contact between the NK cell and the iRBC. NK cells 
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respond to iRBCs only in the presence of a source of IL-12/IL-18, and the subset of 
NK cells that preferentially respond to iRBCs expresses high levels of the lectin-like 
receptor CD94/NKG2A (Artavanis-Tsakonas et al. 2003). Recently, it has been shown 
that, in addition to IFN-γ, NK cells can also produce perforin and granzyme against 
parasite iRBCs (Korbel et al. 2005).  
 
1.10.2 Innate immunity to malaria: genetic mutations that confer resistance 
Malaria parasites have co-evolved together with the human host for many years 
(Jongwutiwes et al. 2005; Kwiatkowski 2005). This has resulted in the selection or 
fixation of inherited traits within the human population that confer survival advantages 
against malaria, as evidenced by their high frequencies in malaria-endemic regions 
(Kwiatkowski 2005). Host-genetic factors alone have been shown to account for 
approximately 25% of the variation in protection seen with malaria in Africa (Mackinnon 
et al. 2005). To date, some of the best-described malaria-protective polymorphisms 
relate to genes that affect the structure or function of the RBCs (Williams et al.2006). 
These hereditary red cell disorders are broadly classified into three groups: the 
haemoglobinopathies (structural and functional aberrations of haemoglobin), red cell 
membrane proteins and red cell enzymes Table 1.2 (Williams et al. 2006). In addition 
to determining these genetic disorders and their frequencies, great strides have also 
been made in understanding their mechanisms of action in order to find new 
approaches for the prevention and treatment of malaria Table 1.2. 
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Table 1.2 Genetic traits that affect immunity to malaria 
Component Mechanism References 
Membrane proteins 
Gerbich blood group 
negativity  
Protection against EBA-
140 mediated invasion by 
P. falciparum parasites  
(Thompson et al. 2001) 
(Maier et al. 2003) 
Southeast Asian 
ovalocytosis  
 
Resistance to invasion by a subset of virulent P. 
falciparum parasites 
(Cortes et al. 2004) 
Increased adhesion of P. falciparum infected 
ovalocytes to CD36 
(Rowe et al. 2009) 
Complement receptor 1 
(CR1) 
Reduced ability of P. 
falciparum infected CR-
deficient red blood cells 
to form rosettes 
(Cockburn et al. 2004a) 
Red blood cells enzymes 
Glucose-6-phosphate 
dehydrogenase deficiency  
Accelerated removal of 
ring-stage infected 
G6PD-deficient red blood 
cells through improved 
opsono-phagocytosis 
(Ayi et al. 2004) 
Pyruvate kinase 
deficiency 
Major determinant of 
resistance to P. chabaudi 
in the mouse system. No 
confirmatory evidence yet 
available in humans 
(Min-Oo et al. 2003) 
Haemoglobinopathies 
Haemoglobin C (HbC) 
 
Greatest degree of protection seen in homozygotes 
(Modiano et al. 2001; Mockenhaupt et al. 2004) 
Reduced surface expression of PfEMP1 in HbCC 
homozygotes(Fairhurst et al. 2003, 2005) 
 
Haemoglobin S (HbS) 
 
Accelerated removal of ring-stage infected HbAS red 
blood cells through improved opsono-phagocytosis. 
(Ayi et al. 2004) 
Improved acquisition of malaria-specific immunity in 
HbAS children 
(Marsh et al.; Cabrera et al. 2005; Williams et al. 
2005) 
Haemoglobin E (HbE) Reduced invasion of HbAE red blood cells by P. 
falciparum parasites in vitro(Chotivanich et al. 2002) 
Table from (Williams 2006) 
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1.10.3 Naturally acquired immunity to malaria 
More than 110 years ago, Robert Koch demonstrated that individuals living in malaria-
endemic areas develop naturally acquire immunity (NAI) to malaria. Koch based his 
observations on microscopically detectable parasitemia in children, adults and trans 
migrants in highly endemic areas of Papua New Guinea and Indonesia where people 
were exposed to many infectious bites each year. By observing higher rates of 
parasitemia in exposed adults and malaria symptoms more prevalent in children, he 
concluded that immunity develops slowly after many years of exposure, but that sterile 
immunity was never really achieved (Ewers, 1972). Years later, the essential features 
of NAI was been described. It is now generally accepted that natural immunity to 
malaria was (i) effective in adults after uninterrupted lifelong continuous exposure, (ii) 
lost upon cessation of exposure, (iii) species-specific, (iv) somewhat stage-specific, 
and (v) acquired at the rate which was dependent upon the degree of exposure 
(Schwartz et al. 2001; Doolan et al. 2009). The incomplete understanding of how NAI 
to malaria is achieved and maintained remains a significant hurdle in progress towards 
the development of an efficacious malaria vaccine. 
 
1.10.3.1 Antibodies as important mediators of naturally acquired immunity 
Antibodies are known to be important components of naturally acquired immunity to 
malaria. The strongest evidence came from Cohen et al. in which passive transfer of 
purified gamma immunoglobulins from immune African adults to children admitted with 
clinical malaria was shown to significantly reduce parasitemia and led to the resolution 
of fever (Cohen et al. 1961). Serum antibodies, which are made by plasma cells, 
mediate protection by acting predominantly against parasites of the asexual blood-
stages that cause the clinical symptoms of malaria (Fowkes et al. 2016). However, a 
knowledge gap remains regarding which specific antigens induce protective immunity, 
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and which antibody effector functions are the most important in protection from 
disease. 
 
Prospective population-based immuno-epidemiological studies have been useful in 
assessing the temporal association between the presence of antibodies and 
subsequent association with disease (Osier et al. 2007) offering insights into targets 
of protective immunity. In a systemic review of longitudinal studies, the presence of 
IgG antibodies against vaccine candidates such as MSP119, MSP3 and apical 
membrane antigen 1 (AMA1), was associated with protection from symptomatic 
malaria (Fowkes et al. 2010). Other studies have also suggested that members of the 
P. falciparum reticulocyte-binding homologues (PfRHs) and erythrocyte binding 
families (EBAs) would be potential targets (Richards et al. 2013; Weiss et al. 2015; 
Beeson et al. 2016). Noteworthy, most of these studies have only evaluated these 
antigens within a limited geographical area. Future studies, done across multiple 
countries/sites in sub-Saharan Africa with differing malaria transmission, may 
accelerate the rational selection and subsequent validation of antigen targets. 
 
Furthermore, the effector mechanisms that are important for immunity are largely 
unknown. However, studies suggest that some of these effector functions include 
antibody-dependent cellular killing mediated by cytophilic antibodies, binding of 
antibodies to parasite-induced molecules on the surface of RBCs leading to clearance 
of iRBCs, antibody blockage of RBC invasion by merozoites as well as antibody-
induced complement-mediated lysis Figure 1.6. Of note, the relative importance of 
each mechanism remains unclear as the results of different studies have been 
inconsistent (Langhorne et al. 2008; Duncan et al. 2014; Blackman et al. 1990; Boyle 
et al. 2015). For instance, there is inconsistency across studies of naturally acquired 
and vaccine-induced immunity on whether growth inhibitory antibodies are associated 
with protection or not (Duncan et al. 2014). Differences in methodologies do not seem 
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to comprehensively explain this variability (Dent et al. 2008) suggesting that other 
mechanisms may be involved.  
 
 
Figure 1.6 Antibody-mediated effector functions in immunity to P. falciparum malaria.  
Antibodies against merozoites can prevent invasion of erythrocytes, inhibit schizont rupture (growth 
inhibitory antibodies), fix complement leading to merozoite lysis, opsonize merozoites for uptake by 
phagocytic cells (opsonic phagocytosis), and stimulate monocytes and macrophages to release 
molecules that kill parasites (antibody-dependent cellular inhibition). Abbreviations: TNF, tumor 
necrosis factor. Figure modified from (Teo et al. 2016). 
 
1.11 Plasmodium falciparum immune evasion mechanisms 
Malaria parasites have evolved to acquire  strategies that evoke poor immune 
responses and allow an infection to be established even in previously exposed 
individuals (Hisaeda et al. 2005). While some of these mechanisms are essential for 
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parasite pathogenesis, they have hindered efforts to generate an effective malaria 
vaccine. Below is a brief discussion of stage-specific evasion mechanisms. 
1.11.1 Immune evasion strategies during the pre-erythrocytic stages 
The first barrier that sporozoites encounter upon transmission to the host is the skin. 
Thus, the sporozoites have evolved to overcome this barrier by various mechanical 
strategies such as motility and cell traversal (Tavares et al. 2013). Sporozoites are 
equipped with specialized mechanical proteins that help them achieve successful 
passage before reaching the liver. The sporozoite microneme protein essential for cell 
traversal (SPECT-1) and perforin-like protein 1 (PLP1) are critical for Plasmodium 
falciparum sporozoite cell traversal and migration to the liver (Sinnis and Zavala 2012). 
The thrombospondin-related anonymous protein (TRAP) is another protein important 
for motility of sporozoites and it functions to allow the parasite to interact with host 
surface molecules which is critical for gliding motility to exit the dermis. It can also bind 
to sulfated glycoconjugate motifs that aid in the recognition and entry of hepatocytes 
(Müller et al. 1993).  
 
To invade hepatocytes, sporozoites cross a barrier lined with endothelial cells (ECs) 
and Kupffer cells (KCs) (Frevert et al. 2005; Tavares et al. 2013). To overcome this 
barrier, the circumsporozoite protein (CSP) interacts with low-density lipoprotein 
receptor-related protein 1 (LRP-1) and proteoglycans of KCs, which increases the level 
of cAMP/EPAC and prevents the formation of reactive oxygen species (ROS). The 
ROS are a natural by-product produced during environmental stress and can cause 
cellular damage or parasite killing (Ikarashi et al. 2013). In some cases, the binding of 
sporozoites can induce KC apoptosis and reduce expression of major 
histocompatibility complex (MHC)-1 which results in the induction of T cell tolerance 
(Ikarashi et al. 2013; Belachew 2018). 
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1.11.2 Immune evasion strategies during the intraerythrocytic stage 
In most instances, immune evasion by intraerythrocytic parasites is the result of (1) 
antigenic variation, (2) sequestration and cytoadherence or (3) rosetting. 
 
1.11.2.1 Antigenic variation 
Antigenic variation is the expression of variable and distinct proteins at different life-
cycle stages of the parasites which changes the proteins exposed to and recognized 
by the immune system. This enables the parasite to evade immune clearance and 
establish chronic infections. Antigenic diversity has been shown to occur as a result of 
at least two mechanisms: 1) the presence of multicopy gene families encoding variant 
surface antigens (VSA), and 2) the presence of polymorphic alleles in the parasite 
population. While the former is prominent in studies of the infected red cell surface 
antigens, the latter is better studied for merozoites (Dinko and Pradel 2016). 
 
Variant surface antigens (VSA) are encoded by many diverse multigene families 
whose variants are exposed on the surface iRBCs (Su et al. 1995). Three major VSA 
multigene families have been identified in P. falciparum: P. falciparum erythrocyte 
membrane protein 1 (PfEMP1) encoded by the var genes (Smith et al. 1995; Su et al. 
1995), repetitive interspersed families of polypeptides (RIFINs) encoded by the rif 
genes and subtelomeric variant open reading frame proteins (STEVOR) encoded by 
the stevor genes (Cheng et al. 1998). Among these families, the var genes are the 
most extensively studied and have been shown to be important in the pathogenesis of 
malaria. There are about 60 distinct copies of var in the P. falciparum 3D7 reference 
clone (Gardner et al. 2002). The expression of var is monoallelic with only a single var 
being transcribed and expressed by a single parasite while the remaining var genes 
are maintained in a transcriptionally silent state (Chen et al. 1998; Voss et al. 2006; 
Scherf et al. 2008). Also, the parasites can switch the expression of var genes leading 
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to different PfEMP1 molecules within a clonal population. While each variant of 
PfEMP1 appears to be a major target of human acquired humoral immunity (Bull et al. 
1998; Chan et al. 2012; Bull and Abdi 2015), the clonal switching of var genes enables 
the parasite to evade the host immune response that has been already acquired 
against a previously surface expressed PfEMP1 variant Figure 1.7 (Bull and Marsh 
2002). The other multi-gene families, rif and stevor genes, are also involved in 
antigenic variation and immune evasion (Dinko and Pradel 2016) through switching of 
their gene expression. 
 
Antigenic diversity/ polymorphism involves the expression of antigenically different 
alleles of a gene in different parasite populations and is thought to arise due to immune 
selection pressure. In the presence of specific immunity, parasites expressing mutated 
alleles that are not recognized by the immune system would selectively expand. In 
most instances, antigens eliciting immune responses often show extensive 
polymorphism (Hisaeda et al. 2005). For example, merozoite surface protein-1 (MSP-
1) has many alleles (Qari et al. 1998), and some antibodies to one MSP-1 allele do not 
recognize the others (Ekala et al. 2002). Also, apical membrane antigen 1 (AMA-1) is 
known to elicit a robust immune response (Osier et al. 2008), although it has numerous 
distinct haplotypes (Polley et al. 2003). Thus, the polymorphic nature of many malaria 
antigens poses challenges for vaccine development.  
 
1.11.2.2 Sequestration and cytoadherence 
The spleen is essential for the identification and clearance of old and abnormal RBCs 
and therefore represents a severe challenge for circulating iRBC. To avoid the spleen, 
P. falciparum has developed an immune evasion strategy whereby the parasite iRBCs 
adhere to human endothelium cells thereby sequestering in the microvasculature of 
various organs, a process called cytoadherence (Yam and Preiser 2017). 
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Sequestration can occur in the heart, lung, brain, liver, kidney, subcutaneous tissues 
and placenta. The various endothelial cells in these organs and syncytiotrophoblasts 
in the placenta express different and variable amounts of the host receptor. To 
successfully adhere to these cells, the parasites can bind to several receptors Figure 
1.7. The adhesion phenotype is not homogenous, and different parasites can bind to 
variable numbers and combinations of host receptors (Newbold et al. 1997). This 
variability is believed to affect the tissue distribution and pathogenesis of parasites. For 
example, PfEMP1, which is expressed on the surface of infected erythrocytes, 
mediates parasite binding to various receptors through multiple adhesion domains 
(Newbold et al. 1997; Chen et al. 2000b). 
 
It is important to note that the binding to host receptors does not necessarily lead to 
pathogenesis. Indeed compared to infection and mild disease, severe complications 
and deaths are rare (Snow and Marsh 1998). It remains unclear what causes the 
transition from uncomplicated to severe forms of malaria. One possibility is that the 
expression of certain binding properties leads to distinct patterns of sequestration and 
to pathogenic consequences (Miller et al. 2002). An example is the sequestration of 
iRBCs in the placenta, which causes premature delivery, as well as low birth weight. 
Parasitized RBCs isolated from placentas have a unique adhesion property that is 
different from parasites collected from non-pregnant women. These parasites can bind 
to CSA but not to CD36 (Fried and Duffy 1996; Beeson et al. 1999). 
 
1.11.2.3 Rosetting 
Rosetting is a phenomenon where an iRBC binds to many uninfected RBCs. Rosetting 
is thought to protect iRBCs from the host immune response while at the same time 
protecting the newly released merozoites from host invasion-inhibitory antibodies. It 
also provides a favorable environment for the emerging merozoites enabling them to 
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rapidly invade the bound uninfected RBCs (Wahlgren et al. 1989; Deans and Rowe 
2006). Most VSAs have been shown to be mediators of rosetting including PfEMP1 
(Figure 7) (Rowe et al. 1997), STEVOR (Niang et al. 2014) and RIFINs (Goel et al. 
2015). Although the role of rosetting remains unclear, there is evidence to suggest that 
it would be important in the pathogenesis of severe malaria.  P. falciparum field isolates 
have been shown to vary in the extent to which they form rosettes with higher levels 
of rosette formation being strongly associated with severe malaria in numerous studies 
in African children (Carlson and Wahlgren 1992; Ringwald et al. 1993; Rowe et al. 
1995). A polymorphism associated with deficiency of the red blood cell rosetting 
receptor CR1 that reduces the ability to form rosettes (Rowe et al. 1997) has also been 
shown to confer protection from severe malaria (Cockburn et al., 2004).  
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Figure 1.7 PfEMP1 expressed on the surface of P. falciparum-infected red blood cells is 
involved in clonal antigenic variation and can bind to many host receptors through its 
multiple adhesion domains.  
Sequestration of the parasites in the brain and placenta are thought to contribute to the 
development of cerebral malaria and placental malaria respectively. Additionally, binding of 
uninfected erythrocytes (rosetting), and clumping of infected erythrocytes through platelets are 
also associated with the pathogenesis of malaria. Parasite-infected RBC binding to dendritic cells 
is thought to contribute to downregulation of the immune response. HA, hyaluronic acid; TSP, 
thrombospondin; ELAM-1, endothelial/leukocyte adhesion molecule 1; P-Sel., P-selectin; VCAM-
1, vascular cell adhesion molecule 1; PECAM (CD31), platelet endothelial cell adhesion molecule 
1; CR1, complement receptor 1; HS-like GAGs, heparin sulphate-like glycosaminoglycans; IgM, 
immunoglobulin M. Figure from (Miller et al. 2002) 
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1.11.3 Immune evasion by merozoites 
The mechanisms used by the merozoites to evade immunity include extensive 
diversity as well as complexity in the number of proteins that are involved in the 
invasion process, also referred to as redundancy of the invasion pathways (Dinko and 
Pradel 2016). Antigenic diversity/polymorphism has been discussed briefly above (on 
antigenic variation section 1.11.2.1). Two major merozoite invasion ligands have been 
described: 1) merozoite surface proteins (MSPs) (Boyle et al. 2010a), and 2) 
alternative pathway ligands, so-called due to their functional redundancy. The latter 
include two major protein families of reticulocyte binding homologues (PfRh2a, 
PfRH2b and PfRh4) and erythrocytes-binding like homologues (EBA-175, EBA-140, 
EBA-181 and EBL1) (Galinski et al. 1992; Adams et al. 2001; Tham et al. 2012). These 
proteins bind to receptors on the red blood cell surface. While some ligands have 
known receptors, for others, their respective receptors are yet to be determined Figure 
1.8. The redundancy displayed by the EBL/PfRh proteins allows parasites to modify 
their usage of ligands, conferring a broad host range and adaptability to 
polymorphisms on the red blood cells (Harvey et al. 2012). Another mechanism that 
has recently been described for merozoite immune evasion is the hijacking of 
complement regulatory protein factor H (FH). FH functions to  protect host cells from 
complement activation (Zipfel et al. 2002). By recruiting FH the parasite is able to 
disguise itself as host and hence gets protected from complement attack (Kennedy et 
al. 2016). 
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Figure 1.8 Merozoite ligands, their receptors, and methods that have so far been used to 
ablate their interactions.  
1) heparin sulphate blocks MSP142 binding to unknown erythrocyte glycoproteins, 2) treatment with 
neuraminidase (NM) removes sialic acids on glycophorin A (GYPA) hence preventing binding of 
EBAs, 3) genetic deletion of EBA175, NM treatment and complement receptor 1 (CR1) fragments 
inhibits PfRh4 binding to CR1, 4) anti-PfRh5 and anti-basigin IgGs blocks the binding of PfRh5 to 
basigin, and 5) peptides of R1 and RON2 inhibits AMA1–RON2 interactions, figure from (Weiss et 
al. 2015). 
 
1.12 The complement system 
Complement was originally discovered in the 1880s by scientists Nuttal and Buchner. 
They observed that blood depleted of white blood cells was still capable of killing 
infecting bacteria (Buchner et al.1894; Nuttall et al. 1988). At that time, complement 
was termed “Alexin” from the Greek meaning to “ward off.” Thus, along with phagocytic 
cells, complement was one of the first components identified in the innate immune 
system. Within a few years of its discovery, the term “Alexin” was changed 
to complement when Border (a Nobel Prize winner) showed that it could “complement” 
 37 
the bactericidal activity of serum antibodies (Bordet et al. 1899; Bordet et al. 1900) and 
the term complement was thereafter universally adopted.  
 
The complexity of complement as we now know it with multiple proteins (over 50 
proteins) involved in the three major pathways was unraveled slowly with the 
advancement of technology. For example, improvement in molecular technology 
provided insight into the role of complement outside the traditional definition of 
complement as merely “the first line of defense against invading pathogens.” There is 
now plenty of data to suggest that complement is involved in normal homeostatic 
processes including the mobilization of hematopoietic cells, tissue regeneration, and 
clearance of immune complexes. Apart from these, complement has been shown to 
play an essential role in B cell activation and antibody production and regulation of T 
cell responses (Müller-Eberhard 1988; Lachmann 2006; Carroll 2008; Dunkelberger 
and Song 2010; Mastellos et al. 2013; Phieler et al. 2013; Morgan and Harris 2015; 
Sim et al. 2016). Moreover, it is now known that there is crosstalk between the 
complement system and some cell effector systems (Kolev et al. 2014) 
 
1.12.1 Complement pathways 
Three major complement pathways exist: the classical pathway, the lectin pathway 
and the alternative pathway Figure 1.9. All three share the common step of activating 
the central component C3, but they differ according to the nature of recognition. They 
ultimately lead to the formation of the membrane attack complex which is responsible 
for the lysis of invading pathogens Figure 1.9. 
1.12.1.1 Classical pathway 
The classical complement pathway is triggered by the recognition of antibody-antigen 
complexes on foreign cell surfaces. Initiation of the pathway occurs when C1q, in 
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complex with C1r and C1s serine proteases (the C1 complex), binds to the Fc region 
of complement-fixing antibodies (mostly IgG1 and IgM) attached to pathogenic 
surfaces (Dunkelberger and Song 2010). During the last two decades it became clear 
that, in addition to IgG and IgM, C1q also recognizes a variety of structurally different 
self- and non-self-target molecules, such as C-reactive protein (CRP), pentraxin 3 
(PTX3), bacterial porins (e.g. OmpK36 from Klebsiella pneumoniae), a large number 
of extracellular membrane-associated receptors, among others (Kishore et al. 2004; 
Ghai et al. 2007; Kojouharova et al. 2010). Autocatalytic activation of C1r and C1s, in 
turn, cleaves C4 and C2 into larger (C4b, C2a) and smaller (C4a, C2b) fragments. The 
larger fragments associate to form C4bC2a on pathogenic surfaces and this complex 
is termed the C3 convertase (Dunkelberger and Song 2010). C3 convertase cleaves 
C3 into anaphylatoxin C3a and the opsonin C3b. In addition, C3b complexes with the 
C3 convertases to form the C5 convertases (C4bC2aC3b). The C5 convertases then 
cleave C5 to form C5a and C5b. The membrane attack complex (C5b-9, MAC) also 
termed as the terminal complement complex (TCC) is then initiated by C6 and C7 
binding to C5b and then C8 and multiple molecules of C9 binding to the C5bC6C7 
complex. The MAC complex forms a pore by inserting itself into cell membranes, 
resulting in cell lysis (Dunkelberger and Song 2010; Sarma et al. 2011). 
 
1.12.1.2 Lectin pathway 
The lectin pathway uses germline-encoded pattern recognition receptors (PPRs), such 
as mannose-binding lectin (MBL) and ficolins, for pathogen recognition. MBL is 
structurally similar to the classical pathway recognition protein C1q. However, MBL 
can form carbohydrate-recognition domains and binds N-acetyl glucosamine and 
mannose, which are common among invading pathogens. Ficolins like MBL 
recognizes N-acetyl glucosamine and mannose structures. Both MBL and ficolins are 
associated with serine proteases, which activate C2 and C4 leading to the formation 
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of central lectin and classical pathway C3 convertase C4bC2a (Carroll 2004). The 
subsequent steps are the same as described for the classical pathway (Degn et al. 
2007). 
 
1.12.1.3 Alternative pathway 
The alternative pathway (AP) is able, in a robust manner, to discriminate normal human 
cells from microbes and damaged or transformed human cells in an antibody-
independent manner. Another critical feature of the AP is that it can amplify its 
activation regardless of which pathway was initiated (Meri 2016). The AP is initiated 
by low-level, spontaneous hydrolysis of C3 to the C3b analog, C3(H2O) which binds to 
Factor B and in turn allows cleavage of Factor B into Bb and Ba in the presence of 
Factor D and hence form the alternative C3 convertase, C3(H2O) Bb. The formation of 
C3 convertase is the basis of an amplification loop by which C3 is broken down to C3b 
and C3a, similar to the C3 convertase (C4bC2a) of the classical and the lectin 
pathways. C3b triggered in such a manner can bind to surfaces nearby and associate 
with Factor B, which can, in turn, be activated by Factor D to form C3bBb, the 
predominant alternative pathway C3 convertase. As a result of the continuous 
activation and the ability to form a feedback amplification pathway, there are many 
regulatory proteins which function to confine complement activation to appropriate 
contexts to prevent unintended complement activation in healthy cells (Dunkelberger 
and Song 2010) discussed in more details on the complement regulation section 
1.12.2. The AP C5 convertase is formed by the association of a second C3b molecule 
to the AP C3 convertase. The subsequent steps leading ultimately to the formation of 
MAC are identical to the other pathways. 
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1.12.2 Complement regulation 
The complement system is tightly controlled by fluid phase regulators  (e.g. factor H, 
FHL-1, C4b binding protein, and C1 inhibitor) and also on cell membranes (e.g., by 
CR1/CD35, MCP/CD46, DAF/CD55, and protectin/CD59) to prevent inappropriate 
complement activation and cell destruction Figure 1.9 (Merle et al. 2015; Hovingh et 
al. 2016). Complement receptor type 1 (CR1/CD35), membrane cofactor protein 
(MCP/CD46), decay-accelerating factor (DAF/CD55) and CRIg inhibit complement 
activation at the C3 convertase level. Protectin/CD59 prevents complement activation 
by binding to C8 and C9, thereby preventing C9 from polymerizing and forming the 
MAC (Farkas et al. 2002; Zipfel and Skerka 2009; Ricklin et al. 2010; Thielen et al. 
2018). Of the soluble regulators, C1-inhibitor (C1-INH) and C4b binding protein (C4BP) 
inhibit the initial steps of the classical pathway while clusterin and vitronectin inhibit the 
terminal pathway. While factor H and Factor H-like 1 (FHL-1), an alternatively spliced 
product of the factor H gene, regulate the amplification loop of the alternative pathway 
(Meri et al. 2008). 
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Figure 1.9 The complement system activation and regulation.  
The complement system forms the first line of defense against invading pathogens. It can be 
activated through three major pathways: the classical pathway, the lectin pathway, and the 
alternative pathway. Upon activation there is the initial deposition of C3b on a surface which can 
also initiate a feedback amplification loop. Through the formation of C3 convertases, these pathways 
culminate in the formation of the opsonin C3b and the anaphylatoxin C3a. Subsequent C5 
convertase formation leads to C5b and anaphylatoxin C5a generation, with C5b initiating the 
formation of the membrane attack complex (MAC) or also called terminal complement complex 
(TCC) which is inserted into target membranes. Host tissues and cells are protected from 
complement deposition through fluid-phase and cell-bound regulators. C1 inhibitor (C1-INH) inhibits 
the functions of C1r, C1s, and mannan-binding lectin-associated serine protease 2 (MASP2). C3b 
(and C4b) are inactivated by complement Factor I and one of several cofactor proteins (surface-
bound CD46 and complement receptor type 1 (CR1) or fluid phase Factor H and C4b-binding protein 
(C4BP). Convertases are regulated through disassembly by regulators that have decay-accelerating 
activity, surface-bound CD55 and CR1 or fluid-phase Factor H and C4BP, and the formation of the 
MAC is controlled by the activities of CD59 and vitronectin. Figure from (Kolev et al. 2014). 
 
1.12.3 Complement factor H/CFHR gene family  
Factor H is encoded by a single gene (HF1) located on human chromosome 1q32 
within the regulators of complement activation (RCA) gene cluster. HF1 is closely 
related to the FHR1, FHR2, FHR3, FHR4 and FHR5 genes encoding five complement 
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factor H-related human plasma (FHR) proteins Figure 1.10 (Rodríguez De Córdoba 
et al. 2004). The FHR1-5 genes originated from the HF1 gene by tandem duplication 
events (Pérez-Caballero et al. 2001). More than 550 single nucleotide polymorphisms 
(SNPs) in the human HF1 gene are known, that may sometimes lead to an amino acid 
substitution in the FH protein (De Córdoba and De Jorge 2007). Some of these 
mutations have been associated with increased risk for diseases such as renal 
disorders type II membranoprofilic glomerulonephiritis and atypical haemolytic-
uraemic syndrome (aHUS) (Pickering and Cook 2008), and also age-related macular 
degeneration (Ansari et al. 2013). The RCA family also encodes complement receptor 
1 (CR1 or CD35), decay accelerating factor (DAF or CD55), and membrane cofactor 
protein (MCP or CD46), which are expressed on the surface of host cells (Skerka et 
al. 2013).  
 
 
Figure 1.10 Factor H is a member of the regulators of complement activation (RCA) gene 
cluster.  
The human RCA gene cluster is located on human chromosome 1q32 and includes more than 60 
genes, of which 15 are complement-related. All of the complement-related genes are arranged in 
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tandem within two groups. The two groupings are a telomeric DNA segment which contains the 
C4BPB, C4BPA, C4BPAL1, C4BPAL2, DAF, CR2, CR1, MCPL1, CR1L1 and MCP genes and a 
centromeric DNA segment that contains HF1, FHR3, FHR1, FHR4, FHR2 and FHR5, as well as the 
gene coding for the B subunit of the coagulation Factor XIII, F13B. These two gene groups are 
separated by DNA-containing genes that are unrelated to complement and that have diverse 
functions. The bottom part of the figure illustrates the existence within the RCA centromeric region 
of many large genomic duplications (A–D) including different exons of the HF1/FHR1–5 genes. 
Figure from (Rodríguez De Córdoba et al. 2004). 
 
1.12.4 The factor H/FHR protein family 
The FH/FHR proteins comprise repetitive units of approximately 60 amino acids 
named short consensus repeats (SCRs) or also called complement control proteins 
(CCPs), arranged continuously Figure 1.11. The C- terminal region (CCPs 18-20) and 
CCPs 6/7 of FH, harbouring the major surface recognition sites of human complement 
FH, are retained with differing degrees of conservation in all FHRs, explaining their 
ability to interact with most of the FH ligands, although with varying avidity, and 
immunological cross-reactivity (Zipfel et al. 1999; Józsi and Zipfel 2008; Skerka and 
Zipfel 2008). However, none of the FHRs contains regions similar to the FH CCPs 1-
4, which has cast doubt on the conservation of the complement regulatory activities of 
FH in the FHRs.  
 
The most striking characteristics of FHR-1, FHR-2, and FHR-5 is that the two N- 
terminal CCPs, which are almost identical in these FHRs, contains a dimerization 
domain (Goicoechea de Jorge et al. 2013). The dimerization domain means that they 
always circulate in the plasma as dimers or tetramers (Goicoechea de Jorge et al. 
2013; Tortajada et al. 2013). Besides, FHR-1, FHR-2, and FHR-5 have higher affinity 
to surface-bound C3b, resulting in more efficient competition with factor H. For several 
of them the ability to competitively inhibit factor H binding to specific host ligands has 
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been demonstrated. Examples include surface-bound C3b and the pentraxins CRP 
and PTX3 (Goicoechea de Jorge et al. 2013; Chen et al. 2014; Csincsi et al. 2015, 
2017). In addition, FHR-3 was shown to compete with factor H for a bacterial ligand, 
the fHbp protein of Neisseria meningitides (Caesar et al. 2014), and most recently, 
FHR1 has been shown to compete with FH for binding to the malaria parasite, 
Plasmodium falciparum merozoites and intra-erythrocytic schizonts (Reiss et al. 2018). 
 
Generally, the circulating plasma levels of complement FH related proteins (FHR) are 
100-fold lower than FH (Abarrategui-Garrido et al. 2009; Pouw et al. 2016). The 
competition in vivo between FH and FHR is thought to be as a result of similarities 
between these proteins; the conserved domains of FHR proteins are homologous to 
CCPs 6-9 and 19-20 of FH Figure 1.11. As a result of this similarity, they can bind to 
the same ligands, albeit to varying degrees (Józsi and Zipfel 2008). For example, FH 
and FHR3 bind to the same region in N. meningitidis fHbp and hence competition for 
binding between these two and their circulating levels can influence disease 
susceptibility (Caesar et al. 2014).   
 
An alternative splice version of the FH gene encodes the Factor H-like 1 protein (FHL-
1), which consists of FH CCPs1-7 plus four additional residues at its C-terminus. The 
main difference between FHL-1 and FH is that while FHL-1 regulates complement at 
the fluid phase using its CCP1-4 domain, FH is both a fluid phase and membrane 
regulator due to its additional CCP19-20 which functions in host recognition (Schmidt 
et al. 2016). 
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Figure 1.11 Schematic presentation of the human factor H family proteins.  
Factor H consists of 20 complement control protein (CCP) domains, also called short consensus 
repeats (SCR). Factor H-like 1 (FHL-1) is identical with the CCPs 1–7 of factor H but has four unique 
amino acids at its C-terminus. The factor H-related (FHR) proteins are composed of 4–9 CCP 
domains, with varying degrees of amino acid sequence identity to specific factor H domains (same 
colors indicate a complete or very high degree of sequence identity). The CCPs 1-2 of FHR-1, FHR-
2, and FHR-5 (shown in green) are closely related to each other and are responsible for dimerization 
of these FHRs. Due to the conservation of domains homologous to factor H CCPs 6-9 and 18-20 
among the FHRs, FHRs can bind some of the ligands of factor H; thus, factor H and the FHRs can 
be argued to have partly overlapping ligand-binding profiles. GAGs, glycosaminoglycans; MDA, 
malondialdehyde; CRP, C-reactive protein; PTX3, pentraxin 3; CR, complement receptor. Figure 
modified from (Józsi et al. 2018). 
1.12.5  FH as a complement regulator 
The FH protein is a 155 kDa glycoprotein composed of 1213 amino acid residues 
(Ripoche et al. 1988) and is the primary central fluid phase regulator of the alternative 
pathway. It consists of 20 complement control protein (CCP) modules also called short 
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consensus repeats (SCR) Figure 1.12. Domains 1-4 of FH function to dissociate the 
C3 convertase (C3bBb), also called decay-accelerating activity. FH also acts as a co-
factor for factor I-mediated cleavage and inactivation of formed C3b. Besides, factor H 
also can recognize specific markers on host cells and control complement on the cell 
surfaces using domains 6-8 and 19-20 Figure 1.12.  
 
Continuous activation of the alternative pathway means that there is always deposition 
of C3b on host cells. Factor H detects and binds to C3b deposits in combination with 
specific polyanionic markers, primarily sialic acid, and sulfated polysaccharides such 
as heparin sulphate on host cells. The ability to detect C3b binding allows alternative 
pathway activation to proceed on any other surface to which factor H cannot bind 
efficiently due to lack of host or host-like markers (Pangburn 2002; Ferreira et al. 2010). 
The FH protein is mainly synthesized by the liver (Fagerberg et al. 2014). It is found in 
human plasma at highly variable concentrations which is thought to influence disease 
susceptibility (Esparza-Gordillo et al. 2004; Scholl et al. 2008). These variable 
concentrations appear to be a result of both environmental and genetic conditions 
(Esparza-Gordillo et al. 2004).   
 
Previous studies have measured circulating FH levels both in healthy adults (Pouw et 
al. 2016) and children (Davis et al. 1979; Sonntag et al. 1998) and even during disease 
state (Ansari et al. 2013).  What has been observed in many studies is that there is 
variation in FH levels across different populations. In a large study by Ansari et al. 
investigating the genetic influence on plasma FH and its role in age-related macular 
degeneration (AMD), they reported a three-fold variation in circulating FH levels mean, 
min-max (400.2, 218-654.1) ug/ml in their cross-sectional survey of Croatians 
(n=1004).  In the same study, their Scottish AMD cases (n=382) had a four-fold 
variation in plasma FH levels, mean, min-max (412.6, 127.8-540.2) ug/ml (Ansari et al. 
2013). In a Spanish population (n=358), plasma levels of FH showed a five-fold range 
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(116-562 ug/ml) (Esparza-Gordillo et al. 2004). Furthermore, a recent study by van 
Beek et al. measured FH levels in healthy Dutch children with a mean age 10.3 years 
observed a nearly three-fold variation in the levels, median 281ug/ml 95% CI (153.5-
432.5 ug/ml).  
 
 
 
Figure 1.12 Functional domains of human complement factor H protein.  
The complement FH protein consists of 20 short consensus repeats (SCRs) or complement control 
protein (CCP) modules that show a certain degree of similarity. However different clusters of SCRs 
have different functional properties as indicated in the figure. Abbreviations: CRP, C-reactive protein; 
GAG, glycosaminoglycans (Boon et al. 2009). 
1.12.6 Complement evasion by pathogenic microbes 
Pathogens exploit multiple strategies to interfere with complement immune recognition 
and effector functions in order to survive in the human host (Zipfel et al. 2007; Blom et 
al. 2009). They express diverse and multiple surface proteins and secrete additional 
molecules to avoid complement attack Figure 1.13 (Zipfel et al. 2007). Commonly 
shared strategies include interference at the activation level, interference at C3 and 
C5 convertase level, and inactivation of the membrane attack complex (C5b-9). 
Additionally, multiple pathogens can interact with complement regulators such as FH 
to inhibit complement activation. These strategies are briefly discussed below: 
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1.12.6.1 Modulation at the complement activation level 
Pathogenic microbes can influence complement activation (Zipfel et al. 2007). A 
notable example is an interaction between Staphylococcal protein A (SpA) and the Fc 
part of IgG. The SpA is a type I membrane protein that is bound to the cell wall of 
Staphylococcus aureus via its C-terminal cell-wall binding region X. In the N-terminal 
half of the protein are its IgG-binding domains E, D, A, B, and C. Through binding of 
IgG, protein A blocks Fc-receptor mediated phagocytosis and also interferes with 
binding of C1q (Goward et al. 1993). Interference at the early stage of complement 
activation is an evasion strategy as it leads to a blockage of downstream effects. 
 
1.12.6.2 Interference at the C3 and C5 convertase level 
Pathogenic microbes can influence the functioning of C3 and C5 convertases in 
multiple ways. For C3 convertase, they can block the enzyme directly, adjust enzyme 
activity, or modulate the strength of the amplification loop (Rooijakkers et al. 2005; 
Laarman et al. 2011). Examples include the immune evasion protein Sbi of S. 
aureus which forms a tripartite complex with C3b and Factor H and allows for tripartite 
complexed C3b processing and inactivation by the complement protease Factor I 
(Haupt et al. 2008). Another example is the Staphylococcal complement inhibitor 
(SCIN). SCIN is an excreted 9.8-kilodalton protein that blocks human complement by 
specific interaction with C4b2a and C3bBb. Staphylococcal complement inhibitor 
binds and stabilizes C3 convertases, interfering with additional C3b deposition leading 
to a considerable decrease in phagocytosis and killing of Staphylococcus aureus by 
human neutrophils (Rooijakkers et al. 2005).  
 
Pathogens can also use proteases that cleave and degrade host C5. The 
staphylococcal SSL7 (staphylococcal superantigen-like protein 7) binds C5 and 
thereby blocks cleavage by the C5 convertase (Langley et al. 2005; Laursen et al. 
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2010). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) from S. 
pyogenes binds to C5a, and the inhibitory action is assisted by ScpA, the streptococcal 
C5a peptidase, which degrades C5a (Terao et al. 2006). 
 
1.12.6.3 Interference at the terminal pathway 
More pathogens control and exploit the terminal pathway of complement. The Gram-
positive bacterium S. pyogenes expresses Streptococcal inhibitor of complement 
(SIC). SIC has been identified as a terminal complement pathway inhibitor since it 
binds the soluble C5b-7 complex and thereby prevents its insertion into the cell 
membrane (Fernie-King et al. 2001). S. mansoni uses schistosoma C inhibitory protein 
type 1 (SCIP-1 ) as a TCC inhibiting protein (Parizade et al. 1994). Borrelia burgdorferi 
confers resistance to the terminal pathway by an 80 kDa surface protein that shares 
both antigenic and functional similarities with human CD59, a natural membrane-
bound inhibitor of MAC. Both CD59 and Borrelial CD59-like inhibit cell lysis by 
preventing the polymerisation of C9 and the formation of MAC. Despite its similarities, 
the CD59-like molecule exhibits many structural and functional differences from human 
CD59. The CD59-like molecule is much larger than CD59, indicating that it is not an 
acquired regulator.  
 
Furthermore, CD59-like interacts with native C8 and C9 while human CD59 binds the 
same molecules only in the context of the assembling MAC. Inhibition of MAC 
formation by membrane-bound CD59-like represents an important survival mechanism 
in B. burgdorferi (Pausa et al. 2003). Some Gram-negative, Haemophilus 
influenzae, Moraxella catarrhalis and P. aeruginosa and Gram-positive bacteria S. 
aureus, S. pneumoniae, and S. pyogenes, as well as yeast C. albicans bind 
vitronectin, the soluble human TCC inhibitor (Singh et al. 2010). Vitronectin binds to 
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and blocks the membrane binding site of C5b-7 and the polymerization of C9 and 
thereby blocks TCC action. 
 
1.12.6.4 Interactions with host regulators for complement immune evasion 
Many bacterial evade complement attack by sequestration of human complement 
regulators to their surface. Well-described examples are bacterial surface proteins that 
bind human C4BP and FH/FHL-1. The regulators are captured in such a way that they 
are still able to interact with C3 convertases and function as cofactors in factor I 
cleavage of C3b/C4b. By binding C4BP, bacteria disturb activation of the 
classical/lectin pathway (Rooijakkers and van Strijp 2007). 
 
Among the most virulent factors of Streptococcus pyogenes (group A streptococcus; 
GAS) is the M proteins. Studies have shown that the M proteins have a remarkable 
ability to bind with high affinity to the N-terminal region of C4BP (Johnsson et al. 1996). 
These M proteins interact with CCP10 and CCP2 of the C4BP a chain (Blom et al. 
2000). Most importantly, the ability to bind C4BP was recently correlated with 
phagocytosis resistance of these bacteria (Carlsson et al. 2003). Furthermore, the 
binding of outer membrane protein A (OmpA) of E. coli K1 to C4BP has been shown. 
C4BP bounding to E. coli K1 acts as a cofactor to factor I in the breakdown of both 
C3b and C4b, hence limiting the ensuing complement cascade. Therefore, a peptide 
corresponding to the complement control protein domain 3 of the C4BP sequence, 
was shown to compete with C4BP binding to OmpA and cause increased deposition 
of C3b. Thus, the binding of C4BP appears to be responsible for the survival of E. coli 
K1 in human serum (Wooster et al. 2006).  
 
Many pathogens capture FH and/or FHL-1 to their surface resulting in alternative 
pathway C3 convertase decay and inactivation of C3b by factor I. To evade the 
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alternative pathway, pathogens commonly recruit FH to their surfaces by binding to 
complement control protein (CCP) 6-7 or CCP 19-20 leaving the critical active site of 
FH CCP1-4 functional (Meri et al. 2013). Bacterial proteins that bind FH via CCP 6-7 
can also recruit FHL-1 due to the shared conserved CCP domains between FH and 
FHL-1 (Meri et al. 2013).  
 
Haemophilus influenzae clinical isolate, Hib 541, has been shown to bind to both FH 
and FHL-1 with higher affinity. The isolate showed increased survival in normal human 
serum and bound to FH using CCP 6–7, and CCP 18–20. Two H. influenzae 
membrane proteins of approximately 32 and 40 kDa were detected with radiolabeled 
FH in far Western blot as the receptors for FH (Hallström et al. 2008). Further 
characterization of these proteins is needed. Fba is an FHL-1 and FH binding protein 
expressed on the surface of the human pathogenic bacterium, Streptococcus 
pyogenes. The Fba binding site was localized to CCP 7, a domain common to FHL-1 
and FH. Binding to FHL-1 was shown to promote the entry of streptococci into human 
epithelial cells in a dose-dependent manner (Pandiripally et al. 2003). Borrelia 
burgdoferi produces several proteins that bind to FH including complement regulator-
acquiring surface protein 1 (CRASP-1) and OspE (Hellwage et al. 2001a; Brooks et al. 
2005). The binding site for OspE was localized at CCP 15-20 (Hellwage et al. 2001a). 
Importantly, some pathogens bind FH using other CCP modules. Factor H binding 
inhibitor of complement (Hic) of Streptococcus pneumoniae recruits FH via CCP 8-11 
and CCP 12-14 (Kohler et al. 2015).  
 
Perhaps the most extensively studied protein with respect to FH binding is the human- 
specific lipoprotein factor H binding protein (fHbp) of Neisseria meningitidis. Binding of 
FH to fHbp is a high-affinity interaction involving both N- and C- terminal parts of fHbp 
and CCP 6-7 of FH (Schneider et al. 2009). Besides recruitment of FH, fHbp is also 
capable of binding to FHR3 (Caesar et al. 2014), which is a known competitive 
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antagonist of FH (Józsi et al. 2015). It is thought that recruitment of FHR-3 over FH 
would render a strain more susceptible to alternative pathway complement-mediated 
killing (Hovingh et al. 2016). Of note is that P. falciparum has also been shown to 
recruit complement regulatory proteins (Simon et al. 2013; Rosa et al. 2015; Kennedy 
et al. 2015) in order to escape complement activation. 
 
It is important to note that although binding to FH has long been considered to be 
beneficial for the pathogen, it is possible that the host can use it to its advantage. For 
example, FH binding to Candida albicans mediates phagocytosis and killing via 
interaction with CR3 on neutrophils (Losse et al. 2010). Therefore, future studies will 
benefit by interrogating host and pathogen benefits of recruitment of FH. Elucidating 
the molecular mechanisms underlying complement evasion may help to identify novel 
vaccine antigens and also improve our understanding of the molecular and functional 
basis of good vaccine antigens (Serruto et al. 2010). 
 
 
Figure 1.13 Complement evasion proteins of pathogenic microbes interfere with cascade 
progression and amplification.  
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Complement activation can be controlled at the activation level, e.g., by proteases, C3 acquiring 
proteins, as well as host bound pre-proteases like plasminogen. Complement evasion proteins bind 
to C3b, interfere with C3a function. Besides, many pathogenic microbes bind host plasma proteins 
and complement regulators like Factor H, FHL1 and C4BP, which influence C3 convertase activity 
and favor dissociation of the assembled cascade. Microbial proteins interfere with the C5 circuit by 
degrading C5a, binding and blocking C5b. Similarly, microbial pathogens acquire CFHR1 a human 
C5 convertase inhibitor. Microbial proteins interfere with the terminal pathway by binding to 
components like C7 and by acquiring the human TCC inhibitors clusterin and CFHR1. G−, Gram-
negative bacteria; G+, Gram-positive bacteria; F, fungi. Figure from (Zipfel et al. 2013). 
 
1.12.7 Complement evasion molecules as vaccine candidates 
The current “complement vaccine” research, in particular for infectious diseases, has 
mostly focused on recognition of pathogenic proteins that bind to complement 
regulatory proteins. It is argued that if binding of the complement regulators is 
prevented, complement activation will proceed on or near the microbial surface leading 
to opsonization, phagocytosis or lysis of the microbes (Meri et al. 2008). This concept 
has been explored, and a successful component vaccine developed and licensed for 
use. Factor H binding protein (fHbp), a lipoprotein present on the surface of Neisseria 
meningitidis is a component of Bexsero (Novartis) and Trumenba (Pfizer), two recently 
approved vaccines against meningococcus. Bexsero contains fHbp var1.1 in 
combination with two additional recombinant proteins (NHBA and NadA) and 
membrane vesicles from the New Zealand outbreak strain NZ98/254 (Giuliani et al. 
2006). Trumenba contains two recombinant lipidated fHbp subvariants (var1.55 and 
var3.45) (Jiang et al. 2010). Antibodies directed against fHbp can act in many ways. 
Those with serum bactericidal activity can mediate direct bacteriolysis and can also 
promote phagocytosis and subsequent intracellular killing. Additionally, fHbp-specific 
antibodies can block binding of factor H, and hence increase bacterial susceptibility to 
killing via the alternative pathway (Madico et al. 2006; Schneider et al. 2006; Welsch 
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et al. 2008). In fact, the killing of the bacteria by anti-fHbp antibodies in the presence 
of human complement (serum bactericidal assay) is used to predict the efficacy of the 
vaccine in humans (Biagini et al. 2016).  
 
1.12.8  Complement dysfunction and disease susceptibility 
Numerous studies have associated genetic variation in complement regulatory 
proteins with some chronic and infectious diseases (de Cordoba et al. 2012; Rodriguez 
et al. 2014; K. Liszewski and Atkinson 2015; de Córdoba 2016). Genetic mutations in 
complement factor H (FH) have extensively been implicated in renal disorders type II 
membranoprofilic glomerulonephiritis, atypical haemolytic-uraemic syndrome (aHUS) 
(Pickering and Cook 2008; Ricklin et al. 2016) and age-related macular degeneration 
(AMD) (Ansari et al. 2013). Notably, aHUS is strongly associated with polymorphisms 
and mutations of activators (C3 and FB) and regulators (CD46, FH, and FI) of the 
alternative pathway (Mele et al. 2014). More than 300 aHUS-associated genetic 
alterations are listed in the FH aHUS mutations to date, with mutational hotspots 
primarily in the C-terminus of complement factor H (Rodriguez et al. 2014). Table 1.3 
below indicates common factor H genetic variants and their respective disease 
phenotypes.  
 
Table 1.3 Complement factor H genetic variants and disease phenotypes 
Disease 
association 
Genetic 
variant 
CCP Effect  Reference 
Hemolytic 
uraemic 
syndrome 
C-257T 
A2089G 
G2881T 
Promoter 
CCP11 
CCP16 
- 
Silent 
Glutamic acid-to-
Aspartic acid change 
(Caprioli et al. 
2003) 
W1183L 
 
L1189R 
 
V1197A 
CCP20 Tryptophan-to-leucine 
change 
Leucine-to-arginine 
change 
Valine-to-alanine 
change 
(Pérez-Caballero et 
al. 2001) 
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Dense deposit 
disease 
T431A 
 
K224 
  
G184A 
 
T1277C 
CCP7 
 
CCP4 
 
CCP1 
 
CCP7 
Cysteine-to-serine 
change 
Deletion of a single 
Lysine residue 
Valine-to-isoleucine 
change 
Tyrosine-to-histidine 
change 
(Dragon-Durey et 
al. 2004) 
(Licht et al. 2006) 
 
(Abrera-Abeleda et 
al. 2011) 
(Abrera-Abeleda et 
al. 2011) 
age-related 
macular 
degeneration 
T1277C CCP7 Tyrosine-to-histidine 
change 
(Sofat et al. 2012) 
 
 
Although the mechanism of how these mutations affect disease outcome are yet to be 
fully defined, some are known. It has been shown that fH62I alters the formation of 
alternative pathway convertase or its regulation (Heurich et al. 2011). Others such as 
fH402H haven been implicated in the reduction of the binding of FH to its natural ligand 
such as malondialdehyde (Weismann et al. 2011), a phenomenon implicated in the 
development of AMD. The CCP 7 domain where Y402H mutation occurs mediates 
recruitment of Streptococcus pyogenes (Parente et al. 2017a). In vitro experiments 
have shown that the Y402H polymorphism causes reduced binding of FH to this group 
A streptococcus leading to its increased killing via phagocytosis in the blood 
(Haapasalo et al. 2008). Future mechanistic studies can evaluate how the Y402H 
polymorphism affects malaria parasite binding to FH and how this affects its survival 
in the human host. On the other hand, delLys224 impedes FH recognition of C3b, 
resulting in loss of its function (Wu et al. 2009). The work presented in this thesis was 
the first to attempt to link whether the FH variant the Y402H is associated with malaria 
disease. Only one study has examined whether FH levels vary within different malaria 
disease state (van Beek et al. 2018). Still, the study findings were not linked to genetic 
changes in the FH gene.   
 
For infectious diseases, it is now well appreciated that some single nucleotide 
polymorphisms (SNPs) have been associated with susceptibility or protection from 
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infection and disease. For example, a genome-wide association study (GWAS) of 
Caucasians has found variations within the complement FH gene family that are linked 
to host susceptibility to meningococcal disease. This study identified SNPs within 
complement FH and in complement Factor H-related protein 3 as being responsible 
for the susceptibility (Davila et al. 2010). A similar study will need to be done in an 
African population to corroborate these findings. It has also been shown that genetic 
variation could influence the circulating levels of FH. Individuals possessing some 
polymorphisms within FH have been shown to have increased serum FH protein 
levels, reduced bactericidal activity against meningococci and an increased risk of 
meningococcal disease (Haralambous et al. 2006). Put together these findings 
implicate complement control in setting disease risk.  
 
 With regards to malaria, previous studies have focused on the Mannose-Binding 
Lectin (MBL) gene and the complement receptor 1 gene. Three polymorphisms of the 
MBL gene (MBL2) exon 1 that result in non-synonymous substitutions have been 
linked to decreased serum levels of MBL (‘B’ G54G, ‘C’ G57E, and ‘’D R52C) 
(Lipscombe et al. 1995). Of these alleles, the MBL2 C allele is found almost exclusively 
in the African population suggesting that it might provide a survival advantage in that 
population (Lipscombe et al. 1992; Madsen et al. 1998; Biryukov et al. 2014). 
Importantly, of the several studies that have studied the association of MBL 
polymorphisms with parasitemia and disease, while some have shown an association 
(Luty et al. 1998; Holmberg et al. 2008, 2012; Boldt et al. 2009) others have not (Garred 
et al. 2003; Mombo et al. 2003; Thevénon et al. 2009). The lack of consistent results 
among these studies is probably due to differences in experimental design, population 
demographics such as age and gender, differences in transmission intensity, and 
statistical rigour (Biryukov and Stoute 2014). Nevertheless, these results suggest that 
the role of MBL in protection against P. falciparum malaria would be significant 
(Biryukov and Stoute 2014). A carefully, well-designed case-control study, done across 
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multiple sites in malaria-endemic regions with varying malaria transmission intensities, 
will be essential to elucidate if there is an association of the MBL specific alleles with 
protection from or susceptibility to P. falciparum infections and disease.  
 
Several studies have related complement receptor 1 to malaria pathogenesis. CR1 
has three major polymorphisms: those affecting the polypeptide size variants; 
quantitative variants that affect the number of CR1 molecules on RBCs; and missense 
mutations of CR1. CR1 mutations form the basis of the Knops blood group system of 
antigens that includes the antithetical antigen pairs of Swain-Langley 1 and 2 (Sl1 and 
Sl2) and McCoy a and b (McCa and McCb) (Krych-Goldberg and Atkinson 2001; 
Schmidt et al. 2015). Quantitative blood group polymorphisms impact on CR1’s ability 
to form rosettes (Chen et al. 2000). Rosetting is mediated either by PfEMP1 binding to 
ABO blood groups antigens (Rowe et al. 2007) or to CR1 (Rowe et al. 1997). Although 
it has been argued that rosetting might mediate severe malaria and hence CR1 
deficient individuals should be protected from severe forms, studies investigating this 
phenotype have given inconsistent findings. While some show that low CR1 numbers 
are associated with protection (Cockburn et al. 2004b; Thomas et al. 2005), others 
have not (Nagayasu et al. 2001; Teeranaipong et al. 2008). Intriguingly the knobs 
antigens McCb and S12 are unusually high in the African population (Figure 2) in (Opi 
et al. 2018), which might suggest a possible survival advantage against malaria (Rowe 
et al. 1997; Opi et al. 2018). Put together, the role of the CR1 molecule in the 
pathogenesis of severe malaria remains unresolved and further studies are indeed. It 
remains unclear whether there are any genetic polymorphisms in FH that would 
influence the complement evasion efficiency of the malaria parasite. Also, whether 
they have a geographical distribution coinciding with varying malaria transmission 
intensity especially in Africa.  
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1.12.9 The Y402H variant of FH 
The most widely studied mutation in FH is the Y402H variant, which is a histidine 
replacement of tyrosine at position 402 (using the pro-protein sequence numbering). 
Structurally, the Y402H polymorphism occurs in the seventh of FH’s twenty 
complement control protein (CCP) domains (Schramm et al. 2014) and does not alter 
the overall conformation of the protein (Herbert et al. 2007). However, the Y402H alters 
the binding of FH to many ligands, most notably C-reactive protein, Streptococcus M 
protein and sulfated polyanions, such as glycosaminoglycan (GAG) chains of 
proteoglycans (Clark, Bishop, & Day, 2010). It is important to note that this SNP has 
been linked strongly to AMD. Heterozygous individuals for the Y402H polymorphisms 
have a 2.3- fold increased risk of developing the disease, and homozygous 5.2 fold 
(Sofat et al. 2012). Around 30% of people of European descent carry at least one copy 
of the 402H risk allele (Sofat et al. 2012). A proposed explanation for the high 
prevalence of the Y402H polymorphism is that the 402H allele provides a survival 
advantage against streptococcal infections in early life (Haapasalo et al. 2008). The 
FH binding protein of streptococcus has a lower affinity for 402H than 402Y, which 
would enhance activation of the alternative pathway on these bacteria.  
 
 
1.12.10 Complement and naturally acquired immunity to malaria  
Several lines of evidence support the idea  that acquired and vaccine-induced human 
antibodies recruit complement and interfere with RBC invasion by the malaria parasite 
(Boyle et al. 2015; Feng et al. 2018). Boyle et al. have described an antibody effector 
function known as antibody-mediated complement dependent (Ab-C’) inhibition, in 
which antibodies use the complement to limit parasite growth in vitro. In some 
individuals, the antibodies were shown to be non-inhibitory in the absence of 
complement. Antibodies that fix C1q were shown to be associated with protection from 
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clinical episodes of malaria (Boyle et al. 2015). The importance of complement is 
further supported by the association of protection from malaria with levels of cytophilic 
IgG1 and IgG3 that activate complement via C1q (Roussilhon et al. 2007; Stanisic et 
al. 2009; Richards et al. 2010). Furthermore, antibodies that fix complement have been 
shown to inhibit P. falciparum sporozoite invasion of hepatocytes (Behet et al. 2018; 
Kurtovic et al. 2018; Zenklusen et al. 2018) implying that antibody complement 
interactions have many roles in immunity against different stages of malaria.  
 
Perhaps a significant step forward in our understanding of the antibody-complement 
effector function is that the specific targets for complement-fixing antibodies are now 
known (Reiling et al. 2019). The work of Reiling et al. has shown that EBA140 RIII-V, 
RASPI, GAMA, PfRH2, MSP-DBL1, PfRH5, EBA 175-RIII-V, and MSP2-3D7 
merozoite proteins are targets of complement-fixing antibodies. Importantly, antigen-
specific complement-fixing antibodies were strongly associated with protection from 
malaria in a longitudinal study of children. Also, using statistical modeling, they 
observed that combining three antigen targets of complement-fixing antibodies could 
increase the potential protective effect to over 95%. These findings support antibody-
complement interactions against merozoite antigens as important antimalaria immune 
mechanisms (Reiling et al. 2019). 
 
In contrast, Biryukov et al. have shown that anti-merozoite antibodies and complement 
activation can paradoxically aid the malaria parasite to invade red blood cells. Using a 
monoclonal antibody directed against the merozoites and human polyclonal IgG from 
merozoite vaccine recipients in a standard invasion inhibition assay, they showed that 
in the presence of complement and antibodies, there was enhanced invasion (Biryukov 
et al. 2016). However, unlike the previous studies, this study suffers one major 
limitation of not testing the enhancement of invasion using sera from immune adults 
that have traditionally been used to measure antibody effector functions. 
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1.12.11 Complement and severe malaria anaemia 
The pathogenesis of severe malaria anaemia (SMA) remains poorly understood 
although it is thought to arise as a result of direct destruction of RBCs during schizont 
rupture, increased destruction of uninfected RBCs and impaired erythropoiesis due to 
bone marrow suppression (Jakeman et al. 1999; Awah et al. 2011). A significant body 
of evidence suggests that complement activation may be responsible for the loss of 
uninfected red blood cells hence contributing to SMA. Children with severe malaria 
anaemia tend to have higher levels of immune complexes (Mibei et al. 2005) and show 
a considerably lower complement hemolytic activity (CH50) along with the decreased 
activity of all the major complement pathways (Nyakoe et al. 2009). Additionally, it has 
been observed that red blood cells in children with SMA have increased surface IgG 
and deficiencies in complement regulatory proteins CR1 and CD55 (Waitumbi et al. 
2015). Erythrocyte deficiencies of CR1 and CD55 in children with SMA result in 
reduced immune complex (IC) binding capacity and are associated with increased 
deposition of C3b on erythrocytes during malaria infection (Odhiambo et al. 2008; 
Owuor et al. 2008). It, therefore, can be postulated that in the absence of CR1 and 
CD55, there would be increased deposition of complement products C3b marking 
these RBCs for phagocytosis or complement-mediated lysis. Parasite antigens can 
also cause erythropoietic dysfunction. In vitro work by Layez et al. indicated that 
rhoptry protein RSP2 had a higher affinity for erythroid precursors in the bone marrow 
pointing to the possibility that parasite antigens may limit the production of erythrocytes 
(Layez et al. 2005).  
 
1.12.12 Complement and cerebral malaria 
There is evidence from animal models and human studies that suggest that 
complement could be implicated in the development of cerebral malaria (CM), although 
 61 
this is mostly correlational (Silver et al. 2010). Infection of mice with Plasmodium 
berghei ANKA is the most commonly used animal model for CM. One study observed 
up-regulation of complement factors C1q and C5 in the brain of mice with CM (Lackner 
et al. 2008). Susceptibility of P. berghei-induced CM correlated with the expression of 
C5, as C5 deficiency has been shown to cause resistance to CM. Transfer of the C5-
defective allele from A/J (CM resistant) into C57BL/6 (CM-susceptible) mice confers 
increased resistance to CM (Patel et al. 2008).  
 
Furthermore, the treatment of wild-type mice with anti-C5aR or anti-C5a Ab protected 
against the development of experimental CM, and anti-C5aR Ab significantly inhibited 
monocyte-derived cytokine production (Conroy et al. 2009). Conversely, in another 
study C5aR−/− mice were found to be fully susceptible to disease (Ramos et al. 2011). 
Nevertheless, these data suggest that C5 is essential in the pathogenesis of CM. On 
the other hand, C3−/− mice have also been shown to be highly susceptible to 
experimental cerebral malaria (Ramos et al. 2012). In humans, a case-control study 
observed that the median levels of C5a at presentation were significantly higher in 
children with CM versus those in children with UM (43.7 versus 22.4 ng/ml; P < 0.001) 
(Kim et al. 2014). Thus, overactive complement in the form of C5 fragment production 
may contribute to severe malarial disease and efforts to regulate this could lead to 
better patient outcomes (Schmidt et al. 2015). 
 
1.13 Scope  
Many pathogens can establish infections despite exposure to the complement system. 
They have evolved mechanisms to evade complement-mediated clearance through, 
among others, the ability to hijack human complement regulatory protein factor H  (FH) 
(Lambris et al. 2008). Numerous studies have shown that Plasmodium falciparum 
recruits FH for immune evasion (Simon et al., 2013; Kennedy et al., 2015; Khattab et 
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al., 2015a; Rosa et al., 2016). Specifically, within the blood stages, merozoite protein 
Pf92 has so far been identified as the merozoite receptor for FH (Kennedy et al. 2015). 
I hypothesized that potentially more merozoite proteins are involved in complement 
evasion. I used a combination of modified ELISA binding assay and surface plasmon 
resonance and tested a library of recombinant merozoite proteins to discover new 
proteins that interact with FH other than Pf92 (Kennedy et al. 2015). Next, I tested 
whether antibody responses to the newly identified merozoite FH receptor proteins 
were associated with protection using a malaria cohort study. I also tested whether FH 
levels influence susceptibility to malaria infection and whether a common FH variant, 
Y402H (Sofat et al. 2012), influences FH levels and is associated with clinical malaria 
using a longitudinal and case-control study in children respectively. 
 
I hypothesized that many merozoite proteins are involved in the interaction with FH 
because of previous observations in Plasmodium falciparum and also in bacteria. In 
studies published by Kennedy et al. Pf92 was characterized as an interacting partner 
with FH using a parasite knockout. They showed only a modest reduction in growth in 
the presence or absence of complement. This implies two possibilities, either Pf92 is 
not the only protein involved, or the parasite evades complement by interacting with 
other complement regulatory proteins (Kennedy et al. 2015). Indeed in follow-up 
studies, Kennedy et al. and colleagues identified MSP3.1 as another protein that 
interacts with C1-INH for parasite complement immune evasion (Kennedy et al. 2017). 
A similar mechanism of redundancy had been observed in bacteria. Gram-negative 
bacterium Borrelia burgdorferi has been shown to have two or three FH binding 
proteins: CspA, CspZ; and OspE (Hellwage et al., 2001; Brooks et al., 2005, Kraiczy 
and Stevenson, 2013) for FH interaction. Gram-positive bacterium Streptococcus 
pyogenes has also been shown to have three FH binding proteins, M1 protein, Fba 
and Scl1.6 (Pandiripally et al. 2002, 2003; Reuter et al. 2010).   
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Lastly, it is known that the parasite has many proteins, its genome encodes over 5000 
proteins. Given what is known of parasite biology, it is highly unlikely that an important 
parasite survival strategy is entrusted to only one protein. For example, for parasite 
invasion, we know multiple parasite proteins have been shown to engage different 
ligands on erythrocytes and that the parasites can switch between different invasion 
pathways (Weiss et al. 2015). With variant surface proteins, again the parasite uses a 
complex strategy of switching sequential and variable parasite proteins to avoid 
immune clearance (Dinko and Pradel 2016) presumably. These examples show a 
pattern of the parasite using an array of proteins rather than single proteins to promote 
its survival. 
 
1.14 Composition of the thesis 
Chapter 1 provides a broad introduction to malaria, immunity and the complement 
system.  
In chapter 2 I outline the cohorts analyzed in this project and the range of laboratory 
methods applied. Subsequently, the data chapters are: 
Chapter 3: Identification of blood stage Plasmodium falciparum merozoite antigens 
that interact with human complement factor H for complement evasion 
Chapter 4: Analysis of antibody responses to merozoite FH receptor proteins and their 
association with protection against clinical malaria 
Chapter 5: Association of human complement FH levels and Y402H variant with 
susceptibility and severity to Plasmodium falciparum malaria 
Each chapter contains summary and aims, a brief introduction, methods, results, and 
discussion.  
Chapter six contains the overall discussion of the findings, further areas of research 
and conclusions. 
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CHAPTER TWO 
2 Materials and Methods 
2.1 Summary and aims 
This chapter describes the laboratory methods used in the subsequent chapters of this 
thesis (Chapter 3,4 and 5), the data source population, and the analysis methods. The 
experimental work was conducted at the Immunology Laboratory, KEMRI-Wellcome 
Trust Research Programme, Kilifi, Kenya and at the Department of Bacteriology and 
Immunology, University of Helsinki, Finland. The recombinant merozoite proteins used 
in this study have been previously described (Zenonos et al. 2014; Kamuyu et al. 2018; 
Crosnier et al. 2013) and were part of a bigger study led by Prof Faith Osier with the 
aim to define the merozoite targets of protective immunity against Plasmodium 
falciparum malaria. The specimens analyzed are continuously collected and are 
archived as part of on-going studies to understand acquired immunity to malaria in 
children in Kilifi County, Kenya.  
 
The current study involved the systematic screening of a recombinant merozoite 
proteins library (Crosnier et al. 2013; Zenonos et al. 2014; Kamuyu et al. 2018) to 
determine interaction partners of complement regulatory protein factor H (FH). The 
aim is to improve our understanding of complement immune evasion by the malaria 
parasites. Human serum and blood EDTA samples were used to: analyze antibody 
responses to merozoite FH receptors and their association with protection against 
malaria; inter-individual variation in FH levels and its association with malaria 
susceptibility and severity; and the influence of FH Y402H polymorphism on the risk of 
developing the disease. 
 
Samples were processed according to established standard operating procedures and 
stored at −80°C within an hour of collection. During subsequent handling by individual 
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investigators, samples are at all times kept on ice and immediately returned to −80°C 
freezers. Sample handling is controlled as the sample request is managed centrally. 
Since the samples are managed and owned by the KEMRI-Wellcome Trust Research 
Programme, they are a shared resource and several investigators have requested for 
them over the years. These samples have previously been requested 10 times 
(according to the records with the Biobank Manager). As long as samples are 
appropriately handled, complement protein measurement should not be affected 
(Yang et al. 2015).   
 
2.2 Study location 
The epidemiological studies, which were the source of the specimen analyzed in this 
thesis project, were part of a series of studies to understand naturally acquired 
immunity to malaria. The studies were conducted at Kilifi County, located along coastal 
Kenya. Specifically, this project used archived serum and blood EDTA samples 
collected from residents of the Kilifi Health and Demographic Surveillance System 
(KHDSS) area (Scott et al. 2012; Nyiro et al. 2018) attending Kilifi County Hospital 
(KCH), and children presenting with uncomplicated malaria at the Junju dispensary 
(located in the south of KHDSS) Figure 2.1. Archived serum samples from the Junju 
malaria longitudinal study of children (described in the next section 2.4) were also 
used. KHDSS spans an area of 891 km2, 50 km north and south, and 30 km west with 
reference to KCH. KCH is the largest and only referral hospital within the KHDSS 
offering both outpatient and in-patient services while Junju dispensary offers outpatient 
services only. Figure 2.1 indicates the location of KHDSS in relation to KCH and other 
major health facilities. 
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Figure 2.1. A map of the Kilifi Health and Demographic Surveillance System (KHDSS) area, 
coastal Kenya  
The map is expanded from a map of Kenya showing population density (person per km2) and the 
health facilities. Figure modified from (Nyiro et al., 2018) 
 
 
2.3 Study population 
The population of Kilifi County according to the last Kenyan government census of 
2009 is approximately 1 million, of which around 260,000 are within the KHDSS (Scott 
et al. 2012; Nyiro et al. 2018). The majority resides in rural areas. The population is 
predominantly of the “Mijikenda” ethnic group and consists of mainly small-scale 
subsistence farmers of maize, cassava, cashew nuts, and coconuts, as well as goats 
and dairy cattle. The majority of malaria infections in this region are due to Plasmodium 
falciparum (Mwangi et al., 2005). 
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2.4 Junju longitudinal study of children 
The study comprised an initial cross-sectional survey and subsequent longitudinal 
monitoring for six months Figure 2.2. The cross-sectional survey was conducted at 
the start of the malaria transmission period to enable the prospective monitoring of 
clinical cases of malaria Figure 2.2. At the cross-sectional survey, a blood sample was 
collected to test for malaria infection using a rapid diagnostic test (RDT) in the field. 
Samples that were positive by RDT were re-tested in the laboratory using microscopy 
and PCR. Active surveillance was done through weekly home visits by trained 
fieldworkers where children are tested for fevers associated with Plasmodium 
falciparum malaria. The fieldworkers are also available to assess any fevers occurring 
in-between the weekly visits. Children found with fevers and positive using the RDT 
were referred to the nearest health dispensary where a clinical officer reviewed them 
and administered anti-malaria drugs. Since the cohort is under active surveillance, 
children who develop malaria, including having multiple clinical episodes during the 
follow-up period are treated and recorded. 
 
 Severe cases with complications are referred to the Kilifi County Hospital for 
admission. On admission, an electronic case record was filled capturing age, 
residence, vital signs, clinical history and examination and Blantyre coma score. In 
addition, the following tests were done: malaria blood slide, full blood count, blood 
glucose and blood culture tests (Njuguna et al. 2019). In this region of Junju sub-
location, the peak malaria transmission occurs during the rainy months (long rains from 
May to July and short rains from November to December). The Plasmodium falciparum 
parasite prevalence in 2-10-year-olds (PfPR 2-10) is around 30% (Ndungu et al. 2015; 
Wamae et al. 2018). A clinical episode of malaria was defined as a body temperature 
of >37.5 oC with a parasite density of ≥ 2500 parasites/ µL (Smith, Schellenberg and 
Hayes, 1994; Mwangi et al., 2005). 
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Figure 2.2. Illustration of the Junju malaria longitudinal study of children 
Children aged 0-15 years are recruited into the study. Infants born into the participating 
households are also continuously recruited. Malaria case detection is done both actively through 
visits by trained fieldworkers and passively at selected participating health facilities 
 
2.5 Kilifi County Hospital case-control study 
A case-control study of well-defined severe malaria cases was designed. The KEMRI 
hospital surveillance study draws its participants from children presenting at KCH and 
who need admission. Children are included in the study only if their parents' consent.  
The timing for the collection of blood samples was prior to admission. Children meeting 
the clinical definition for malaria (see section 2.5.1 and 2.5.2) were used for the work 
presented in this thesis. Upon admission, basic demographic data such as age and 
residence were electronically recorded in addition to vital signs, clinical history and 
examination and Blantyre coma score. The following laboratory tests were also 
routinely done: malaria blood slide, full blood count, blood glucose and blood culture 
test (Njuguna et al. 2019). Any child that developed another clinical episode of malaria 
and re-admitted was captured in the Kilifi Health Demographic Surveillance System as 
long as they remained residents at the time of hospital presentation. Hence their 
multiple malaria clinical episodes were treated and recorded. In this PhD work, I 
sampled cases only once irrespective of the number of times the child was admitted.  
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Three categories of children were selected according to the presenting symptoms: 
severe malaria anaemia (SMA); severe malaria without anaemia (SM); and 
uncomplicated malaria (UM).  
 
Cases were residents of Kilifi Health Demographic Surveillance Systems (KHDSS) 
presenting at Kilifi County Hospital (KCH) with severe malaria. KCH is the largest 
referral hospital within KHDSS Figure 2.1. Controls were children presenting with mild 
malaria at Junju dispensary outpatient clinic located within the KHDSS. The KHDSS 
has several outpatient’s health facilities Figure 2.1, but the KEMRI Wellcome Trust 
Research Programme has established an active malaria cohort within the Junju 
dispensary catchment area. There was no direct matching of the controls to the cases 
but they were both recruited from the KCH catchment area and under the age of 5 
years old (Hayes et al. 1992). 
 
2.5.1 Severe malaria case definition  
Severe malaria anaemia (SMA) was defined as Hb <5 grams per deciliter (g/dl) with 
parasitemia of ≥ 10,000 parasites/µL of blood (Marsh et al., 1995). Severe malaria 
without anaemia (SM) was defined as children with impaired consciousness defined 
as Blantyre coma score (BCS) of < 3, chest in-drawing or deep breathing (English et 
al. 1996). To avoid overlap with SMA, children with severe malaria without anaemia 
(SM) were defined by a haemoglobin of >5 g/dl. The SM group enabled an equivalent 
comparison of severity that did not include SMA.  
2.5.2 Uncomplicated malaria case definition 
Criteria for selecting uncomplicated malaria included children with a parasite density 
of ≥ 2500 parasites/ µL of blood in children 1–15 years old and temperature of >37.5 
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oC (Smith, Schellenberg and Hayes, 1994; Mwangi et al., 2005). Selection of this third 
group was necessary in order to determine whether the differences in antibody 
responses could be attributed to lower parasite densities. 
 
2.6 Detection of Plasmodium falciparum infections 
P. falciparum detection in blood samples collected at hospitalization or during the 
cross-sectional survey was achieved principally with light microscopy. Briefly, finger 
prick blood was collected, and thick and thin blood films prepared and stained using 
Giemsa. Slides were examined under a light microscope. Parasite density was 
determined as the number of parasites per 8,000 white blood cells per microliter of 
blood. Real-Time PCR was used to measure submicroscopic infections (Lundblom et 
al. 2013; Murungi et al. 2016). 
 
2.7 Ethics statement 
The samples in this study were collected after receiving informed written consent from 
each participant over the age of 18 years or through a guardian or parent for 
participants under 18 years. All children assented to participate if aged >13 and <18 
years. The KEMRI Scientific and Ethical Review Unit (SERU) approved the protocols 
covering work for this thesis project (SERU/017/3149).  
2.8 Key resources for the laboratory experiments 
Details of the key reagents used for various laboratory experiments are listed in Table 
2.1 below. 
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Table 2.1. Key resources 
Reagent  Source Identifier (Cat 
No.) 
Antibodies 
anti-factor H goat polyclonal antibody, 
IgG 
Calbiochem  341276 
Donkey anti-goat IgG Antibody, HRP Calbiochem  AP180P 
Monoclonal anti-FH 3D11 Seppo Meri Lab - 
Monoclonal anti-FH 196X Seppo Meri Lab - 
Monoclonal anti-FH 131X Seppo Meri Lab - 
Monoclonal anti-FH 86X Seppo Meri Lab - 
Peroxidase Affinipure rabbit anti-
mouse IgG (H+L) 
Jackson ImmunoResearch 
Europe Ltd 
315-035-003 
Anti-His(C-term)-HRP Antibody Invitrogen R931-25 
Complement C3b Antibody (10C7), 
IgG1 
ThermoFisher Scientific MA1-70054 
Goat anti-mouse HRP conjugate Bio-red 170-5047 
Donkey anti-human IgG-Alexafluor 
647 conjugated 
Jackson ImmunoResearch 
Europe Ltd 
709-606-098 
Complement proteins/serum 
Complement C3b, human Calbiochem 204860-250UG 
Factor H, Human Calbiochem 341274 
FH Depleted serum CompTech A337 
Complement commercial ELISA assays 
MicroVue SC5b-9 Plus EIA Quidel A020 
MicroVue Complement Factor H EIA Quidel A039 
Factor H, 402H/Y variant detection, 
Human, ELISA kit 
HycultBiotech 
 
HK353 
 
Protein expression reagents 
QIAGEN Plasmid midi kit Qiagen 12143 
Opti-MEM® I Reduced-Serum 
Medium  ThermoFisher Scientific 31985062 
Expifectamine 293 Transfection  ThermoFisher Scientific A14525 
Expi293™ Expression Medium ThermoFisher Scientific A1435102 
Ni-NTA agarose (100 ml) ThermoFisher Scientific  R90110 
InstantBlue Expedeon ISB1L 
Novex® ECL Chemiluminescent 
Substrate Reagent Kit Invitrogen 
WP20005 
 
Western blot reagents  
Tris-glycine SDS sample buffer Novex by life technologies LC2676 
Proto-gel quick cast National diagnostics EC-895 
PVDF Transfer Membrane Thermo Scientific™ 88518 
Surface Plasmon resonance reagents 
N-hydroxysuccinimide (NHS) GE Healthcare BR-1000-50 
1-Ethyl-3-(3-dimethylaminopropyl) 
carbodiimide (EDC) 
GE Healthcare BR-1000-50 
Ethanolamine GE Healthcare BR-1000-50 
HEPES buffer Gibco, Life technologies 15-630-080 
Experimental strain   
Plasmodium falciparum 3D7 strain -  
Software and algorithms 
Graphpad Prism San Diego, CA, USA Version 7 
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BiaEvaluation GE Healthcare  
R R Core Team (2013)  
 
2.9 Parasite culture 
3D7 P. falciparum strain was routinely cultured in complete medium (incomplete 
medium Table 2.2 supplemented with 10% Albumax) added to O+ erythrocytes. The 
parasites were maintained under an atmosphere of 1% O2, 3% CO2 and 96% N2 and 
at <10% parasitemia and 2% hematocrit. Parasite synchronization to early stages 
(rings) was achieved using 5% (w/v) D-sorbitol (Sigma) (Lambros and Vanderberg 
1979) for 20 minutes at 37oC in a water bath with gentle hand agitation (two times 
during incubation)  or using magnetic isolation with MACs LD columns (Miltenyi 
Biotech). 
 
Table 2.2 Composition of incomplete medium 
Reagent Volume 
RPMI 1640 500ml 
HEPES 1M (Gibco) 18.75ml 
L-glutamine 200nM (Gibco) 5.0ml 
Gentamicin 10mg/ml (Gibco) 1.25ml 
20% glucose (VWR) 5.0ml 
Sodium hypoxanthine (Sigma) 3.0ml 
 
To prepare complete medium, 10% Albumax (Gibco) was added to 90% incomplete 
medium. 
 
2.10 Modified growth inhibition assay 
Growth inhibition assay (GIA) (Persson et al. 2006; Rono et al. 2012; Murungi et al. 
2016) was modified to test the effect of presence or absence of FH on parasite growth. 
Briefly, 40 µL of highly synchronous P. falciparum 3D7 mid-trophozoite parasites at 
0.5% parasitemia and 1% hematocrit (resuspended in incomplete media) was added 
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to individual wells of sterile 96-well U-bottom plates (Falcon). Thereafter, 5 µL of serum 
depleted of FH (Complement Technologies, Inc.) and 5 µL of 1X sterile PBS were 
added in duplicate, alongside experimental controls, and the plates were placed in a 
sealed humidified gas chamber and incubated at 37°C in 5% O2, 5% CO2, and 90% 
N2. At the end of the second growth cycle (after 96hrs), 10 μg/ml of ethidium bromide 
(molecular grade) diluted in 1X sterile PBS was added to each well, and the plates 
were incubated for 30 mins at room temperature in the dark. The plates were 
centrifuged at 1,000 rpm for 1 min, and the pellet was resuspended in 200 µL of 1X 
PBS. Parasitemia was determined by analyzing 50,000 events on a FACS Canto (BD) 
flow cytometer. 
 
2.11 Isolation of Plasmodium falciparum merozoites 
Merozoites were prepared as described by Boyle et al. (Boyle et al. 2010b) Figure 2.3. 
Parasite cultures were centrifuged at 2000rpm for 5 minutes (TOTANTA 460R) and 
resuspended into 30 ml complete medium. MACs columns (Miltenyi Biotech) were pre-
wetted, and the resuspended parasite cultures were passed through the columns. 
Unbound parasites and uninfected blood cells were washed out of the column before 
removing the column from the magnet and trophozoites collected and centrifuged at 
1800rpm to concentrate the trophozoites. The pellet was re-suspended in the culture 
medium, without the addition of red blood cells and incubated with 10μM of trans-
Epoxysuccinyl-L-leucylamino (4-guanidino) butane (E- 64) protease inhibitor until 
distinct merozoites were visible under the light microscope. Segmented schizonts were 
centrifuged at 2000g for 5 minutes and re-suspended in 20ml of the incomplete 
medium before passing them through a pre-wetted 1.2 μm filter to release merozoites. 
Trapped merozoites were removed by rinsing the filter and the merozoites centrifuged 
at 2000g for 5 minutes. The merozoites were resuspended in 1X Pierce protease 
inhibitor (Thermo Fisher Scientific) and stored at -20oC.  
 74 
 
Figure 2.3. Isolation of Plasmodium falciparum merozoites by membrane filtration.  
Magnetic purification was used to remove uninfected red blood cells from highly synchronized 
trophozoites. When the parasite develops to segmented schizonts, they are treated with trans-
Epoxysuccinyl-L-leucylamido (4-guanido) butane (E64) for 6-10h until mature merozoites have 
formed. Merozoites are then released by membrane filtration through a 1.2 μm filter. Figure from 
(Boyle et al. 2013).  
 
2.12 Maintenance of Expi293 mammalian cells 
To start the cell culture, frozen vials containing human embryonic kidney cells (Gibco 
Expi293 cells) were obtained from liquid nitrogen. The cells were thawed rapidly in a 
37oC water bath and added to 30ml of pre-warmed Expi293 expression media 
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(ThermoFisher Scientific). Cells were grown in standard corning flasks (120-500 ml; 
Sigma) and maintained in a humidified incubator with 8% CO2 supply at 37oC, free of 
any antibiotics. Cells were regularly checked to ensure that the viability (determined 
using countess automated cell counter (Invitrogen)) was maintained at 90%. Cells 
expressing recombinant proteins (see section 2.14 on transfection) were left to grow 
and secrete proteins for six days post-transfection. For the preservation of Expi293 
cells, the cells were washed and re-suspended in FCS with 10% DMSO and 
transferred into cryo-vials (ThermoFisher Scientific). Cells were frozen at -70oC before 
transfer to liquid nitrogen.  
 
2.13 Protein expression 
Expression plasmids containing recombinant Plasmodium falciparum antigens have 
been previously described and are available at Addgene (Crosnier et al. 2013; 
Zenonos et al. 2014). Briefly, regions of the genes corresponding to the ectodomain 
fragments of proteins from the P. falciparum 3D7 strain were predicted using trans-
membrane, GPI- anchor or signal peptide prediction software (Sonnhammer et al. 
1998; Eisenhaber et al. 1999; Dyrløv Bendtsen et al. 2004). Sequences encoding the 
extracellular domains were codon-optimized for expression in human cells and 
synthesized at Geneart AG, Germany. Furthermore, due to previous data showing that 
Plasmodium proteins are not N-glycosylated in vivo (Dieckmann-Schuppert et al. 1992; 
Kimura et al. 2000), these sites were mutated to prevent inappropriate glycosylation. 
Protein coding sequences were flanked with unique NotI and AscI restriction sites and 
subcloned into a derivative of the pTT3 expression plasmid between a 5’ mouse 
variable κ light chain signal peptide (Crosnier et al. 2010) and a 3’ tag consisting of the 
rat Cd4 domains 3 and 4 (Cd4 tag) (Brown and Barclay 1994) followed by a hexa-
histidine tag (Zenonos et al. 2014; Crosnier et al. 2013). Plasmids were transformed 
into One ShotTM TOP10 Chemically Competent E. coli culture (Invitrogen) and 
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incubated overnight in LB broth media (BD) supplemented with ampicillin sodium salts 
(Sigma). Subsequently, amplified plasmids were purified using the Qiagen Plasmid 
Mini kit. The purified plasmid DNA was assessed for quantity and quality by measuring 
the absorbance at 260 nm (A260) and 280 nm (A280) using a Nanodrop 
spectrophotometer (ThermoFisher Scientific).  
 
2.14 Transient transfection of protein expression plasmids 
The recombinant protein expression plasmids were transiently transfected using 
human embryonic kidney Expi293 cells. Briefly, cells were split into 30-240 ml of fresh 
Expi293™ expression medium at a density of 2.0 ×106 cells/ml. Density and viability 
were determined by staining the cells with 0.4% trypan blue stain (Life technologies) 
and placing them in the cell counting chamber slide (Invitrogen) followed by counting 
using the countess automated cell counter (Invitrogen). Only cells with viability of 
higher than 85% were used for transfection. For each 30-mL transfection or an 
adjusted volume depending on the protein quantity required, the preparation was done 
as follows. Plasmid DNA was diluted in 1.5ml of Opti-MEM® I Reduced Serum Medium 
and mixed gently. A volume of 80ul of ExpiFectamine™ 293 Reagent were added to 
1.5ml Opti-MEM® I medium and mixed gently. Diluted DNA and ExpiFectamine™ 293 
Reagent were incubated separately for 5 minutes at room temperature. Diluted DNA 
and diluted ExpiFectamine™ 293 reagents were then mixed and incubated for 20 
minutes at room temperature so that the DNA-ExpiFectamine™ 293 Reagent 
complexes could form, and finally, the complexes were added to the flasks containing 
viable cells. After 16-18 h incubation in a humidified incubator with 8% CO2 and an 
orbital shaker platform, a mixture of 150 µL of ExpiFectamine™ 293 Transfection 
Enhancer 1 and 1.5 mL of ExpiFectamine™ 293 Transfection Enhancer 2 were added 
to the flask. The protein was harvested six days post-transfection. 
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2.15 Purification of His-tagged recombinant proteins using Ni-NTA Purification 
System 
His-tagged proteins were purified using Ni2+NTA resins (novex, life technologies) 
according to the manufacturer’s instructions with slight modifications. Briefly, the Ni-
NTA resin was prepared by centrifuging the required amount of resin at 800rpm at 4oC 
for 5 minutes. The supernatant was discarded, and the resin underwent 3 washing 
steps with distilled water. For the final washing a 1X native binding buffer with 
imidazole was used. In a 50ml culture supernatant, 50 µL of Nickel(ll) chloride were 
added together with the resin. The mixture was incubated at 4oC overnight while 
rotating. To purify the proteins, the mixture (resin with Nickel (ll) chloride and harvested 
culture supernatant) was centrifuged at 800rpm for 10 minutes at 4oC and supernatant 
removed, and the resin transferred to the filter columns (Qiagen). The resin was 
washed 3 times with native wash buffer. The proteins were eluted using native elution 
buffer and quantification of the expressed proteins was performed using Pierce BCA 
Protein Assay Kit (Thermo Fisher Scientific). 
 
5X Native purification buffer 
250mM sodium phosphate monobasic 7g 
2.5M NaCl 29.2g 
Water 
pH 8.0 
1X Native purification buffer 
5X native purification buffer 
Water 
pH 8.0 
 
Native binding buffer 
With Imidazole  
1X Native Purification Buffer 
3 M Imidazole, pH 6.0 
pH 8.0  
 
Native wash buffer 
1X Native Purification Buffer 
20mM Imidazole, pH 6.0 
pH 8.0  
 
Native elution buffer 
1X Native Purification Buffer 
3 M Imidazole, pH 6.0 
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pH 8.0  
 
2.16 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was 
carried out based on the method described by Laemmli (Laemmli, 1970). Samples 
were mixed with reducing sample-buffer (β-mercaptoethanol) and Tris-glycine SDS 
sample buffer (Novex by Life Technologies) in a 1:1 ratio and boiled for 5 min at 95 °C 
in a heating block. Samples were also run under non-reducing conditions depending 
on the aim of the experiment. Freshly prepared 10% resolving gels and 2% stacking 
gels using proto-gel quick cast (National Diagnostics) were used for all experiments. 
A prestained broad range protein ladder (Page Ruler plus, Fermentas) was used as a 
size standard. Gels were electrophoresed in running buffer at a maximum voltage of 
140V for 1h. Staining was carried out for 5 min using instant blue (Expedeon). 
 
2.17 Western blotting  
Western blotting was applied: to confirm the presence/absence and quality of the 
expressed recombinant merozoite proteins; to test merozoite interaction with FH and 
to determine complement activation by merozoites leading to C3b formation. 
Depending on the experimental goal, samples were mixed with reducing sample buffer 
(β-mercaptoethanol) in a ratio of 1:1 and heated for 10 minutes at 60°C. The samples 
were fractionated by 12% SDS-PAGE under reducing conditions (140V for 1hr). Wet 
(tank) transfers were conducted to transfer the separated proteins from the gel onto 
an activated nitrocellulose membrane (activation was done using 100% methanol for 
30 sec followed by soaking in transfer buffer).  
 
Pre-soaked sponge pads, blotting paper, resolved SDS gel, PVDF membrane, blotting 
paper, and additional pre-soaked sponge pads were assembled in that order on the 
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cathode core of the XCell II Blot module (Invitrogen) and sealed and assembled onto 
the X-cell Surelock mini-cell system. The blot module was filled with transfer buffer and 
an outer chamber filled with distilled water or ice. Transfer was done at 100V for 45 
minutes. Following transfer, the PVDF membrane was incubated with 4% Blotto, non-
fat dry milk (Santa Cruz Biotechnology) prepared in TBS-T for 1 h. The membrane was 
then incubated with the primary and secondary antibody with in-between washes using 
TBS-T. Detection was done using Novex® ECL Chemiluminescent Substrate 
(ThermoFisher Scientific). 
 
2.18 Mass spectrometry 
Mass spectrometry technique was used to confirm the identity of the recombinantly 
expressed proteins. Briefly, proteins were treated with dithiothreitol (DTT) and 
iodoacetamide followed by trypsin digestion overnight at 37oC. The peptides were then 
purified using C18 Zip-Tips (Millipore, Germany) and injected into the liquid 
chromatography-mass spectrometry Q Exactive. Peptide identification was done using 
MASCOT search engine against the combined database of PlasmoDB. 
 
2.19 ELISA binding assay using polyclonal anti-FH antibody (“Kilifi ELISA 
binding assay”) 
To narrow down merozoite proteins that interact with FH, a library of recombinant 
merozoite proteins (over 100 proteins) was systematically screened using an ELISA 
binding assay developed at Kilifi (also referred to as “Kilifi ELISA binding assay”). The 
assay was performed as follows. Individual 96-well plates, Dynex 4HBX Immunolon 
plates (Dynex Technologies Inc.), were coated with a starting concentration of 128 
μg/ml or less of the recombinant proteins, followed by a twofold serial dilution in 100 
µL of carbonate coating buffer. The plates were incubated overnight at 4oC before 
washing four times with PBS/ 0.05%Tween (PBS-T; also called wash buffer). The 
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plates were then blocked using 1% skimmed milk in wash buffer and incubated at room 
temperature for 5 hours.  
 
After another round of four times washing with PBS-T, the plates were incubated with 
100 µL of FH (Calbiochem) diluted at 0.42 ng/mL in blocking buffer and incubated 
overnight at 4oC. Plates were washed four times again and incubated for three hours 
at room temperature with 100 µL anti-Factor H Goat pAb (Calbiochem, USA) at 1/2500 
in blocking buffer. Plates were again washed followed by addition of 100 µL of 
Horseradish Peroxidase (HRP) conjugated donkey anti-goat IgG antibody, (Chemicon, 
USA) at 1/5000 in blocking buffer and incubated at room temperature for three hours. 
A final wash was done followed by detection using o-phenylenediamine 
dihydrochloride (OPD) (Sigma). The reaction was stopped with the addition of 25 µL 
of 2M H2SO4 per well and absorbance read at 492nm. 
 
Coating buffer (Carbonate buffer pH 9.4-9.6) 
1.59g Na2CO3 
2.93g NaHCO3 
1L distilled water 
 
 
2.20 ELISA binding assay using monoclonal anti-FH antibody (“Helsinki ELISA 
binding assay”) 
 
The ELISA binding assay developed in Kilifi (“Kilifi ELISA binding assay”) had some 
limitations discussed later in chapter three. I, therefore, improved this assay in Helsinki 
(also referred to as “Helsinki ELISA binding assay”) by using different buffers and 
detection antibodies. “Helsinki ELISA binding assay” was conducted as follows. 
Recombinant merozoite proteins or Cd4 tag (16 ug/ml) in coating buffer (carbonate 
buffer pH 9.4) were coated onto MaxiSorp microtiter plates (Nunc) at 4°C overnight. 
After washing three times using 1X PBS-T blocking was done using 1% BSA in 1X 
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PBS-T for 1 hour followed by addition of  FH (Calbiochem) in 0.1% BSA in 0.25X 
VBS++ was added and another round of incubation for 1 hr and after that washing was 
done with PBS-0.01% Tween. Afterwards monoclonal anti-FH antibody (isotype 
IgG2bk; clone 131X, directed against CCP8-15) diluted at (1:500 0.1% BSA in 0.5X 
VBS++) was added and after an hour of incubation HRP rabbit anti-mouse antibody 
(at 1:2000 in 0.1% BSA in 0.5X VBS++) was added. The reaction was developed with 
OPD (Sigma) and stopped by the addition of 25 µL of 2M H2SO4 per well and 
absorbance read at 492nm. 
 
5X VBS buffer 
83.0 g NaCl 
10.19 g Sodium 5,5-diethylbarbiturate 
Water 
Adjust pH to 7.3 
 
2.21 Surface plasmon resonance 
Surface plasmon resonance (SPR) is a label-free, real-time method that allows the 
determination of the affinity and kinetics of a wide range of molecular interactions (such 
as protein-protein interactions, DNA-DNA, DNA-protein, lipid-protein) (Cooper 2002). 
It remains the gold standard for measuring protein-protein interactions (Yang et al. 
2016) and is extensively applied in multiple stages of drug discovery and development 
(Myszka and Rich 2000). The main advantage of SPR is that it allows highly sensitive 
measurement of low-affinity interactions among macromolecules that could otherwise 
be missed if using other techniques (Hoffrogge et al. 2003; Hornemann et al. 2003). 
SPR can also be used as a confirmatory test downstream of an avidity-based 
extracellular interaction screen (AVEXIS) (Crosnier et al. 2011; Dundas et al. 2018) 
and yeast two-hybrid screen (Hoffrogge et al. 2003; Hornemann et al. 2003). For this 
study, SPR was used to confirm the interaction observed with the “Helsinki ELISA 
binding assay.” The SPR experiments were all conducted using a Biacore T100 and 
the amine coupling kit (GE Healthcare). 
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2.21.1 Buffer exchange for the recombinant merozoite proteins 
Before running the merozoite recombinant proteins on the SPR platform, buffer 
exchange was performed to allow for compatibility with the SPR buffers. Zebra spin 
desalting columns (Thermo Scientific) were used for buffer exchange. Briefly, the 
procedure entailed inverting the spin column to suspend the slurry, removing the cap 
of the column, placing the column in a 1ml microcentrifuge collection tube. The 
columns were centrifuged at 1500g for one minute. The flow-through discarded and 
300ul of 0.5X VBS++ added for a three times wash. 40-100ul of the recombinant 
antigen was added and collected in a new centrifuge tube after spinning at 1500 g for 
2 minutes. The eluted protein was quantified using a Nanodrop spectrophotometer 
(ThermoFisher Scientific).  
 
2.21.2 Ligand immobilization 
Human complement factor H (FH) (Calbiochem) and FH fragments produced in-house 
at Prof Seppo Meri’s laboratory at the University of Helsinki were immobilized onto flow 
cells in the CM5 sensor chip using a standard amine coupling protocol Figure 2.4. 
First, the carboxyl groups on the sensor surface were activated by injecting a fresh 
mixture of (1-ethyl-3-3-dimethylaminopropyl) carbodiimide (0.4M) mixed 1:1 with N- 
hydroxysuccinimide (0.1M). Second, FH or FH fragments prepared at 30 mg/mL in 10 
mM sodium acetate (pH 4.5) were injected over the activated surface, to allow for 
covalent attachment through their primary amines. Lastly, the excess reactive esters 
were blocked with 1 M ethanolamine, a process called regeneration. The goal of 
regeneration is to elute any non-covalently bound analyte without disrupting the activity 
of the ligand. Regeneration allows the sensor chip flow cell to be reused many times 
(Mullett et al. 2000; Ahmed 2008; Drescher et al. 2018). Each step was performed with 
a 7-min injection at a 5 ml/min flow rate. Flow cell one was left blank to provide a 
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reference surface. In a typical SPR experiment what is immobilized is called a ligand 
and the analytes (i.e. the samples) are injected into. 
 
  
Figure 2.4 Schematic of a typical amine coupling of ligands to the sensor chip.  
Activation of the dextran matrix on the sensor chip is done using a mixture of 1-ethyl-3- (3- 
dimethylaminopropyl) carbodiimide (EDC) and N- hydroxysuccinimide (NHS) to expose the reactive 
esters. When the ligand is passed over the surface and the esters react spontaneously with amino 
so that the ligand covalently attach to the matrix. After injection of ligand, ethanolamine is passed 
over the sensor surface to deactivate remaining active esters.  
 
 
2.21.3 Analysis of protein-protein interactions by using CM5 sensor chip 
Analysis of protein-protein (FH-merozoite proteins) interactions was conducted as 
follows. The CM5 sensor chip was docked on the Biacore T100 instrument and after 
immobilization of the ligand (FH) as stated above, 0.5 uM of the analyte (recombinant 
merozoite proteins) prepared in running buffer (10mM HEPES pH7.4, 150 mM NaCl, 
0.005% Tween20) were injected into the experimental and reference flow cells at a 
flow rate of 20 ul/ml. For each experiment, a blank flow cell was used as the reference 
surface. The NaCl solution (1 M) was used to regenerate the surface after each 
injection cycle. All buffer solutions were freshly prepared, degassed, and passed 
through a 0.22 mm pore size filter. Results were analyzed using the BiaEvaluation 
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software (GE Healthcare). An example of the expected real-time SPR response data, 
which is referred to as a sensorgram is illustrated in Figure 2.5. 
 
Figure 2.5. Schematic of a typical surface plasmon resonance sensorgram.  
Before injecting an analyte, the baseline response should be stable. An increase in response during 
the association phase represents protein-protein interaction. Equilibrium is achieved when an equal 
number of analyte molecules associate with and dissociate from the surface at the same time. After 
washing the surface, the decay rate of the complex can then be obtained during the dissociation 
phase. Following regeneration, the binding response should return to the initial baseline position. 
Figure adapted from (Myszka and Rich 2000). 
 
2.22 Protein microarray 
Antibody responses to merozoite FH receptor proteins were analyzed using KILchip 
v1.0 protein microarray (Kamuyu et al. 2018). Briefly, each well in the slide wa washed 
3 times with 250 µL of wash buffer 1 with a 5-minute incubation following each wash. 
The wells were additionally washed 3 times with 250 µL wash buffer 2. Non-specific 
binding was blocked using blocking buffer for 2 hours at room temperature in the dark 
while rotating. Wells were then washed 3X with 250 µL of wash buffer 1 with a 5-minute 
incubation followed by a single wash in wash buffer 2. Serum was then added to the 
wells after a 1:400 dilution in the diluent buffer and incubated overnight at 4°C while 
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rotating. Wells were subsequently washed 3X with 250 µL of wash buffer 1 with a 5-
minute incubation followed by a single wash in wash buffer 2. Afterwards, 150 µL of 
secondary antibody (Donkey anti-human IgG-Alexafluor 647 conjugated) at a 1:400 
dilution in diluent buffer was added. The samples were incubated for 3 hours at room 
temperature while rotating in the dark. After the incubation three washes were 
performed using wash buffer 1 with a 5-minute incubation and subsequently two 
washes with wash buffer 2. Slides were carefully disassembled from hybridization 
cassettes and rinsed using wash buffer 3 in coplin jars. Slides were dried by 
centrifugation using a blotting paper-lined Eppendorf combiSlide adapter for 5 minutes 
at 300g. Finally, slides were scanned using a genepix 4000B scanner coupled to 
GenePix pro7 Microarray acquisition and analysis software. Data processing and 
further analysis were performed in R (R Core Team, 2013). Figure 2.6 illustrates the 
steps involved in the microarray experiment.  
 
 
Figure 2.6. Overview of protein microarray procedure  
After initial washing and blocking, serum is added to the wells and incubated overnight at 4°C while 
rotating followed by additional washing steps. Thereafter a secondary antibody (donkey anti-human 
IgG-Alexafluor 647-conjugated) is added. After another round of washing the slides are scanned 
using genepix 4000B scanner coupled to GenePix pro7 Microarray acquisition analysis software and 
data analyzed using R (R core Team (2013)). 
 86 
10X HEPES buffer saline (HBS) buffer 
1.4M NaCl, 50mM KCl, 20mM CaCl2, 10mM MgCl2, 100mM HEPES  
 
Wash buffer 1 
0.1 % Tween 20/1X HBS  
 
Wash buffer 2 
1 X HBS  
 
Wash buffer 3 
MilliQ water 
 
Block and diluent buffer 
2% IgG free Bovine Serum albumin (BSA)/0.1 % Tween 20/ 1X HBS 
 
2.23 Quantification of the soluble terminal complement complex (sC5b-9)  
To determine the level of complement activation in children with severe malaria and 
uncomplicated malaria, MicroVue sC5b-9 Plus Enzyme Immunoassay kit (Quidel) was 
used. The kit measures the concentration of soluble terminal complement complex 
(sC5b-9) hence showing the status of the terminal complement pathway in the 
analyzed specimen. The plates come coated with a monoclonal antibody to the C9 
ring of the sC5b-9 to capture the complex. The trapped sC5b-9 is subsequently 
detected with HRP-conjugated antibodies that bind to antigens of the sC5b-9 complex. 
All the experiments were conducted according to the manufacturer’s instructions. 
 
2.24 ELISA for TCC activation by merozoites 
Potential merozoite-dependent activation of complement leading to terminal 
complement complex formation (TCC) was tested (Rosa et al., 2015).  Merozoites 
were incubated with cell culture medium containing 20 vol% NHS or HIS for 1 hr at 
37oC (Rosa et al. 2015b). The merozoites were spun down, and supernatant collected 
for TCC quantification using MicroVue sC5b-9 Plus Enzyme Immunoassay kit (Quidel, 
USA) following the manufacturer’s instruction. Absorbance at 450 nm was measured. 
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2.25 Quantification of FH using ELISA 
FH was measured using an available commercial kit, MicroVue Factor H EIA (Quidel, 
USA). The kit is a three-step procedure utilizing: a micro assay plate coated with a 
monoclonal antibody that binds specifically to human Factor H Figure 2.7; an HRP-
conjugated murine anti-human Factor H; and a chromogenic substrate. The kit comes 
complete with standards of known concentrations and controls. The specimen diluent 
was applied to select few wells as blanks, to control for background. Serum samples 
were suspended in specimen diluent kit buffer and the procedure then followed the 
manufacturer’s instructions. OD was measured for absorbance at 450 nm. Due to the 
cross-reactivity of FH with other FH related proteins (Józsi et al. 2018) the kit uses 
antibodies that are very specific for FH, shown in Figure 2.7.  
 
 
Figure 2.7. FH and FH related proteins  
Circled in red are the specific regions that are targeted by antibodies of the  MicroVue Factor H 
EIA kit (Quidel, USA). Figure adapted from Józsi et al. 2018. 
 
2.26 DNA extraction 
Archived EDTA blood samples (stored at -80oC) were used to extract DNA using the 
QIAmp DNA blood kit (Qiagen). Due to the limited available starting materials for some 
samples, adjustments were made to extract from 10 µL of the EDTA blood samples. 
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The sample volume was topped up to 50ul using 1X filtered sterile PBS. 10ul of 
proteinase K and 50ul of buffer AL were added, vortexed and incubated at 56oC for 10 
minutes. After the addition of 50ul of 100% ethanol, the contents were transferred to 
QIAamp Mini spin column, washed twice and eluted in 40uL of buffer AE. DNA material 
was quantified using Nanodrop. 
 
2.27 Polymerase chain reaction  
The Polymerase Chain Reaction (PCR) was performed in order to genotype the Y402H 
variant in the severe malaria cohort. The T to C transition at nucleotide position 1277 
in exon 9 of complement factor H results in a tyrosine to histidine substitution at codon 
402 of the protein (Rodríguez De Córdoba et al. 2004). PCR was performed with the 
use of 5’- TCATTGTTATGGTCCTTAGGAAA -3’ as the forward primer and 5’- 
TTAGAAAGACATGAACATGCTAGG-3’ as the reverse primer (Lau et al. 2006). The 
composition of a typical 10 µL PCR reaction using the ExpandTM High Fidelity PCR 
System (ThermoFisher Scientific) is shown in Table 2.3 while the standard cycling 
parameters are shown in Table 2.4. 
 
Table 2.3. Composition of a typical PCR reaction 
Ingredients  10ul reaction 
Mix1 
dH2O 2.7 µL  
dNTPs 0.2 µL  
MgCl2 1.0 µL  
Forward primer 0.3 µL (10 pmol) 
Reverse primer 0.3 µL (10 pmol) 
Mix 2 
dH2O 3.86 µL  
Expand High Fidelity Buffer (10×) 
with 15 mM MgCl2 
1.0 µL 
Expand High Fidelity Enzyme  0.14 µL 
DNA 0.5 µL 
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Table 2.4. Standard PCR cycling parameters 
Step Temperature Duration No. of cycles 
Initial melting 94oC 2 min 1 
Melting 94oC 15 sec 35 
Annealing 56oC 30 sec 
Extension 72oC 1 min 
Final extension 72oC 7 min 1 
 
 
2.28 Agarose gel electrophoresis 
Generated PCR products were analyzed by agarose gel electrophoresis. Two percent 
of agarose gels were prepared in 1X 0.5% TBE buffer (Invitrogen). After cooling Red 
Safe (iNtRON Biotechnology) was added into the melted agarose for visualization of 
the DNA under ultraviolet (UV) light.  The set gels were run in TBE buffer after samples 
were loaded with loading dye (6x from NEB). Gels were run at 90-100V for 
approximately an hour. The DNA was visualized using the Molecular Imager 
ChemiDox XRS imaging system (BioRad).  
 
2.29 Sequencing for Y402H positive variants 
Products of PCR reaction were cleaned up using ExoSAP-IT (Affymetrix) in order to 
remove unused primers and nucleotides. Five microliters of the post-PCR reaction 
product were added with 1ul of ExoSAP-IT. This was followed by an incubation at 37oC 
for 20 minutes to degrade remaining primers and nucleotides and an additional 
incubation at 80oC for 20 minutes to inactivate ExoSAP-IT reagent. The cleaned PCR 
products were diluted by addition of 45ul of PCR water (SIGMA-ALDRICH). The cycle 
sequencing reaction was then set up. Table 2.5 below shows the reaction volumes per 
sample and Table 2.6 shows the cycling conditions. 
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Table 2.5. Composition for the cycle sequencing reaction 
Ingredients  Reaction vol. (µL) 
Big dye enzyme mix 0.5 µL 
5X BigDye sequencing buffer 1.75 µL 
dH2O 4.75 µL 
DNA PCR product 1.0 µL  
Forward primer 1.0 µL (5 pmol) 
Reverse primer 1.0 µL (5 pmol) 
 
Table 2.6. Cycle sequencing PCR thermal cycling condition 
Step Temperature Duration No. of cycles 
Initial melting 95oC 30 sec 1 
Melting 95oC 10 sec 25 
Annealing 50oC 0.05 sec 
Extension 60oC 4 min 
Final extension 15oC 7 min 1 
 
 
To remove excess dye terminators, cycle sequencing PCR products, ethanol/EDTA 
precipitation was executed. Briefly, 1ul of 125mM EDTA (Sigma) and 1ul 3M sodium 
acetate were added to the cycle sequencing PCR product. After incubating for 15 
minutes, the samples were centrifuged/spun at maximum speed for 20 minutes at 
20oC. The plates were gently inverted on a paper towel in order to drain off the 
supernatant and spinning was done briefly at 400rpm for one minute to ensure 
complete drain off. Next, 100ul of 70% ethanol was added to each sample well and 
centrifugation done at a maximum speed of 20oC for 5 minutes. Supernatant was 
drained off and the plates were left to air dry at room temperatures for 30 minutes. Hi-
Di at 10ul was then added and samples were denaturated at 95oC for 3 minutes. 
Capillary electrophoresis was done in the ABI 3130xL (Applied Biosystems). 
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2.30 Human Complement Factor H, 402H variant detection using ELISA 
In addition to sequencing, ELISA was implemented to detect the 402H or Y402 variant 
using Factor H, 402H/Y variant detection, Human, ELISA kit (Hycult Biotech). This was 
possible due to the availability of paired EDTA blood and heparin serum samples for 
most of the severe malaria hospital case-control subjects. The ELISA is based on a 
sandwich principle in which the plates come coated with a monoclonal antibody to the 
402H or Y402 variants, and the samples are incubated together with the peroxidase-
conjugated antibody. The conjugated antibody binds to the captured factor H variants 
and tetramethylbenzidine (TMB) substrate is used for detection. Absorbance was read 
at 450 nM. 
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CHAPTER THREE 
3 Multiple blood stage Plasmodium falciparum merozoite antigens interact 
with human complement factor H and may facilitate complement evasion 
 
3.1 Summary and aims 
In this chapter, I sought to identify merozoite proteins other than the previously 
described Pf92 (Kennedy et al. 2016) that interact with human complement regulatory 
protein factor H and may, therefore, allow Plasmodium falciparum to evade 
complement-mediated destruction. To achieve this, I used two techniques: i) a 
modified ELISA binding assay and ii) surface plasmon resonance (SPR), to screen 
over 100 recombinant merozoite proteins. The merozoite proteins have previously 
been described (Crosnier et al. 2013; Zenonos et al. 2014; Kamuyu et al. 2018) and 
were part of a larger study to define antibody targets of protective immunity led by Prof 
Faith Osier. Thereafter, I localized the binding sites of these proteins in FH and 
subsequently used a modified growth inhibition assay to assess the significance of the 
interaction between FH and the malaria parasite. For the modified ELISA binding 
assay and SPR, I used Pf92 (Kennedy et al. 2016) as the positive control and Cd4 tag 
(present in each antigen) as the negative control.  
 
3.2 Introduction 
Malaria remains among the leading causes of childhood morbidity and mortality 
globally (WHO 2018b). Scaling up of malaria control interventions such as insecticide-
treated bed nets (ITNs), indoor residual spraying (IRS), larvicides, chemoprophylaxis 
and artemisinin-based combination therapies has led to reduction in malaria-
associated hospitalization and deaths (Bhatt et al. 2015; WHO 2015; Murray et al. 
2012; Ceesay et al. 2008; O’Meara et al. 2008; Aregawi et al. 2011). However, these 
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gains may be thwarted by the rapid spread of antimalarial drug resistance (Ashley et 
al. 2014). The most advanced malaria vaccine, RTS,S is only partially protective 
against disease, and the obtained immunity wanes over time (White et al. 2015). 
Therefore, designing the next second-generation vaccine will benefit from 
understanding how to interrupt the complex parasite life cycle and the discovery of new 
vaccine targets. 
 
Complement forms part of the innate immune system and consists of a tightly regulated 
network of proteins that are important in host defense and inflammation. Complement 
activation results in opsonization of target microbes and their subsequent removal by 
phagocytosis, as well as cell lysis (Sarma and Ward 2011). There are three established 
mechanisms of complement activation: classical, lectin, and alternative pathways. All 
the three pathways converge on the C3 molecule, where activation leads to covalent 
deposition of the opsonins C3b and iC3b, generation of inflammatory anaphylatoxins 
C3a and C5a and formation of the membrane attack complex (Lambris et al. 2008; 
Dunkelberger and Song 2010). Under normal circumstances, activation of complement 
is controlled by the coordinated action of soluble (e.g. C1-INH, C4bp, factor H, factor 
I, S-protein and clusterin) and membrane-associated (DAF, CR1, MCP, CRIg, and 
CD59) complement regulatory proteins (Lambris et al. 2008; Serruto et al. 2010). 
Complement regulation ensures that activation is focused on surfaces of invading 
microorganisms and, on the other hand, limited against host cells and tissues (Walport 
et al. 2010). 
 
Pathogens exploit multiple strategies to interfere with complement immune recognition 
and effector functions (Zipfel et al. 2007; Blom et al. 2009). A common strategy 
employed by many pathogens for immune evasion is the hijacking of human 
complement regulatory proteins such as FH, essential for alternative pathway 
regulation and C1- esterase inhibitor (C1-INH) that regulate both the classical and the 
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lectin pathways. Once they recruit the complement regulatory proteins to their 
surfaces, microbial surfaces disguise themselves as “self” and are protected from 
complement activation and amplification. Identifying pathogen proteins that act to 
inhibit complement activation can lead to the discovery of new vaccine antigens and 
enhance our understanding of pathogen biology. 
 
Recent studies suggest that Plasmodium falciparum avoids complement activation by 
recruiting complement regulatory proteins C1-INH (Kennedy et al. 2017) and FH 
(Simon et al. 2013; Rosa et al. 2015; Kennedy et al. 2015; Simon et al. 2018). It has 
been suggested that merozoite proteins actively recruit C1-INH to their surfaces, 
allowing the parasite to limit the alternative and the classical pathway proteases and 
hence avoid downstream complement activation (Kennedy et al. 2017). PfMSP3.1 was 
identified as the C1-INH interacting partner. Interestingly, although PfMSP3.1 parasite 
knockouts showed reduced C1-INH recruitment and increased C3b deposition, which 
would imply that they were more susceptible to complement-mediated killing, the 
knockout paradoxically had enhanced red blood cell invasion in the presence of active 
complement (Kennedy et al. 2017). More studies are needed to interrogate the host 
benefit of pathogen recruitment of regulatory proteins. However, parasite hijacking of 
FH for immune evasion has recently gained prominence.  
 
During the mosquito stage of development, Plasmodium falciparum gametes recruit 
factor H (from the human blood ingested during a blood meal) to their surface to evade 
human complement attack within the mosquito midgut. Gamete surface protein GAP50 
binds factor H (FH) and uses bound FH to inactivate the complement protein C3b. 
Furthermore, a monoclonal antibody directed against GAP50, when taken with the 
infected blood meal, led to impaired gametogenesis and blocked parasite transmission 
to the mosquito, pointing to the possibility of using GAP50 as a potential transmission-
blocking vaccine candidate (Simon et al. 2013). Additionally, the Anopheles mosquito 
 95 
midgut cells protect themselves from active complement in the blood meal by capturing 
factor H. Factor H inhibited complement on the midgut cells by promoting inactivation 
of C3b to iC3b and preventing the activity of the alternative pathway amplification C3 
convertase enzyme. Interference of the FH regulatory activity by monoclonal 
antibodies, carried to the midgut via blood, resulted in increased mosquito mortality 
and reduced fecundity (Khattab et al., 2015). The study by Khattab et al. also identified 
a hitherto unknown mosquito midgut FH receptor (Khattab et al., 2015) that warrants 
further investigation. 
 
Within the human host, there is evidence that intraerythrocytic schizonts and free 
merozoites bind FH and FH-like protein (FHL-1) to their surfaces. This binding 
inactivates C3b to ensure survival during the erythrocytic replication phase (Rosa et 
al. 2015). Indeed, of all the parasite asexual stages, free merozoites and intracellular 
mature schizonts have been shown to significantly bind more FH molecules than 
trophozoites and rings (Simon et al. 2018). So far only merozoite protein Pf92 has 
been characterized as the protein responsible for interaction with FH. Deletion of the 
Pf92 gene led to somewhat increased complement-mediated destruction of 
merozoites (Kennedy et al. 2016). I hypothesized that more merozoite proteins are 
involved in complement evasion. 
 
3.3 Specific aims 
a) Expression of a library of recombinant merozoite proteins 
b) Develop an ELISA-binding assay to test for binding between FH and 
merozoite proteins 
c) Use Surface Plasmon Resonance (SPR) to confirm the binding observed in 
(b) above 
d) Localize the FH CCP modules involved in binding 
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e) Demonstrate the consequences of the binding 
 
3.4 Materials and methods 
To determine which merozoite proteins interact with human complement FH for 
parasite survival during asexual blood stage, recombinant proteins were expressed, 
and a modified ELISA binding assay used to down-select antigens that bound to FH. 
The initial modified ELISA binding assay (also referred to as the Kilifi binding assay) 
was used to screen over 100 proteins. However, the Kilifi ELISA binding assay had 
some limitations and was subsequently modified. This latter assay is referred to as the 
Helsinki ELISA binding assay. Surface Plasmon Resonance (SPR) was used to 
confirm the interactions observed with the Helsinki ELISA binding assay. Both the 
modified ELISA binding assays and SPR are described in detail in the materials and 
methods chapter section 2.19, 2.20 and 2.21.  
 
Previous studies that identified merozoite receptors, Pf92 and MSP3  as antigens that 
interact with complement regulatory proteins FH and C1-INH  respectively, used pull-
down assays, co-immunoprecipitation, followed by identification using mass 
spectrometry (Kennedy et al. 2015, 2017). The same methods were used to identify 
PfGAP50 as a gamete protein receptor for FH (Simon et al. 2013) during parasite 
sexual stage development in the mosquito. I used modified ELISA binding assay and 
SPR as these techniques would allow me to test each antigen for interaction with FH 
individually.  
 
Similar approaches have been used to detect interacting partners between proteins. 
Galaway et al. used Avidity-based Extracellular Interaction Screen (AVEXIS) to screen 
a library of recombinant merozoite proteins and showed that P113 binds to the N-
terminal domain of RH5, RH5Nt (Galaway et al. 2017). Furthermore, SPR was used 
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to quantify the biophysical properties of P113 and RH5Nt (Galaway et al. 2017). 
AVEXIS uses the same principle as the ELISA binding assay, but the only difference 
is that in the former the recombinant proteins need to be produced in two forms; as a 
biotinylated bait and a pentamerized enzyme-tagged prey (Kerr and Wright 2012). 
Other examples include the use of an ELISA binding assay to demonstrate that RH4 
bound better to CCP1-3 compared to CCP10-11, 15-17, 21-22 and 15-25 of CR1 
(Tham et al. 2011) and the mapping of the binding site of vitronectin to peptide 
fragments of SERA5 (Tou et al. 2018).  
 
Multiple alignment of merozoite antigens that bound well to FH was done using 
MUSCLE software https://www.ebi.ac.uk/Tools/msa/muscle/ to determine whether 
there are shared motifs within the amino acid sequences of these antigens. 
 
3.4.1 Statistical analysis 
Spearman correlations were calculated using the GraphPad Prism (San Diego, CA, 
USA) version 7. Surface Plasmon Resonance (SPR) data were analyzed using 
BIAevaluation software (GE Healthcare).  
 
 
3.5 Results 
3.5.1 Merozoites activate complement causing deposition of C3b and TCC 
formation 
During the asexual stage parasite development, malaria antigens either on infected 
red blood cells, antigens released during schizont rupture or membrane-bound 
organelles containing malaria pigment hemozoin (digestive vacuoles) can all activate 
complement (Greenwood and Brueton 1974; Glew et al. 1975; Adam et al. 1981; 
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Dasari et al. 2012). I determined whether merozoites specifically activate complement 
causing C3b deposition Figure 3.1 A, which can lead to the formation of the terminal 
complement complex (TCC). Merozoites were prepared as described in (Boyle et al. 
2010b). They were then incubated with normal human serum (NHS), or heat-
inactivated complement/serum (at 56oC for 30 minutes) or using EDTA of 500 mM or 
125 mM concentration. Merozoite incubation in PBS was used as a negative control. 
After incubation for one hour at 37oC, the pellet was tested for C3b deposition using 
Western Blotting under reducing conditions while the supernatant was tested for TCC 
formation using a commercial ELISA kit (Quidel).  
 
Complement C3b and its breakdown product iC3b containing fragments α’1 and α’2 
were observed to accumulate on the merozoites in the presence of active complement 
(NHS). C3b accumulation was not observed in the negative control Figure 3.1 B. A 
previous study had observed that indeed C3b gets deposited on the merozoites, but 
its binding was reduced in HIS and completely absent when complement was 
inactivated by 10 mM EDTA (Kennedy et al. 2015). To interrogate the results further, I 
used schizonts to test whether they could also activate complement and lead to C3b 
formation, and whether there could be differences between C3b deposition in NHS or 
HIS. I observed no differences in C3b deposition on schizonts whether using NHS or 
HIS, similar to what I found out with merozoites Appendices Figure 3.1. Differences 
in experimental procedures could account for the contradictory results with what was 
seen with Kennedy et al. work.  
 
Merozoites also activated complement and led to TCC formation Figure 3.1 C. Heat 
inactivation of serum to reduce complement activity has traditionally been done in 
various laboratories (Soltis et al. 1979), however, there is no clear evidence to show 
how much of complement activity is reduced by heating per se. I speculate that the 
current observation of C3b deposition and TCC formation might imply that the 
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complement inactivation by heating or treatment with EDTA did not completely reduce 
complement activity. More likely, however, since there was no difference between the 
active and inactivated serum, the result indicates that the merozoites can defend 
themselves against complement attack. 
 
 
Figure 3.1 C3b deposition and TCC formation by merozoites 
(A) Schematic depiction of C3 molecule structure. The polypeptide sizes are: C3 (180 kDa); C3a (9 
kDa); C3b α (109 kDa), β (75 kDa); α’ (101 kDa), α’1 (67 kDa) and α’2 (40 kDa). (B) Merozoites were 
incubated with normal human serum (NHS), heat inactivated serum (HIS) or NHS inactivated using 
EDTA (NHS-E 500 mM or NHS-E 125 mM) at 37oC for 1 hr. The proteins from the pellet were 
washed, and separated on SDS-PAGE under reducing conditions, transferred to an activated 
nitrocellulose membrane and probed for C3b using anti-C3b antibody and HRP detection antibody. 
Merozoite incubation with PBS was used as a negative control. (C) Merozoites were incubated with 
same conditions as (B). The supernatant was used to detect TCC formation using a commercial 
MicroVue sC5b-9 Plus Enzyme Immunoassay kit. 
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3.5.2 Merozoites bind FH from human serum as the complement source 
The previous observation of merozoites resisting activation of complement Figure 3.1 
could imply involvement of FH in order to facilitate the rapid breakdown of C3b, a 
process important for complement immune evasion. To test this assumption, 
merozoites were incubated with 20 vol% normal human serum (NHS), 20 vol% heat-
inactivated serum (HIS), complement inactivated by EDTA (NHS-E) or with PBS and 
incubated at 37oC for one hour. Thereafter the merozoites were washed three times 
and the pellet proteins resolved by SDS-PAGE under reducing conditions followed by 
western blotting. Recombinant FH diluted at 1:400 in sterile PBS was loaded as a 
control. As shown in Figure 3.2 merozoites bound FH from NHS and heat-inactivated 
serum and the band was resolved at the molecular weight of 155 kDa similar to 
recombinant FH. Some studies have suggested that, due to the close similarities 
between FH and FHL-1 (Józsi et al. 2018), pathogens that recruit FH also bind FHL-1 
to their surfaces (Hellwage et al. 2001; Pandiripally et al. 2002). Apparently, the 
sensitivity of the assay used was not high enough to detect the small amount of serum 
FHL-1 or the FH binding proteins bound to domains other than those present in FHL-
1.  
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Figure 3.2 Merozoites recruit FH to their surfaces from human serum. 
Merozoites were incubated with NHS, HIS, NHS-E (500 mM EDTA) or PBS buffer only for one hour 
at the 37 degrees in the incubator. After three washes, the pellet proteins were resolved by SDS-
PAGE and analyzed by western blotting using polyclonal anti-FH antibody and HRP antibody. 
Recombinant FH diluted in 1:400 in sterile PBS was also loaded as a control for the western blotting 
experiment. 
3.5.3 Expression of Plasmodium falciparum merozoite proteins 
The selection of genes of interest, cloning, and production of plasmids has been 
previously published (Kamuyu et al. 2018). The criteria for selection of the proteins 
was based on whether they were known to be on the surface of the merozoites, were 
involved in erythrocyte invasion and had previously been associated with protection 
from malaria. Included on the list were also newly discovered antigens identified using 
a combination of immuno-proteomics and bioinformatics and that have not previously 
been tested in the context of naturally acquired immunity to malaria (Kamuyu et al. 
2018). A complete list of the proteins used in this study is included in Supplementary 
Table 1 of (Kamuyu et al. 2018). Plasmids were already available from a previous 
study (Kamuyu et al. 2018) and I used these to express a selection of proteins. The 
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proteins were expressed using the Expi293 mammalian expression system and 
purified them using Ni-NTA purification system (Novex, life technologies). Figure 3.3 
below shows a western blot for a subset of randomly selected antigens. For some of 
them, 12/29 proteins demonstrated a single, distinct band of expected size, while the 
rest 17/29 had a band of expected size as well as smaller non-specific or degradation 
bands, which are not uncommon (Zenonos 2013). 
 
 
Figure 3.3 A selection of Plasmodium falciparum recombinant merozoite proteins that were 
expressed. 
After expression of Plasmodium falciparum merozoite proteins, they were resolved by SDS-PAGE 
under reducing conditions, wet transferred to an activated nitrocellulose membrane and probed with 
anti-His antibody. Each protein contains a Cd4 tag of approximately 25kDa.   
 
 
3.5.4 Development of the Kilifi ELISA binding assay 
3.5.4.1 Checkerboard titration to optimize antigen coating concentration 
I used an existing ELISA protocol (Osier et al. 2008) to develop the Kilifi ELISA binding 
assay Figure 3.4 A. I began by testing whether there would be recognition of FH by 
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Pf92 as previously shown (Kennedy et al. 2015), and subsequently used this as a 
positive control. The Cd4tag (present in all antigens), a non-parasite antigen, was used 
as a negative control. A checkerboard titration using varying concentrations of antigen 
was performed to determine the optimal concentration. A starting concentration of 128 
ug/ml of Pf92 or Cd4 tag in two-fold dilutions was used. As shown in Figure 3.4 Pf92 
bound to FH in a dose dependent manner and antigen saturation was achieved from 
16 ug/ml. There was low reactivity detected with the negative control.  
  
 
 
Figure 3.4 Binding of FH to immobilized Pf92 occurs in a dose-dependent manner and is 
saturable 
(A) Schematic presentation of Kilifi ELISA binding assay (B) Microtiter wells were coated with Pf92 
or control Cd4-tag. FH was added, and interaction detected using polyclonal anti-FH and HRP-
conjugated antibody.  
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3.5.4.2 Checkerboard titration to optimize FH dilution 
A checkerboard titration was performed to optimize the dilution of FH. The Pf92 and 
Cd4 proteins were immobilized on the microtiter plate. A varying concentration of FH, 
ranging from 0.525-0.131 ug/ml was added. Concentrations of the primary and 
secondary antibodies were kept constant at 38.3 and 0.16 ug/ml, respectively. As 
shown in Figure 3.5, no differential binding was observed in the range of dilutions 
tested for either Pf92 or Cd4 tag. 
 
 
Figure 3.5 Checkerboard titration to optimize FH dilution.  
Pf92 (A) and Cd4 tag (B) was immobilized on microtitrate plate and varying concentration of FH 
tested. The interaction was detected using polyclonal anti-FH and HRP-conjugated antibody  
 
3.5.4.3 Checkerboard titration to optimize primary and secondary antibody dilutions 
A checkerboard titration using varying primary (polyclonal anti-FH) and secondary 
(HRP) antibody were performed to determine the optimal concentrations. The Pf92 
and Cd4 tag proteins were immobilized on microtiter plates. FH was added followed 
by varying primary antibody (starting with 1000 ug/ml) and secondary antibody 
(starting with 0.16 ug/ml). There was reduction in reactivity with reduction of both the 
primary and secondary antibody Figure 3.6.  
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Figure 3.6 Checkerboard titration to optimize antibody dilution for Kilifi ELISA binding assay 
Pf92 (A) and Cd4 tag (B) was immobilized on an ELISA plate. FH was added and varied 
concentration of primary and secondary antibody added. Detection was done using OPD substrate 
and reading done at 492 nm. 
 
In summary, based on the results obtained from Figures, 3.4, 3.5 and 3.6 I used the 
following dilutions for the subsequent Kilifi ELISA binding assay: FH in 1:2500, primary 
antibody 1:2000 and secondary antibody of 1:5000.  
 
3.5.5 Characterizing additional Plasmodium falciparum merozoite antigens that 
bind FH using Kilifi ELISA binding assay 
Although the original publication indicated that Pf92 was the only merozoite protein 
that bound to FH (Kennedy et al. 2016), I hypothesized that the parasite would likely 
have additional proteins that interact with FH as a survival strategy. Having optimized 
the conditions to detect merozoite FH receptors Figure 3.4, 3.5 & 3.6, I therefore 
screened additional antigens to determine which ones bind to FH. An arbitrary cut off 
was used to classify the antigens as high FH binders; those that bound to FH as close 
to or equal to Pf92 (OD 3.64-2.36) Figure 3.7 A; intermediate FH binders bound to FH 
lower than Pf92 and above the negative control of Cd4 tag and have OD reading of 
 106 
2.36-1.20 Figure 3.7 B and low FH binders as antigens that bound to FH as equal to 
the Cd4 tag or lower Figure 3.7 C with OD range of 0.98-0.29. In summary, the Kilifi 
ELISA binding assay identified antigens: PF34, PF3D7_1105800, PF3D7_0629500 
(SEG1), EBA140, AARP, Prohibitin, MSP8 and P12p as probable merozoite FH 
receptors, also termed as high FH binders.  
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Figure 3.7 Differential binding of merozoite proteins to complement regulatory protein FH 
Microtiter wells were coated with merozoite antigens at 128 ug/ml. FH at 1:2500 was added, and 
binding detected using anti-FH (1:2000) and HRP-conjugated antibody at 1:5000. (A) shows 
antigens that recognized FH as well as Pf92 or close to Pf92 also called high FH binders, (B) 
antigens that recognized FH at OD slightly lower than Pf92 but above the Cd4 tag also referred to 
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as intermediate FH binders or (C) antigens whose OD value was equal or lower than Cd4 tag, which 
are referred to as not binding/low FH. The data is representative of two independent experiments. 
3.5.6 Limitations of the Kilifi ELISA binding assay 
One of the major limitations of the Kilifi ELISA binding assay was that FH could not be 
completely titrated out as shown in Figure 3.5 even when using varying concentrations 
of Pf92 Appendices Figure 3.2. To investigate possible explanations, I developed 
another checkerboard titration and tested a range of conditions including: a) no coating 
b) coating no blocking c) coating, blocking (using 1% milk in 1✕PBS-0.005% T), FH 
addition but no primary antibody d) coating, blocking, FH addition, primary antibody 
(anti-factor H goat polyclonal antibody, IgG), no secondary antibody and e) coating, 
blocking, FH addition, primary (anti-factor H goat polyclonal antibody, IgG) and 
secondary antibody. These conditions were first tested for both Pf92 and Cd4 tag 
coated at a constant concentration of 8ug/ml. Figure 3.8 A illustrates the plate map 
for the checkerboard. I observed that blocking did not affect reactivity, but binding 
occurred in the presence or absence of FH Figure 3.8 B and 3.8 C implying direct 
recognition of the Pf92 by the primary antibody. In the absence of primary antibody, 
there was very low, almost background OD reading. 
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Figure 3.8 Limitation of the Kilifi ELISA binding assay.  
(A) Checkerboard titration testing various conditions for the Kilifi ELISA binding assay. (B) and (C) 
no blocking or blocking did not affect OD reading and signal observed both in the presence or 
absence of FH. Circled in red in A is where an OD reading was detected.  
 
 
Next, to check whether the same effect occurred with the other antigens, I tested a 
subset of merozoite antigens that I had in Helsinki under the same conditions but in 
the presence or absence of FH. As shown in Figure 3.9 below, there was no difference 
in reactivity in the presence or absence of FH in the antigens tested still using the same 
anti-factor H goat polyclonal antibody, IgG.  
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Figure 3.9 Polyclonal anti-FH antibody in the Kilifi ELISA binding assay directly recognized 
merozoite antigens 
Antigens at a concentration of 8 ug/ml were coated on the ELISA plates. FH at 1:2500 was added 
and after incubation, polyclonal anti-FH at 1:2000 was added followed by HRP antibody at 1:5000. 
Each antigen was run in duplicate. 
 
3.5.7 Development of the Helsinki ELISA binding assay 
Although the Kilifi ELISA binding assay showed that more merozoite antigens bind to 
FH, the limitations presented above meant that the initial binding experiments were 
inconclusive. I therefore tried to improve this assay by developing a second ELISA 
binding assay, at Prof Seppo Meri’s Complement laboratory at University of Helsinki, 
hence the name Helsinki ELISA binding assay. I began by changing from a polyclonal 
antibody against FH to a monoclonal one. I started off by testing a list of monoclonal 
antibodies 196X, 86X, 3D11 and 131X (Fontaine et al. 1989; Jokiranta et al. 1996; 
Rosa et al. 2015b) that were available in-house for recognition of FH. I included in the 
test the anti-FH polyclonal antibody. Figure 3.10 A below shows the binding sites for 
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the monoclonal antibodies in FH and their reactivity when tested against immobilized 
FH Figure 3.10 B. The results show that polyclonal anti-FH antibody had the highest 
recognition for FH. Monoclonal anti-FH clone 196X and clone 3D11 showed almost 
similar recognition. Monoclonal anti-FH 131X showed the lowest FH recognition. Since 
clone 131X is very specific to FH - its binding sites do not include any regions in FH 
that is closely related to FH like 1 or FH related proteins (CFHR1-5) Figure 3.10 A – 
and it doesn’t bind to regions that have been shown to bind to pathogens such as 
CCP5-7 or CCP 19-20 (Ferreira, Pangburn and Cortés, 2010), I chose to use it in the 
subsequent experiments.  
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Figure 3.10 Recognition of FH by the various monoclonal antibodies and the polyclonal 
antibody 
(A) schematic overview of the various monoclonal antibodies plus the polyclonal antibody on FH 
(Fontaine et al. 1989; Jokiranta et al. 1996; Rosa et al. 2015b) (B) FH at 1 ug/ml was coated unto 
an ELISA plate, various monoclonal/polyclonal antibody was subsequently added and HRP 
conjugated antibody used for detection. Second bar for each sample represents the blank well, 
where no FH was added. 
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Next, I tested various experimental conditions to determine the optimal binding 
between FH and the merozoite proteins. I started by testing, whether the set of 
monoclonal antibodies could recognize Pf92 directly i.e. in the presence or absence of 
FH. As shown in Figure 3.11, only the polyclonal antibody had reactivity in the 
presence or absence of FH confirming that that antibody directly recognized the 
antigen. 
 
 
Figure 3.11 Only the polyclonal anti-FH antibody binds to Pf92 in the presence or absence of 
FH. 
A concentration of 8 ug/ml for Pf92 (A) and Cd4 tag (B) were coated on the ELISA plate and 
incubated overnight. FH in 1:2500 dilution in block buffer (1% milk in 1X PBS-T). Primary 
antibodies were added followed by the secondary antibodies, all diluted in blocking buffer. Washes 
were done using 1 X PBS-0.005%T 
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Next, I tested a series of conditions to determine the optimal reactivity using 
monoclonal anti-FH antibody clone 131X. The optimization included, increasing the 
concentration of FH, changing from PBS-T to using VBS++ buffer, varying the 
concentration of VBS++ buffer and reducing the concentration of PBS-T used for 
washing. Increasing the concentration of FH did not improve the reactivity as the OD 
was very low at 0.15 and there was no distinction between the positive and negative 
control Figure 3.12 A. I reasoned that this could be a low affinity interaction that could 
potentially be improved by a change of buffer. Diluting FH in 0.5X VBS++ buffer 
showed a slight change in OD reading with the negative control now having an OD 
reading of above 0.2, although this was still very low. There was no overlap in OD 
reading at least for FH concentration above 3.75 ug/ml Figure 3.12 B. I observed 
modest increase in OD reading when FH and primary and secondary antibodies were 
diluted in 0.5X VBS++ buffer Figure 3.12 C. The effect was retained even at increased 
concentration of FH Figure 3.12 D.  
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Figure 3.12 Optimization of Helsinki ELISA binding assay. 
(A) Increasing the concentration of FH did not improve binding between FH and Pf92. (B) Dilution 
of FH in 0.5X VBS++ instead of 1 X PBS-0.001% Tween showed slight improvement in OD reading. 
(C) Using 0.5X VBS++ buffer to dilute both FH and antibodies improved the OD reading with a clear 
distinction of positive and negative control at high FH levels. (D) Further increasing the concentration 
of FH and lowering concentration of VBS++ from 0.5X to 0.25X for FH increased OD reading, but 
there was no difference between positive and negative control. Each antigen was run in duplicate. 
 
 
In summary, the main difference between the Kilifi ELISA binding assay and the 
Helsinki ELISA binding assay is that different antibodies against FH were used. The 
binding detected using the monoclonal antibody in the Helsinki ELISA binding assay 
was credible and dependent on FH unlike that by the polyclonal antibody in the Kilifi 
assay. Changing buffers made it possible for the detection of low affinity binding that 
may have been easily overlooked. Table 3.1 summarizes the differences between the 
Helsinki and Kilifi ELISA binding assays. 
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Table 3.1 Differences between Helsinki ELISA binding assay and Kilifi ELISA 
binding assay 
Experimental 
conditions 
Helsinki ELISA binding 
assay 
Kilifi ELISA binding 
assay 
Washing buffer 1X PBS – Tween 20 
(0.01-0.05%) 
1X PBS in 0.05% Tween 
20 
Blocking buffer 1% BSA in 1X PBS 1% skimmed milk in 1X 
PBS-T 
Concentration of FH 
used 
60 ug/ml 0.42 ug/ml 
Dilution buffer for FH 0.1% BSA in 0.25X VBS 
++ 
1% skimmed milk in 1X 
PBS-T 
Primary antibody used Monoclonal anti-FH 
antibody (clone 131X) 
anti-factor H goat 
polyclonal antibody 
Dilution buffer for 
primary and secondary 
antibody 
0.1% BSA in 0.5X VBS 
++ 
1% skimmed milk in 1X 
PBS- 
Time period for the 
ELISA 
One-day ELISA Three-day ELISA 
 
 
3.5.8 Characterizing additional Plasmodium falciparum merozoite antigens that 
bind FH using the Helsinki ELISA binding assay 
Having overcome the challenges of the initial Kilifi ELISA binding assay and developed 
an improved version of the assay, I used the Helsinki ELISA binding assay to screen 
18 merozoite proteins, to determine those that interacted with FH. The proteins 
screened were the same as the top hits on the Kilifi ELISA binding assay; either high 
FH binders or the best of the intermediate FH binders. For the Helsinki ELISA binding 
assay, antigens were defined as high FH binders based on an arbitrary cut off of having 
an OD above the negative control (Cd4 tag). Based on this cut off, merozoite proteins 
PF3D7_ 1105800, PF3D7_ 0206200, PF3D7_0629500 (SEG1), PF3D7_0629500 
(SEG2), RH5, Pf34, EBA140 and P12p showed good binding to FH Figure 2.13. 
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Figure 3.13 Differential binding of merozoite proteins to FH using Helsinki ELISA binding 
assay. 
A concentration of 16 ug/ml of each antigen was coated on an ELISA plate for an overnight 
incubation. The following day the plates were washed using PBS-0.05%T and blocked using 1% 
BSA in 1X PBS for 1hr. FH at 60 ug/ml in 0.1% BSA in 0.25X VBS++ was added and incubated for 
2hr at room temperature, thereafter the plates were washed using 1X PBS-0.05%. Primary antibody, 
monoclonal 131X in 1:500 dilution was added and incubated for 1 hr, followed by rabbit anti-mouse 
IgG HRP. The antibodies were diluted in 0.1% BSA in 0.5X VBS++. After addition of primary and 
secondary antibody washing was done using 1X PBS-0.05% T. Detection was done using OPD and 
the reaction was stopped using 0.5M H2SO2  
 
 
3.5.9 Using surface plasmon resonance (SPR) to confirm interaction between FH 
and selected merozoite proteins 
One general limitation of ELISA binding assay is that it is possible to overlook  low 
affinity interactions (Hoffrogge et al. 2003; Hornemann et al. 2003). As shown in Figure 
3.12 the difference in OD value between the positive control (Pf92) and the negative 
control (Cd4 tag), is not major. Surface plasmon resonance (SPR) allows for real time 
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detection of low affinity interactions and remains the gold standard for measuring 
protein-protein interactions (Yang et al. 2016). Table 3.2 below highlights the 
advantages of using SPR over ELISA binding assays (Cooper 2002; Yang et al. 2016). 
 
Table 3.2 Advantages of SPR over ELISA binding assay 
Surface Plasmon Resonance ELISA binding assay (protein-protein 
binding assay) 
Label free detection of interaction Requires antibodies 
Allows for real time monitoring of 
interaction 
- 
Lower sample consumption- requires 
smaller volumes, lower concentration 
Low affinity binding may require higher 
sample volume at higher concentrations 
Reusable sensor chips ELISA plates once used cannot be 
reused 
Can test interactions from crude 
samples 
Requires sample purification to reduce 
background signal 
Replicate injection of same sample to 
test reproducibility 
Duplicate/ triplicate sample analysis 
needed to test reproducibility 
  
3.5.9.1 Immobilization of FH ligand on the sensor chip 
A typical SPR experiment starts with immobilization of ligand on a sensor chip. Each 
sensor chip has four flow cells. Depending on the nature of the experiment, 
immobilization can be done on two or all the flow cells, as long as one flow cell is left 
as a blank to act as a reference flow cell. After immobilization, a confirmatory test is 
done to test whether the immobilization was successfully before the actual test 
samples are run. With regard to the current study, I immobilized FH on one flow cell 
using 10 mM sodium acetate, pH 5.0, via amine coupling chemistry. Buffer was 
injected into another flow cell to act as a blank and as also a reference flow cell to 
account for background signal. Next, I tested whether the immobilization worked using 
C3b of varying concentration. C3b is a host-generated protein regulated by FH (Boon 
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et al. 2009). As shown in Figure 3.14 B, nothing was bound to the blank flow cell, while 
FH was immobilized on the flow cell Figure 3.14 C. Dose-dependent binding of C3b 
to the immobilized FH confirmed that the immobilization had indeed worked. 
 
 120 
 
Figure 3.14 Amine coupling of FH ligand to the flow cell on the sensor chip.   
(A) schematic sensorgram of a typical amine coupling of ligands to the flow cell of a sensor chip. 
The procedure involves activation of the matrix on the sensor chip with a mixture of 1-ethyl-3- (3- 
dimethylaminopropyl) carbodiimide (EDC) and N- hydroxysuccinimide for activation. Ligand is then 
passed over the surface, which is then covalently attached to the matrix. After injection of ligand, 
ethanolamine is passed over the sensor surface to deactivate remaining active binding sites. A 
distinction between the amount bound and the amount immobilized is also shown on the schematic 
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sensorgram. (B) No ligand was attached to the blank (C) FH bound to the flow cell (D) Dose-
dependent binding of C3b to FH. 
 
3.5.9.2 Optimization of the merozoite protein binding conditions on the flow cell 
To determine the right experimental conditions that could allow for interactions 
between merozoite proteins and FH, different running buffers were tested. They 
included: 0.5X VBS++, 10 mM HEPES-0.01% TWEEN and 1/3 of 10 mM HEPES with 
no TWEEN. As shown in Figure 3.15 below, 0.5X VBS++ and 10 mM HEPES-0.01% 
TWEEN gave a negative and low signal sensorgram reading respectively Figure 3.15 
A and Figure 3.15 B. On the other hand, using 1/3 of 10 mM HEPES with no TWEEN 
gave a positive sensorgram reading implying that it allowed the interactions to occur 
Figure 3.15 C. All the subsequent test experiments were conducted using 1/3 of 10 
mM HEPES with no TWEEN in the running buffer Figure 3.15 C.  
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Figure 3.15 Optimization of surface plasmon resonance experimental binding buffers 
(A) 0.5 VBS++ buffer gives a negative sensorgram. (B) Using HEPES-Tween slightly improved the 
binding (C) 1/3 of 10mM HEPES with no Tween in the buffer enhanced binding.  
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3.5.10 Surface plasmon resonance confirms binding of a subset of merozoite 
proteins to FH and reveals new FH binders 
After optimization of the running buffer conditions Figure 3.15, the 18 merozoite 
proteins were tested for an interaction with FH. All antigens were normalized to a 
concentration of 0.56 uM. I also included another in-house recombinantly expressed 
protein Outer surface protein E (OspE) as an internal positive control. OspE has been 
shown to bind to FH and hence protect Borrelia burgdorferi from complement mediated 
opsonophagocytosis and killing (Hellwage et al. 2001; Alitalo et al. 2002). SPR was 
used to confirme the binding that was observed with the Helsinki ELISA binding assay.  
 
The SPR results showed interaction between FH and merozoite proteins (Figure 3.16 
A and Figure 3.16 B). The figures are split for illustration purposes. In fact, 
PF3D7_1105800 bound to FH almost as well as OspE. The other antigens 
PF3D7_0206200, RH5, Pf12, PF3D7_1252300, PF3D7_0629500 (SEG1) and P12p 
bound to FH even better than Pf92 Figure 3.16 C. The sensorgram for the second 
independent experiment is in Appendices Figure 3.3. I observed a weak positive 
correlation between SPR and Helsinki ELISA binding assay, although not significant 
(Spearman correlation r= 0.333 P= 0.177) using SPR response 1 and Spearman 
correlation r= 0.185 P= 0.463 using SPR response 2 Appendices Figure 3.4. It is 
important to note that only a small subset of the 18 antigens were available for testing 
for both the Helsinki ELISA binding assay and SPR. Head to head comparison 
between ELISA binding assay and SPR using a bigger sample set will be more 
informative. 
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Figure 3.16 SPR confirms that many merozoite proteins interact with FH.   
(A) and (B) are sensograms showing interactions between merozoite proteins and immobilized FH. 
The graphs are split for illustration purposes. (C) A summary graph of the RU responses for the 
merozoite proteins.  
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3.5.10.1 Reproducibility of the SPR experiments 
The reproducibility of measuring binding affinity of merozoite protein to FH for the SPR 
experiment was assessed by injecting varying concentration of different antigens and 
running same antigens on different days using different sensor chips. Due to limited 
antigen availability, only two antigens (PF3D7_0206200 and PF3D7_1105800) using 
varying concentration were tested on the same flow cell. PF3D7_0206200 and 
PF3D7_1105800 interacted with immobilized FH in a dose-dependent manner as 
shown in Appendices Figure 3.5. Correlation analysis done for two independent 
experiments of merozoite FH interaction showed that there was strong correlation for 
the experiments done on different days using different sensor chips (Spearman 
correlation r= 0.593 P= 0.009; Figure 3.17, indicating that the data are highly 
reproducible. 
 
 
Figure 3.17 Correlation for the SPR experiments done using the same antigens but on 
different days, using different sensor chips. 
FH was immobilized on the flow cell and merozoite antigens n=18 tested for interaction with FH on 
different days using different sensor chips. 
 
 
0 200 400 600 800
0
200
400
600
800
1000
Day 1
D
ay
 2
r = 0.5934
P = 0.0094
 126 
In summary, the interaction of merozoite proteins with complement FH was performed 
using a series of assays. Since the ELISA binding assay offers a chance for high-
throughput analysis, I used it to screen over a 100 recombinantly expressed merozoite 
proteins. However, the ELISA binding assay that was initially developed – Kilifi ELISA 
binding assay - had some limitations. The polyclonal anti-FH used bound to the 
antigens directly Figure 3.8 and 3.9. I improved the assay and developed Helsinki 
ELISA binding assay in which a monoclonal antibody replaced the polyclonal anti-FH. 
The SPR platform was used as a confirmatory test. Figure 3.18 below shows a 
summary of binding characterized of high FH binding antigens across the different 
assays used. 
 
 
Figure 3.18 Summary of merozoite proteins that were identified using different assay. 
The assays used included Kilifi ELISA binding assay, Helsinki ELISA binding assay and the 
surface plasmon resonance test. 
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Majority of the antigens that were observed to be high binders with the Helsinki ELISA 
binding assay were identified as high binders on the SPR platform Figure 3.18. 
However, some other antigens such as Pf34, EBA 140 and EBA 175 that were high 
binders with Helsinki ELISA binding assay failed binding on the SPR. Indeed, I 
observed a weak positive correlation between these two assays Appendices Figure 
3.4 which, however, was not significant. Although the number of antigens tested were 
few and could in part account for the results, it points to the fact that ELISA binding 
assay is not a robust way to assess protein-protein interactions. With advancement in 
technology, there are now superior SPR machines that allow for high throughput 
analysis (Nguyen et al. 2015). Future studies should therefore consider using high-
throughput SPR platforms that allow for real time protein-protein interaction detection. 
3.5.11 Localization of the FH CCP modules involved in binding to merozoite proteins 
I used a series of truncated FH fragments (CCP1-5, CCP1-6, CCP1-7, CCP5-7 and 
CCP1-20) to localize CCP binding modules of high FH binders. The FH CCP modules 
were already expressed and available in-house at Prof Seppo Meri’s Complement 
Laboratory at the University of Helsinki. Each CCP module is approximately 7kDa. As 
shown in Figure 3.19 on the SDS-PAGE, all the modules were of the expected 
molecular weight. CCP 1-6, CCP 1-7 were available in small volumes and at lower 
concentrations, and therefore were not used for the subsequent SPR experiments. 
Recombinant FH (CCP1-20) was loaded as a control.  
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Figure 3.19 Complement control protein (CCP) modules for the complement regulatory 
protein FH. 
Illustrated in (A) is the schematic of the 20 CCP domains (grey circles) that represent FH. Black bars 
beneath the schematic span the different recombinant FH fragments, and the numbers on the right 
side refer to the CCP domains that are within them. (B) SDS_PAGE of FH recombinant fragments.  
 
Complement FH fragments CCP 1-5, CCP 5-7 and CCP 19-20 were first immobilized 
unto the flow cells. A blank flow cell was prepared to be used as a reference cell. 
Sensorgram for the immobilized FH fragment is shown in Appendices Figure 3.6. As 
OspE and C3b binding sites in FH are known, I used those to test whether 
immobilization to the FH fragment had worked. OspE binds to FH CCP19-20 (Hellwage 
et al. 2001; Alitalo et al. 2002), while C3b has two binding sites, CCP 1-4 and CCP 19-
20 (Boon et al. 2009). As shown in Figure 3.20, OspE bound to CCP 19-20 and not 
CCP 1-5 or CCP 5-7. Similarly, C3b bound to CCP 1-5 and CCP 19-20 and not CCP 
5-7. Although there was no known protein to test for CCP 5-7 immobilization, the fact 
that OspE did not bind to that region but bound to CCP19-20, and they were in the 
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same sensor chip and injected into all the flow cells was used as confirmation that 
immobilization was specific. 
 
 
Figure 3.20 Validation of FH fragment immobilization to the flow cells on the sensor chip. 
(A) A schematic of OspE and C3b binding sites in FH. (B) OspE and C3b bound to the expected 
CCP modules in FH. 
 
Next, the merozoite proteins were tested against the immobilized FH fragments to 
localize their binding sites in FH. Initially, CCP 1-5, CCP 5-7 and CCP 19-20 were 
immobilized on the same sensor chip, but CCP 1-5 failed and was therefore repeated 
using a different sensor chip. Due to this fact, the data is presented as the original 
response units, and the experiments were not pooled together. Although the 
correlation for the response for the same antigen done on different days on the same 
flow cell is high (Pearson correlation r= 0.847 P= <0.001) Appendices Figure 3.7, 
there is an equally good correlation for same antigens tested on different days using 
different sensor chips Figure 3.17. As shown in Figure 3.21 below, antigens 
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PF3D7_0206200, PF3D7_0629500 (SEG1) and Pf12 bound more strongly to FH CCP 
5-7 compared to CCP 1-5 or CCP 19-20. Although the antigen P12p bound slightly 
better to FH CCP 5-7 compared to CCP 1-5 or CCP 19-20, it had generally lower 
responses compared to the rest of the antigens. There was no preferential binding for 
Pf92 to any of the three tested CCP module fragments. The wide confidence intervals 
could be due to protein expression batch to batch effects. Due to volume limitations 
antigens RH5 and PF3D7_1252300 were only tested for binding to FH CCP 5-7 and 
CCP 19-20. Hence, the results are inconclusive 
 
 
Figure 3.21 Merozoite protein interactions with the various FH CCP fragment modules  
From the top (A) PF3D7_1105800, (B) PF3D7_0206200 (C) Pf12 (D) PF3D7_0629500 (E) RH5 (F) 
P12p (G) PF3D7_1252300 and (H) Pf92. FH fragments CCP1-5, CCP5-7 and CCP19-20 were 
immobilized on the flow cells and tested for interaction with the selected merozoite antigens. 
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3.5.12 Reduced parasite growth in serum depleted of FH 
I have demonstrated that multiple Plasmodium falciparum parasite proteins bind to 
complement regulatory proteins FH Figure 3.16. It has been argued that parasite 
binding to FH is important for immune evasion (Rosa et al. 2015b). Therefore, I 
hypothesized that there would be reduced parasite growth in the absence of FH. I 
tested this assumption using a modified growth inhibition assay. Parasites at a starting 
parasitemia of 0.5% were allowed to grow for 2 cycles (96 hrs) in the presence of 
complement (using normal human serum), heat-inactivated serum, serum depleted of 
FH (CompTech) and serum depleted of FH but reconstituted by the addition of varying 
concentrations of FH. Thereafter, the parasites were stained with ethidium bromide 
and parasitemia determined using flow cytometry. There was significant reduction in 
parasite growth in serum depleted of FH compared to either NHS or Albumax. There 
was no difference in parasite growth in NHS or HIS (at 56oC for 30 minutes) conditions, 
although a slightly better growth was observed in NHS compared to Albumax (mean 
parasitemia was 12.5% for NHS and 10.4% for Albumax). Reconstitution of serum 
depleted of FH by the addition of FH only resulted in a modest gain in parasite growth 
using 50 ug/ml to 250 ug/ml of FH but no further gain in growth was achieved when 
500 ug/ml of FH was added Figure 3.22.  
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Figure 3.22 Parasite growth in the presence or absence of FH. 
Parasites were diluted in incomplete media to a starting parasitemia of 0.5%. A reaction mix of 50 
ul was used with 40 ul being diluted parasites and 10ul of the experimental conditions of RBCs, 
Albumax, AB-NS (AB normal human serum). AB-HI (AB serum heat inactivated) and serum depleted 
of FH (FH-D). FH-D was reconstituted by the addition of 50 ug/ml, 250 ug/ml and 500 ug/ml of FH 
denoted as FH-D 50, FH-D 250 and FH-D 500, respectively. Parasites were allowed to grow for two 
cycles and parasitemia measured using flow cytometry. The data are representative of four 
independent experiments. Complement FH was obtained commercially, from a pool of healthy adults 
(Sigma). The same serum batch was used for these experiments and was also heat-inactivated to 
get the HI serum. FH depleted serum is normal donor serum but devoid of FH and was obtained 
commercially (Complement Technology). Unfortunately, FH concentration in this commercially 
obtained serum was not measured; omitting a crucial step. 
 
3.5.13 Amino acid alignment of merozoite FH receptor antigens 
Next, I tested whether there were any similarities in the merozoite FH receptor proteins 
that could explain why they were all binding to FH. A multiple sequence alignment of 
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the merozoite FH receptor protein amino acid sequences indicated that three short 
regions were aligned across all the sequences without gaps, although there was no 
shared short amino acid stretch among the regions Figure 3.23. Further analysis using 
Nuclear Magnetic Resonance (NMR) and X-ray crystallography will be required to 
characterise in detail the nature of binding and specifically the binding sites between 
FH and these antigens (Bhattacharjee et al. 2013). 
 
 
Figure 3.23 Illustration of the amino acid regions alignment 
Regions A, B and C of the merozoite FH receptor proteins are the truncated sections that aligned 
together. They are truncated from the entire amino acid alignment. 
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3.6 Discussion 
Complement immune evasion strategies have been extensively described for bacterial 
pathogens (Hellwage et al., 2001; Zipfel, Würzner and Skerka, 2007; Serruto et al., 
2010; Luo et al., 2013). For the malaria parasite Plasmodium falciparum there is far 
less evidence, most of this having been described quite recently. We now know that 
the merozoite antigen Pf92 interacts with FH to avoid complement-mediated lysis 
(Kennedy et al. 2015). The results obtained from my study suggest that in addition to 
Pf92, there are other merozoite proteins including PF3D7_1105800, PF3D7_0206200, 
RH5, Pf12, PF3D7_1252300, PF3D7_0629500 (SEG1) and P12p that interact with FH 
for potential immune evasion. These results support my hypothesis that multiple 
merozoite antigens may be involved.  
 
The observation that Plasmodium falciparum uses several proteins to acquire 
complement regulatory protein FH suggests a mechanism of redundancy. A similar 
phenomenon has been observed in other pathogens. For example, the Gram-negative 
bacterium Borrelia burgdorferi has been shown to have two or three FH binding 
proteins: CspA, CspZ; and OspE (Hellwage et al., 2001; Brooks et al., 2005, Kraiczy 
and Stevenson, 2013) for FH interaction. Another example is the Gram-positive 
bacterium Streptococcus pyogenes, which has been shown to have three FH binding 
proteins, M1 protein, Fba and Scl1.6 (Pandiripally et al. 2002, 2003; Reuter et al. 
2010). On the other hand, there are instances, where pathogens use only one 
molecule to inhibit several complement regulatory proteins. An example is Pra1 (pH-
regulated antigen 1) in yeast Candida albicans that binds FH, FHL1, C4bP and 
fibrinogen (Zipfel et al. 2011) and hence limits complement activation at several 
stages. Taken together, this highlights the complexity of complement and immune 
evasion mechanisms used by several pathogens.  
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The majority of the additional antigens that interact with FH (merozoite FH receptors) 
were observed to use CCP 5-7 modules. Interestingly, this is the same region that 
gametes use (Simon et al. 2013), while schizont-infected red blood cells have been 
shown to use CCP5 and CCP 20 (Rosa et al. 2015b). Studies on other pathogens 
indicate preferential usage of CCP 5-7. Haemophilus influenzae, Streptococcus 
pyogenes and Neisseria meningitidis have been shown to bind to FH using sites 
located along CCP 5-7 (Pandiripally et al. 2003; Hallström et al. 2008; Schneider et al. 
2009). It has been argued that microbial proteins which bind FH via CCP 6-7 can also 
recruit FHL-1 due to the shared conserved CCP domains between FH and FHL-1 (Meri 
et al. 2013). However, this study did not directly test the merozoite FH receptors for 
binding to FHL-1. FH CCP19-20 has also been shown to be an essential binding site 
for other pathogens (Meri et al. 2013). However, none of the merozoite FH receptors 
showed preferential binding to CCP 19-20, although those that bound to CCP 5-7 also 
had some binding to CCP 19-20. Both CCP 5-7 and CCP 19-20 have 
glycosaminoglycan binding sites (Schmidt et al. 2008) and it can be speculated that 
there could be some similarities in these modules allowing pathogens to recognize 
them with varying degrees. 
 
Out of the eight identified merozoite FH receptors, three are known to be surface 
glycosylphosphatidylinositol (GPI)-anchored proteins: P12, P12p and Pf92. RH5 is a 
member of the reticulocyte binding homologue family and plays an important role in 
the invasion of the parasites to the red blood cells (Baum et al. 2009). PF3D7_0206200 
is known to be a panthothenate transporter proposed to be essential for erythrocyte 
invasion (Hu et al. 2010), while PF3D7_0629500 is an amino acid transporter. The 
other proteins PF3D7_1105800 and PF3D7_1252300 are of unknown function 
(Kamuyu, PhD thesis 2017). Of note is that other than Pf92 (Kennedy et al. 2015), 
none of these proteins have been studied in the context of involvement with 
complement either for immune evasion or mediating invasion.  
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The standard growth inhibition assays are normally conducted in complement-free 
media and form part of a set of assays used to asses antibody effector functions (Dent 
et al. 2008; McCallum et al. 2008; Wilson et al. 2011; Murungi et al. 2016). I modified 
the GIA and tested for parasite growth in the presence of complement (NHS) or in 
serum depleted of FH. The GIA was modified in that I did not use serum from malaria 
immune individuals as traditionally used for this assay. Using this modified GIA, I 
observed reduced parasite growth in serum depleted of FH compared NHS. The 
difference between parasite growth in albumax and NHS was not significant. Albumax 
does not contain FH Appendices Figure 3.8. This could imply that the current parasite 
culture protocols that use albumax allow the parasite to grow in the absence of FH. On 
the other hand, work done by Rosa et al. in which they cultured parasites in NHS, HIS, 
NIS supplemented with monoclonal antibody (mAb) to FH and also albumax showed 
reduced parasite growth in NHS with mAb compared to NHS without FH mAb or 
albumax (Rosa et al. 2015b). Their results somewhat agree with what this study found 
out in terms of reduction in parasite growth in the absence of FH. However, in Rosa et 
al, work, they did not show a titration curve to indicate whether by addition of mAb to 
NHS they were able to deplete out FH. They also determined parasitaemia using 
microscopy, which is not as robust as flow cytometry. A clearer way to assess the role 
of FH will be to use antibodies to merozoite FH receptors individually or in a “cocktail” 
and test whether blocking this interaction would have an effect on parasite growth. 
 
The current study has a number of limitations. As mentioned previously the Kilifi ELISA 
binding assay that was used to down select the antigens before further analysis with 
SPR proved to be non-specific; the polyclonal antibody directly recognized the 
recombinant merozoite proteins. In addition to the limitations of Kilifi ELISA binding 
assay discussed, the Helsinki ELISA binding assay was not optimal. It could not clearly 
distinguish between negative and positive controls. As these two assays were used to 
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down select the parasite merozoite antigens that were confirmed using the surface 
plasmon resonance (SPR), it is possible that potential antigens that interact with FH 
were missed out. In addition, since there is a weak correlation between ELISA binding 
assay and SPR Appendices 3.4, it is possible that the former selected some antigens 
that are not true FH binders. However, since the majority of the proteins from ELISA 
binding assay were taken through SPR, which is the gold standard for protein-protein 
interaction, the data produced is robust and shows that multiple proteins interact with 
FH. Due to limitations in the quantity of recombinant proteins, the SPR experiments 
for binding to FH CCP fragments were not robustly assessed.  
 
In conclusion, this study provides evidence that Plasmodium falciparum uses multiple 
merozoite proteins to bind to complement FH for possible immune evasion. Indeed, an 
analysis of stage-specific FH receptor proteins revealed that merozoites and schizonts 
bind significantly more to FH molecules than other parasites stages (Simon et al. 
2018), lending support to the current study observation. With the recent observation 
that the malaria parasite could also bind C1-INH (Kennedy et al. 2017), future study 
that comprehensively screens known and even stage-specific parasite proteins 
against complement inhibitors will give a clearer picture of the complexity of the 
parasite complement immune evasion mechanism. Nevertheless, the current study 
provides the first major evidence of multiple interaction partners for malaria parasites 
and could be a major addition to the field. 
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CHAPTER FOUR 
4 Antibody responses to merozoite FH receptor proteins and association with 
protection against malaria 
4.1 Summary and aims 
Pathogenic proteins or antigens responsible for limiting complement activation may be 
attractive as vaccine candidates because (i) immune responses against them could 
prevent the establishment of infection and (ii) they provide an opportunity to neutralize 
virulence factors (Meri et al. 2008). The same approach has been applied in a 
successful vaccine against meningococcus (Giuliani et al. 2006).  
 
Neisseria meningitidis is among the leading causes of bacterial meningitidis and sepsis 
(Jafri et al. 2013; Borrow et al. 2017). Pathogenic strains are classified based on the 
antigenic structure of their polysaccharide capsule. So far thirteen types have been 
described, six of these serotypes (A, B, C, W135, X, and Y) are responsible for the 
invasive disease (Pollard 2004). One of serogroup B’s main virulence protein is Factor 
H binding protein (FHbp). FHbp is responsible for the recruitment of FH and enables 
the bacteria to resist complement-mediated killing (Madico et al. 2006; Schneider et 
al. 2006). Interestingly, FHbp is now a component of Bexsero (Norvatis) and Trumenba 
(Pfizer), two recently approved vaccines against meningococcus (Giuliani et al. 2006) 
and fHbp-specific antibodies block binding of factor H, and hence increase bacterial 
susceptibility to killing via the alternative pathway (Madico et al. 2006; Schneider et al. 
2006; Welsch et al. 2008). For malaria, we hypothesize that similarly, parasite antigens 
that help to recruit FH to avoid complement destruction may be blocked by antibodies, 
and thus could be potential vaccine candidates.  
 
In chapter 3, I narrowed down to a subset of merozoites proteins that are responsible 
for interaction with FH (also referred to merozoite FH receptors) and potentially may 
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enable the parasite to establish infection. The antigens identified included 
PF3D7_1105800, PF3D7_0206200, RH5, Pf12, PF3D7_1252300, PF3D7_0629500 
(SEG), P12p and  Pf92 (Kennedy et al. 2015). P12p was among the antigens available 
but did not get printed onto the KILchip v1.0 Microarray, Supplementary Table 1 of 
(Kamuyu et al. 2018) and hence was not included in the subsequent antibody 
measurement and analysis. In this chapter, I test the hypothesis that the ability to make 
antibody responses to these antigens is associated with protection from clinical 
malaria.  
 
4.2 Introduction 
Antibodies targeting merozoites have been known to play a role in naturally acquired 
immunity to malaria (Sabchareon et al. 1991b; Doolan et al. 2009b; Fowkes et al. 
2010). The strongest evidence comes from seminal passive transfer studies that 
showed that transfer of IgG from immune adults cleared parasitemia and led to a 
resolution of clinical symptoms in children admitted to hospital with P. falciparum 
malaria (Cohen et al. 1961). These studies provide a rationale for designing malaria 
vaccines that target the merozoites proteins as they are thought to be able to limit 
parasite growth and hence prevent clinical disease (Richards and Beeson 2009). 
Although knowledge has been sought on the targets and mechanisms of protective 
antibodies, and advances made (Beeson et al. 2008; Richards and Beeson 2009) our 
understanding is still limited. 
 
The general approach used for identifying targets of protective antibodies is to assess 
how antibodies are acquired and their association with protection from malaria. 
Immuno-epidemiological studies involving longitudinal observation offer a powerful 
tool to examine relationships between measured antibodies and malaria outcomes 
(Fowkes et al. 2010; Osier et al. 2007). Evidence of merozoite antigens and 
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association with protection has so far been inconsistent. While some studies show 
evidence supporting the role of specific antibodies with protection, others have not  
(Cavanagh et al. 2004; Polley et al. 2006; Stanisic et al. 2009; Fowkes et al. 2010; 
Dodoo et al. 2008). Additionally, antibodies that target blood-stage malaria function in 
many ways. These protective antibodies can recognize merozoite antigens on the 
surface of merozoites or on infected red blood cells, can act to block parasite adhesion 
and invasion or can act in conjunction with immune cells such as neutrophils (Teo et 
al. 2016). Somewhat surprisingly, virtually no attention has been paid to the role of 
antibodies in blocking essential parasite functions or virulence factors. 
 
Recent studies have demonstrated that complement could be an important mediator 
of immunity to malaria. It has been shown that acquired and vaccine-induced human 
antibodies recruit complement and interfere with malaria parasite RBC invasion (Boyle 
et al. 2015; Feng et al. 2018). Boyle et al showed that antibodies that fix C1q were 
associated with protection from clinical episodes of malaria in most individuals while in 
others, antibodies were shown to be non-inhibitory in the absence of complement 
(Boyle et al. 2015) suggesting that other mechanisms could be involved. There is also 
evidence that antibodies that fix complement can inhibit P. falciparum sporozoite 
invasion of hepatocytes (Behet et al. 2018; Kurtovic et al. 2018; Zenklusen et al. 2018). 
Furthermore, many specific targets for complement-fixing antibodies are now known 
(Reiling et al. 2019). They include merozoite proteins EBA140 RIII-V, RASPI, GAMA, 
PfRH2, MSP-DBL1, PfRH5, EBA 175-RIII-V and MSP2-3D7 (Reiling et al. 2019).  
 
To the contrary, very little is known of the role of antibodies in blocking parasite 
virulence factors and how this relates to the acquisition of immunity to malaria. The 
prior findings that the parasite may be using merozoites antigens such as Pf92 and 
MSP3 to interact with complement regulatory proteins in order to inhibit complement 
activation (Kennedy et al. 2015, 2017) and the identification of additional merozoite 
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proteins by the current study provides a rationale to investigate the potential role of 
antibodies against parasite proteins important for its survival.  
 
4.3 Specific aims 
• Determine whether antibody responses to merozoite FH receptor proteins are 
associated with protection against clinical malaria 
• Test whether antibodies to merozoite FH receptor proteins differ quantitatively 
or qualitatively in children developing severe malaria versus uncomplicated 
malaria controls 
 
4.4 Methods 
The Junju longitudinal cohort of malaria in children and the Kilifi County Hospital case 
control study have been described, as have the antibody responses measurements 
using the microarray platform (see materials and methods section). 
4.4.1 Microarray data cleaning and processing 
The KILchip microarray is a high throughput platform. It has 21 mini-arrays in a slide, 
4 slides are assembled in a hybridization cassette, and 4 cassettes can be run in a 
hybridization workstation. A total of up to 522 samples per run per day can be 
analyzed. Each run has an allocation for positive controls: pooled human immune 
serum (PHIS) and purified malaria immunoglobulin (MIG), and negative controls: 
malaria naïve sera and blanks (Kamuyu et al. 2018). Samples used for this thesis work 
were done in one day utilizing the two hybridization workstations. PHIS, which was 
included in each slide, was used to adjust for variation between slides. Besides, 
sample allocation per slide was done randomly; as the laboratory investigators were 
blinded to age and location. 
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Data was acquired from scanned image files using the GenePix Pro 7 software 
(Molecular Devices). R version 3.4.4 was used for data processing, cleaning, and 
normalization as well as for statistical analyses (Mwai K et al. manuscript in 
preparation). The median fluorescent intensities (MFI) of local spot background 
surrounding each spot was subtracted from the MFI of each antigen spot. To account 
for technical slide-to-slide and batch-to-batch variation, a two-step normalisation 
process was performed according to previously described methods (Huber et al. 2002; 
Delfani et al. 2016). To account for within batch slide-to-slide effects, a ComBat model 
(SVA package in R) was fitted to the MFI data, and after obtaining the batch corrected 
data for the slide effect, a variance stabilization normalization transformation was done 
(Huber et al. 2002; Sundaresh et al. 2006; Johnson et al. 2007; Sboner et al. 2009). 
4.4.2 Statistical analysis 
All the analysis was done in STATA (StataCorp, version 13), R version 3.4.4. and 
GraphPad PRISM (version 7). Unpaired t-test was used to compare the mean parasite 
densities between the two age group categories (0-4 yrs, and > 5 yrs.). Mann-Whitney 
test was used to compare median normalized MFI between the age groups and 
between parasite positive and parasite negative children. For determination of 
association between antibody levels and development of clinical episode of 
Plasmodium falciparum malaria, antibody levels were classified into three tertiles 
based on the responses to the antigen measured as MFI values (high, medium or low). 
Medium and low responses were combined into one (low). The association between 
having a high and new “low response” were tested against protection to at least one 
clinical episode of malaria in the follow-up period using a modified Poisson regression 
model (Zou 2004). Previous analysis had validated the use of this regression analysis 
for similar studies (Osier et al. 2008). A clinical episode was defined as having 
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parasites densities of over 2500 (p/μl) and temperatures of over 37oC (Mwangi et al. 
2005).  
 
Another variable accounting for the individual’s overall response to all the antigens 
was generated and called reactivity score. This variable used a Principal Component 
(PC) analysis to map the position of test samples with reference to the 
positive/negative/blank control spots and accounted for an individual’s samples’ 
inherent reactivity (i.e. characterizing the degree to which samples tended to be 
reactive to the panel of antigens tested). The individuals 4 SD’s away from the mean 
of PC1 values of negative/blank control spots were categorized as high responders 
while the remainder were categorized as low responders. High responder’s PC 
positions were close to the Malaria Immune Serum (PHIS / positive control). This 
variable thus takes into account age (antibody reactivities usually increase with age) 
as well as transmission intensity (more exposure to infectious mosquitoes, more 
antibodies are produced) (Mwai K et al. manuscript in preparation).  
 
I investigated the protective efficacy for all possible combination of antibody responses 
to the merozoite FH receptor antigens. In the first instance, I identified a combination 
of 2, 3, and 4 antigens out of the total 8 antigens, which resulted in 28, 56 and 70 
antigens combinations, respectively. In the second instance, I identified a combination 
of 3 and 4 antigens, but this time from the 5 antigens that showed protection in the 
single antigen analysis. The latter 3 and 4 antigens resulted in 10 and 5 combinations, 
respectively.  The combinations (or also referred to as breadth score) ranged from 0 
to the number of antigen combination used, in this case, either 2, 3 or 4 antigens. The 
breadth score was created for each child and was then fitted as a continuous variable 
in the modified Poisson model while adjusting for the reactivity score variable with the 
clinical episode of malaria in the 6 months follow up period fitted in the model as the 
outcome variable. The protective efficacy was calculated as (1 - IRR) *100, whereby 
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100% represented complete protection. The analysis on protective efficacy or 
combination of antigens was restricted to children who were parasite positive at the 
time of sampling (n=79) and was done as previously described (Osier et al., 2014). 
 
Kruskal Wallis test was used to compare differences in median antibody levels in 
children with severe malaria anaemia (SMA), severe malaria without anaemia (SM) 
and uncomplicated malaria (UM). A logistic regression model was used to assess the 
association between antibody levels and severe malaria by comparing odds of severe 
malaria in tertile 1 (high) and tertile 0 (low) and measuring the effects using odds ratios. 
In the logistic regression model, age and parasite density were fitted as continuous 
variables.  
 
4.5 Results 
4.5.1 Junju cohort description 
I used the Junju 2008 cross-sectional survey in which children were sampled before 
the start of malaria transmission in May and actively followed up for malaria case 
detection through a weekly home visit by trained fieldworkers. The Plasmodium 
falciparum parasite prevalence in 2-10-year-olds (PfPR 2-10) in this area was around 
30% (Ndungu et al. 2015; Wamae et al. 2018). Of worthwhile to note is that the area 
has witnessed a general decline in malaria transmission over the last few years (Okiro 
et al. 2010; Mogeni et al. 2016). A total of 286 individuals with complete antibody 
responses measurement were available for further analysis. Out of which, 27.62% 
(79/286) were parasite positive at the time of sampling. Of note is that the parasite 
prevalence increased with age (4.1% at 0-2yrs, 28.1% at 3-5yrs and 36.6% at 6-10yrs) 
Table 4.1. The older age group had lower mean parasite density compared to the 
younger age group, although not significantly different (> 5 yrs at log10 parasite 
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densities 7.55 while 0-4 yrs at 8.56, P= 0.058, Appendices Figure 4.1). Table 4.1 
below shows the baseline characteristics for the study participants. 
 
 
Table 4.1 Table showing the demographic characteristics for the Junju 2008 
cohort of children 
Characteristics Parasite Positive Parasite Negative Total 
 N % N % N 
Age groups (yrs) 
0-2 yrs 2 4.1 47 95.9 49 
3-5 yrs 32 28.1 82 71.9 114 
6-10 yrs  45 36.6 78 63.4 123 
Sex 
Females 44 30.6 100 69.4 173 
Males 35 24.6 107 75.5 113 
Parasite prevalence % (95% CI) binomial exact 27.6% (22.5 - 33.2) 
Median parasite densities ((p/μl) min-max, IQR) 1920 (40 - 480000, IQR 
6680) 
 
4.5.2 Antibody responses to the merozoite FH receptor antigens by parasite status 
and age 
I measured antibody response in children in the Junju longitudinal cohort of children 
whose ages ranged between 0 to 10 years Table 4.1. As shown in Figure 4.1 below, 
antibody responses to P12, PF3D7_062900_SEG2, PF3D7_1105800, Pf92 were 
significantly higher in children who had parasites than those who did not. Furthermore, 
antibody responses to PF3D7_0206200, PF3D7_0629500_SEG1, and RH5 were 
higher though not significant in the same category of children suggesting that antibody 
levels were boosted by parasite infection. On the contrary, antibody responses to 
PF3D7_1252300 were significantly lower in children who had parasites than those who 
did not.  
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Figure 4.1 Antibody responses to merozoite FH receptor antigens by parasite status 
A comparison of antibody levels in individuals who did not have parasites (Parasite Neg) to those 
who had parasites (Parasite Pos) at sampling to A) P12 B) PF3D7_0629500_SEG1 C) 
PF3D7_1252300 D) PF3D7_1105800 E) Pf92 F) RH5 G) PF3D7_0629500_SEG1 and H) 
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PF3D7_0206200. Data is from the Junju longitudinal children at the pre-transmission cross-sectional 
survey 
 
Next, I tested the magnitude of antibody responses to these same antigens by age. I 
categorized the children into two main groups, 0-4 yrs and above 5 years in order to 
have sufficient numbers to compare. As shown in Table 4.2 below antibody responses 
to P12, PF3D7_0206200, PF3D7_0629500_SEG2, PF3D7_1105800, and RH5 in 
parasite negative children increased with age and were significantly so for 
PF3D7_0629500_SEG2 in line with acquisition of malaria immunity with age and 
cumulative exposure. Antibody responses to PF3D7_1252300, 
PF3D7_0629500_SEG1 and Pf92 tended to decrease with an increase in age in the 
same category of children. In those children who had parasites at the time of sampling, 
responses to PF3D7_0206200, PF3D7_0629500_SEG1, 
PF3D7_1105800_PF3D7_1252300 and RH5 were lower in older children. However, 
antibody responses to P12, Pf92 and PF3D7_0629500_SEG2 increased with age in 
the same category of parasite positive children. 
 
 
Table 4.2 Magnitude of antibody responses to merozoite FH receptor antigens 
Antigen  Parasite positive by microscopy 
0-4 yrs > 5yrs P  0-4 yrs > 5yrs P  
P12 8.49 (8.10-
11.00) 
9.68 (8.25-
11.75) 
0.05 
10.58(9.58-
12.17) 
 
11.95 (8.63-
13.95) 
0.54 
PF3D7_0206200 9.02 (8.18-
12.00) 
9.40 (8.17-
12.19) 
0.95 
11.71 (9.11-
12.96) 
 
10.33 (8.20-
12.99) 
0.14 
PF3D7_0629500_S
EG1 
10.75 (9.64-
11.46) 
10.39 (9.35-
11.00) 0.01 
11.06 (10.61-
11.63) 
10.21 (8.26-
11.27) 0.06 
PF3D7_0629500_S
EG2 
9.86 (8.46-
11.23) 
11.12 (9.19-
12.36) <0.01 
11.16 (9.98-
12.22) 
12.00 (10.67-
12.95) 0.11 
PF3D7_1105800 9.47 (8.09-
11.21) 
9.94 (8.30-
11.35) 0.52 
11.70 (11.31-
12.56) 
11.17 (8.38-
12.03) 0.13 
PF3D7_1252300 10.40 (9.44-
10.80) 
10.00 (8.58-
10.75) 0.05 
10.04 (9.36-
10.39) 
8.67 (7.23-
10.07) 0.06 
Pf92 10.75 (9.64-
11.46) 
10.53 (8.86-
12.00) 0.08 
10.84 (8.49-
12.06) 
11.13 (9.53-
12.74) 0.24 
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RH5 9.44 (8.16-
10.72) 
9.53 (7.98-
10.48) 0.78 
10.60 (8.92-
11.22) 
8.95 (7.00-
11.11) 0.05 
Median MFI values and inter quartile range are shown. Mann-Whitney test was used to compare 
median MFI between the two age groups in the parasite negative and parasite positive children. 
Data is from the Junju longitudinal children at the pre-transmission cross-sectional survey. 
 
4.5.3 Association between merozoite FH receptor proteins and protection against 
clinical malaria 
I investigated the association between antibody responses to merozoite FH receptor 
antigens and association with protection with clinical malaria in the longitudinal cohort 
of Junju children. Univariate analysis for parasite negative children showed that those 
who had high level antibody responses to PF3D7_1252300, Pf92 and 
PF3D7_0629500_SEG1 were protected against risk of developing clinical malaria, 
although this was not statistically significant. On the other hand, children who had high 
antibody responses to PF3D7_0629500_SEG2, P12, PF3D7_0206200 and 
PF3D7_1105800 had an increased prospective risk of P. falciparum malaria compared 
with children with low-level responses, although not statistically significant except for 
PF3D7_1105800. A similar increase risk was observed in children with high responses 
to PF3D7_1252300, PF3D7_0206200, and PF3D7_1105800 although this was in 
children who had parasites (parasite positive). Combining all the children, whether 
parasite positive or negative, increased prospective risk of developing clinical malaria 
was observed for children who made high antibody responses to PF3D7_1105800 and 
PF3D7_0206200 Table 4.3.    
 
When adjustments were made using the reactivity score variable to control for potential 
confounders, the strength of association between antibodies and the prospective risk 
of developing at least one clinical episode of malaria during the 6 months follow up 
period was mostly reduced when parasite positive and parasite negative children were 
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combined. Controlling for the confounders had no effect on the IRR for 
PF3D7_0629500_SEG1 in parasite positive or RH5 and PF3D7_1252300 when 
parasite positive and parasite negative children were combined together Table 4.3. 
Almost similar IRR estimates were obtained when age instead of reactivity score 
variable was adjusted for in the modified Poisson regression model Appendices Table 
4.1. In addition to reactivity score, baseline FH levels was also added to the 
model. 
 
Table 4.3 Antibody responses to merozoite FH receptor antigens and as 
sociation with prospective risk of clinical malaria 
 
Antigen No adjustment Reactivity score and factor 
H adjusted 
 IRR (95% CI) P IRR (95% CI) P 
Parasite negative children 
PF3D7_1252300 0.85 (0.61-1.17) 0.32 0.93 (0.66-1.31) 0.691 
Pf92 0.95 (0.68-1.34) 0.79 0.99 (0.69-1.43) 0.972 
PF3D7_0629500_SEG1 0.91 (0.67-1.24) 0.57 0.97 (0.71-1.34) 0.858 
RH5 1.01 (0.71-1.44) 0.95 1.00 (0.69-1.45) 0.993 
PF3D7_0629500_SEG2 1.11 (0.81-1.54) 0.52 0.96 (0.66-1.41) 0.842 
P12 1.12 (0.81-1.54) 0.50 0.97 (0.67-1.42) 0.882 
PF3D7_0206200 1.27 (0.95-1.71) 0.11 1.27 (0.83-1.96) 0.275 
PF3D7_1105800 1.47 (1.09-1.97) 0.01 1.51 (1.03-2.21) 0.036 
Parasite positive children 
PF3D7_0629500_SEG2 0.64 (0.29-1.43) 0.28 0.58 (0.26-1.32) 0.199 
P12 0.67 (0.30-1.50) 0.34 0.60 (0.26-1.40) 0.234 
PF3D7_0629500_SEG1 0.90 (0.40-2.05) 0.81 0.86 (0.37-1.98) 0.720 
Pf92 0.96 (0.43-2.14) 0.93 1.06 (0.47-2.42) 0.881 
RH5 1.00 (0.43-2.33) 0.99 1.99 (0.41-2.39) 0.982 
PF3D7_1252300 1.30 (0.54-3.12) 0.55 1.28 (0.50-3.30) 0.611 
PF3D7_0206200 1.25 (0.57-2.76) 0.57 1.45 (0.65-3.24) 0.362 
PF3D7_1105800 1.36 (0.60-3.11) 0.46 1.82 (0.47-7.12) 0.386 
All children irrespective of parasite status 
PF3D7_0629500_SEG2 0.87 (0.64-1.20) 0.40 0.78 (0.54-1.12) 0.179 
P12 0.90 (0.66-1.23) 0.49 0.80 (0.56-1.15) 0.226 
PF92 0.88 (0.64-1.22) 0.45 0.98 (0.72-1.37) 0.886 
PF3D7_0629500_SEG1 0.92 (0.68-1.24) 0.59 0.97 (0.71-1.40) 0.918 
RH5 0.96 (0.69-1.34) 0.82 0.98 (0.69-1.35) 0.80 
PF3D7_1252300 0.97 (0.71-1.32) 0.85 1.03 (0.74-1.42) 0.880 
PF3D7_1105800 1.22 (0.91-1.63) 0.19 1.35 (0.92-2.00) 0.122 
PF3D7_0206200 1.23 (0.92-1.64) 0.16 1.41 (0.97-2.06) 0.072 
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Association between antibody levels and risk of developing clinical malaria in the ensuing 6 months 
period using modified Poisson regression model. Data is from the Junju longitudinal children at the 
pre-transmission cross-sectional survey 
 
 
4.5.4 Combination of merozoite FH receptor antigen antibody responses and 
association with protection from malaria 
Previously it has been shown that the breadth of antibody responses was associated 
with protection from clinical episodes of malaria (Osier et al. 2008). The 8 antigens 
were grouped into 2, 3 and 4 combinations and each parasite positive children 
assigned a breadth score. The breadth score was then fitted into a modified Poisson 
model as a categorical variable while adjusting for confounders using the reactivity 
score and clinical malaria episode in the ensuing 6 months period used as the outcome 
variable in the model. Thereafter, the protective efficacy was derived. I found a trend 
towards a slight increase in protective efficacy with increasing breadth of antibody 
responses. In addition, the median protective efficacy of the top best 5 protective 
antibodies (ranked based on individual antigen IRR) also slightly rose with increasing 
combination size Figure 4.2. However, on average (median) the protective efficacy 
was low, <50%, for any of the combination tested. The top 5 most protective antigens 
analyzed include, PF3D7_0629500_SEG2, P12, PF3D7_0629500_SEG1, Pf92, and 
RH5 Table 4.3. Together, these findings suggest that in this cohort of young children, 
the most protective of the four antigens offers the highest protective efficacy. 
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Figure 4.2 Protective efficacy of combination of antibody responses to the merozoite FH 
receptor antigens. 
The IRR for clinical malaria episode obtained from the modified Poisson model were converted to 
protective efficacy (PE= (1-aIRR) *100). The combinations tested are shown on the x axis while the 
y axis shows the protective efficacy. Data is from the Junju longitudinal children at the pre-
transmission cross-sectional survey 
 
4.5.5 Comparison of antibody responses to merozoite FH receptor proteins in 
severe versus mild malaria 
Baseline characteristic of severe malaria cases and uncomplicated malaria controls 
The case-control study included children presenting with severe malaria; severe 
malaria anaemia (SMA) and severe malaria without anaemia (SM), and uncomplicated 
malaria (UM). A total of 131 children had SMA and presented to the hospital with Hb 
<5 grams per deciliter (g/dl), parasitemia of ≥ 10,000 parasites/µL of blood (Marsh et 
al. 1995a) while 87 had SM with symptoms that included; impaired consciousness 
defined as Blantyre coma score (BCS) of < 3, chest in-drawing or deep breathing 
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(English et al. 1996). On the other hand, 96 children had uncomplicated malaria 
defined as children presenting at an outpatient clinic with parasite density of ≥ 2500 
parasites/ µL of blood and temperature of >37.5 oC (Smith, Schellenberg and Hayes, 
1994; Mwangi et al., 2005) but didn’t have malaria severe enough to warrant 
admission. Hemoglobin level measurement was not done at the outpatient clinics; 
hence the data for the children in the UM group are not available. Only children under 
the age of 5 years were selected. Table 4.4 shows the baseline characteristics for 
these categories of children. Clinical parameters were not available for the UM group 
as they are recruited from an outpatient dispensary clinic which conducts only basic 
patient observations. 
 
Table 4.4 Baseline characteristics for the severe malaria cases and 
uncomplicated malaria controls 
Characteristics SM SMA UM Total 
 N (%) N (%) N (%)  
Age groups (yrs) 
0-1 yr 36 (41.38) 66 (50.38) 44 (45.83) 146 
2-5 yrs 51 (58.62) 65 (49.62) 52 (54.17) 168 
Sex     
Females 46 (52.87) 67 (51.15) 47 (48.96) 160 
Males 41 (47.13) 64 (48.85) 49 (51.04) 154 
Median parasite 
density (IQR 
214480 (16848 
– 470400) 
235980 (74460 
-361660) 
18000 (8280 - 170000) 
 
Median Hb levels 
(IQR) 
7.70 (6.50 - 
9.70) 
4.20 (3.70 - 
4.60) 
- 
Thal gene 
Het 24 (27.59) 28 (18.54) - 
Homo 30 (34.48) 62 (41.06) - 
No results 8 (9.19) 7 (4.64) - 
Missing 25 (28.74) 54 (35.76) - 
Sickle cell trait 
AA 61 (100) 79 (98.75) - 
AS 0 (0) 1 (1.25) - 
Co-infection 
Bacteraemia 20 (22.99) 20 (15.27) - 
Missing bacteria 
results 
67 (77.01) 111 (84.73) - 
Median wbc 
levels (IQR) 
13.5 (10.40-
19.00) 
12.70 (8.70- 
20.10) 
- 
Median rbc levels 
(IQR) 
3.5 (2.80-4.40) 1.80 (1.60-2.00) - 
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Median hct (IQR) 24.40 (20.70-
29.90) 
12.90 (11.50-
14.10) 
- 
Median platelet 
(IQR) 
103 (58.00- 
251.00) 
96.00 (64.00-
127.00) 
- 
 
 
Next, I tested whether there were differences in antibody responses to merozoite FH 
receptor antigens in this cohort of SM, SMA and UM. I observed a differential pattern 
in median antibody levels in the clinically different forms of malaria Table 4.5. For 
antigens P12, PF3D7_0629500_SEG1, Pf92, and RH5 the antibody responses did not 
differ among the groups. Statistically significant differences were observed for 
responses to PF3D7_0206200, PF3D7_0629500_SEG2, PF3D7_1105800, and 
PF3D7_1252300. When the children were stratified by age groups, the median 
antibody levels were significantly different for more antigens in children under the age 
of 2 yrs than the 2-5 yrs age category Table 4.5 below.  
 
Table 4.5 Antibody levels in children presenting with SMA, SM or UM 
Median antibody levels for all children  
Antigen  SM SMA UM P 
P12 10.42 10.23 9.73 0.05 
PF3D7_0206200 9.61 10.34 10.30 <0.01 
PF3D7_0629500_SEG1 10.42 10.55 10.14 0.2113 
PF3D7_0629500_SEG2 10.96 10.45 10.80 <0.01 
PF3D7_1105800 11.13 10.46 10.05 <0.01 
PF3D7_1252300 10.65 10.92 10.82 <0.01 
Pf92 10.64 10.14 10.83 0.1219 
RH5 10.14 10.09 9.79 0.1447 
Median antibody levels for children under the age of 2 yrs 
Antigen SM SMA UM P 
P12 9.90 9.73 9.26 0.17 
PF3D7_0206200 9.38 10.11 10.04 <0.01 
PF3D7_0629500_SEG1 10.20 10.31 9.80 0.17 
PF3D7_0629500_SEG2 10.60 10.13 10.99 0.02 
PF3D7_1105800 11.06 10.11 9.79 0.03 
PF3D7_1252300 10.72 11.00 10.75 <0.01 
Pf92 10.12 9.74 10.95 0.03 
RH5 9.97 9.81 9.09 <0.01 
Median antibody levels for children aged 2-5 yrs 
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Antigen SM SMA UM P 
P12 11.12 10.73 10.16 0.18 
PF3D7_0206200 9.72 10.55 10.67 0.02 
PF3D7_0629500_SEG1 10.56 10.72 10.55 0.49 
PF3D7_0629500_SEG2 11.10 10.47 10.75 0.05 
PF3D7_1105800 11.13 10.82 10.28 0.09 
PF3D7_1252300 10.40 10.83 10.83 <0.01 
Pf92 10.90 10.61 10.64 0.72 
RH5 10.18 10.61 10.18 0.67 
Median MFI value as measured using the protein microarray platform are displayed. The 3D7 
reference strain was used for all antigens. Differences in the antibody responses among the groups 
were tested using the Kruskal Wallis test. The differences were again tested when children were 
stratified by ages (<2 yrs and 2-5 yrs). N=310 children. Data is from the Kilifi Hospital case control 
study. 
 
I further interrogated the association between antibody levels and odds of having 
severe malaria using a logistic regression model. Children with either SMA or SM were 
pooled together into one group of severe malaria. Age, sex and parasite density were 
adjusted for, first by testing the effect of age alone then combining age, sex and 
parasite density together. High antibody responses to P12, PF3D7_0629500_SEG1, 
PF3D7_1105800, and RH5 were associated with increased odds of having severe 
malaria but only responses to PF3D7_1105800 were statistically significant when age 
was accounted for but lost when age, sex and parasite density were included in the 
model Table 4.6. Antibody responses to Pf92 were the only ones significantly 
associated with reduced odds of developing severe malaria and remained so after 
accounting for age, sex and parasite density Table 4.6.  
 
Table 4.6 Association between antibody levels and odds of having severe 
malaria 
Antibody Univariate 
analysis 
 Adjusted for age Adjusted for age, sex 
and parasite density 
 OR (95%CI) P OR (95%CI) P OR (95%CI) P 
P12 1.47 (0.87-2.48) 0.15 1.56 (0.91-
2.67) 
0.11 1.60 (0.91-
2.82) 
0.10 
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PF3D7_0206200 0.74 (0.45-1.23) 0.25 0.76 (0.46-
1.26) 
0.28 0.67 (0.39-
1.16) 
0.15 
PF3D7_0629500_SEG1 1.31 (0.78-2.21) 0.31 1.36 (0.80-
2.32) 
0.25 1.17 (0.66-
2.06) 
0.58 
PF3D7_0629500_SEG2 0.76 (0.46-1.25) 0.28 0.76 (0.46-
1.26) 
0.28 0.78 (0.46-
1.33) 
0.36 
PF3D7_1105800 1.83 (1.07-3.13) 0.03 1.87 (1.09-
3.22) 
0.02 1.74 (0.99-
3.08) 
0.06 
PF3D7_1252300 0.98 (0.58-1.64) 0.93 0.95 (0.56-
1.60) 
0.84 1.02 (0.59-
1.76) 
0.96 
Pf92 0.56 (0.34-0.92) 0.02 0.57 (0.34-
0.94) 
0.03 0.56 (0.33-
0.95) 
0.03 
RH5 1.41 (0.83-2.38) 0.20 1.45 (0.85-
2.47) 
0.17 1.40 (0.80-
2.46) 
0.24 
A logistic regression model used to calculate the odds of developing severe malaria in children under 
the age of 5. Age and parasite density were fitted as continuous variable. Antibody levels were fitted 
as a binary variable. Data is from the Kilifi Hospital case control study. 
 
 
4.6 Discussion 
The main aim of this study was to test whether antigens that bind to FH (merozoite FH 
receptor proteins) identified in chapter 3 were associated with protection against 
clinical malaria. The list of antigens tested included PF3D7_1105800, 
PF3D7_0206200, RH5, Pf12, PF3D7_1252300, PF3D7_0629500 (SEG1), 
PF3D7_0629500 (SEG2) and Pf92. In this Junju cohort of young children, most of 
these antigens were associated with protection, although none of the associations was 
statistically significant. However, there was an increase in protective efficacy with the 
increase in breadth responses. These data are in line with the previous observation 
that the breadth of antibody response is a good predictor of immunity against a clinical 
episode of malaria (Osier et al. 2008). However, it will be important that future studies 
are conducted in order to shed light on the generalizability of these findings and to 
identify important antigens across different populations that can be prioritized for 
vaccine development. 
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In a previous study where a similar cohort (Junju 2008 samples) were used, antibody 
levels were required to reach a defined protective threshold in order to be associated 
with protection. In fact, only a small proportion of children in Junju had antibody levels 
above the protective threshold (Murungi et al. 2013). Since the antigens tested were 
different from those used in the current study, a cut off for protective threshold was not 
applied. However, most of the antibody levels increased with age and were boosted in 
the presence of parasite infection as has been observed previously (Osier et al. 2008; 
Rono et al. 2013; Stanisic et al. 2015). 
 
Majority of antigens described in my study are novel in the context of naturally acquired 
immunity to malaria (Kamuyu 2017, PhD Thesis) and have therefore not been 
previously evaluated in a cohort of children. However, in an adult cohort in Nyamisati, 
Tanzania sampled between 1993-1995, antibody responses to PF3D7_0629500 
(SEG2), PF3D7_0206200 and PF3D7_1252300 were found to be associated with 
reduced odds of experiencing a clinical episode of malaria similar to what was 
observed for this current study Table 4.6. However, for the Nyamisati cohort the 
association was not statistically significant when adjustments were made to account 
for multiple comparisons (Kamuyu 2017, PhD Thesis). Other studies indicate that 
antibody responses to RH5 are associated with protection against malaria (Chiu et al. 
2014; Tran et al. 2014). Very few studies have investigated antibody levels to Pf92  
and its association with protection (Osier et al., 2014). 
 
Although immune-epidemiological studies are important in defining the targets of 
protective antibodies, inconsistencies are widely observed in many studies. While 
some show a protective role to a specific antigen, others do not (Fowkes et al. 2010). 
This can be partly be explained due to misclassification bias as to who is protected 
during the follow-up period. For instance, individuals can be classified as protected, 
but due to heterogeneity in exposure in endemic areas, these individuals could have 
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been not exposed to infectious bites (Bejon et al. 2009). I speculate that this could 
perhaps explain why the antigens that were associated with reduced risk of developing 
malaria differed between parasite positive and parasite negative children except for 
Pf92 in this study. To reduce this misclassification, it has been suggested that the 
analysis should be restricted to those children with parasites (asymptomatic) during 
sampling as they would have had equal exposure (Osier et al., 2014). Based on this 
argument only antibody responses to PF3D7_0629500 (SEG2), P12, 
PF3D7_0629500 (SEG1) and Pf92 was associated with reduced risk of developing 
clinical malaria in the follow-up period. However, it is worthwhile to note that only a 
small subset of children, 28% in this cohort had parasites at the point of sampling.   
 
In the group of children with severe malaria (SMA, SM) and UM, I tested whether there 
were differential antibody levels based on their clinical presentation. There were 
statistically significant differences in median antibody levels to PF3D7_0629500 
(SEG2), PF3D7_ 0206200, PF3D7_1105800 and PF3D7_1252300. This is a line with 
a previous study that observed differential antibody levels in children presenting with 
similar clinical phenotypes (Dobaño et al. 2008) although they tested different antigens 
than those used in this current study. To account for the fact that the children in this 
study had different parasite densities Table 4.4 and also age, I used a logistic 
regression model and observed that there was reduced odds of having severe malaria 
for responses to Pf92 even after adjusting for age, sex and parasite densities.  
 
Studies assessing antibody responses using hospital-based case-control designs 
have widely been conducted (de Souza et al. 2002; Perraut et al. 2005; OKECH et al. 
2006; TANGTEERAWATANA et al. 2007; Dobaño et al. 2008; Iriemenam et al. 2009; 
Ahmed Ismail et al. 2013). However, thus far these studies have failed to provide 
consistent results, and this can be attributed to partly due to differences in malaria 
case definition and methodological differences. Future studies with sufficient statistical 
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power and using carefully selected cases and control and head to head comparison 
using similar antigens are warranted to shed a light of the importance of antibody levels 
and susceptibility to severe malaria disease. 
 
The current study is not without limitations. Although antibody levels were measured 
in the longitudinal cohort, potential mechanisms of protective immunity were not 
assessed due to time limitations. In vitro assays that are aimed at identifying antibody 
effector function continue to be developed and validated across different research 
groups (Boyle et al. 2017). What is more interesting is that some assays such as the 
complement-fixing antibody assay can now be specifically tested against an antigen 
(Reiling et al. 2019) unlike most of the other assays where whole merozoites/whole 
parasites are used. It will be interesting to test whether the antibodies to the antigens 
discovered by this thesis project fix complement or whether they work using different 
mechanisms. 
 
In conclusion, this study provides evidence that antibodies against merozoite FH 
receptor antigens are targets of naturally acquired immunity to malaria. Although there 
was no evidence to suggest that antibody responses to these merozoite FH receptor 
antigens were individually associated with protection, some combination of these 
responses were found to be associated with protective immunity. Comprehensively 
characterizing Plasmodium falciparum stage specific antigens that interact with FH for 
parasite immune evasion will be important in determining which of these antigens 
could be good candidates for vaccine development. 
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CHAPTER FIVE 
5 Association of human complement FH levels and Y402H variant with 
susceptibility and severity to Plasmodium falciparum malaria 
 
5.1 Summary and aims 
Many pathogenic microbes have been shown to protect themselves against alternative 
pathway attack by acquiring host FH onto their surfaces (Ferreira et al. 2010; Dinko 
and Pradel, 2016). In the previous chapter, chapter 3, I showed that some Plasmodium 
falciparum merozoite proteins interact with FH, and this could be important in allowing 
the parasite to establish infection. Next, in chapter 4, I showed that these merozoite 
FH receptor proteins are important antibody targets of naturally acquired immunity to 
malaria. In this current chapter, I hypothesize that since in vitro experiments have 
shown that P. falciparum recruits FH unto its surface to protect the parasite from 
complement onslaught (Simon et al., 2013; Kennedy et al., 2016; Rosa et al., 2016), 
plasma levels of FH may influence susceptibility to malaria infection.  
 
Long-standing observations point to the fact that mutations, variations and 
autoantibodies to FH predispose individuals to both infections (Davila et al. 2010), and 
autoimmune diseases (Pickering and Cook 2008; Ansari et al. 2013). Around 30% of 
people of European descent carry at least one copy of the 402H risk allele (Sofat et al. 
2012). A proposed explanation for the high prevalence of the Y402H polymorphism is 
that the 402H allele provides a survival advantage against streptococcal infections in 
early life (Haapasalo et al. 2008). The FH binding protein of streptococcus has also 
been shown to have a lower affinity for 402H than 402Y, which would lead to enhanced 
alternative pathway activation on these bacteria. Here, I hypothesize that there would 
be polymorphisms in the FH gene, particularly the 402H allele that reduces the binding 
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between factor H and the malaria parasite, hence enhancing complement-mediated 
killing and ultimately conferring protection against malaria.  
 
 
5.2 Introduction 
Increased complement activation has been consistently observed in human malaria 
infections (Silver et al. 2010), with all the three major complement pathways activated. 
Malaria antigens expressed on the surface of infected erythrocytes, free antigens 
released from schizont rupture or by immune complexes formed by antibody 
interactions with antigens (Greenwood and Brueton 1974; Glew et al. 1975; Adam et 
al. 1981) can be recognized by IgG antibodies and this, in turn, can trigger the classical 
complement pathway (Roestenberg et al. 2007). Large amounts of hematin activate 
the alternative pathway and lead to increased deposition of C3b and its breakdown 
products on erythrocytes (Pawluczkowycz et al. 2007). Activities of the MBL pathway 
have also been found to be greatly reduced in children with severe malaria anaemia 
unlike their age-matched controls (Nyakoe et al. 2009). 
 
Complement activity has been suggested to partly explain severe malaria anaemia 
(SMA) pathogenesis (Silver et al. 2010; Biryukov and Stoute 2014). SMA is thought to 
arise as a result of direct destruction of RBCs during schizont rupture, increased 
destruction of uninfected RBCs and impaired erythropoiesis due to bone marrow 
suppression (Jakeman et al. 1999; Awah et al. 2011). Children with severe malaria 
anemia have been shown to have higher levels of immune complexes (Mibei et al. 
2005), lower complement hemolytic activity (CH50) in addition to decreased activity of 
all the major complement pathways suggesting increase complement consumption 
(Nyakoe et al. 2009). Likewise, other complement breakdown products such as C3a, 
C4a, and C5a have also been seen to be elevated in children with severe malaria 
(Silver et al. 2010). Similarly, children with SMA have been shown to have deficiencies 
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in complement regulatory proteins CR1 and CD55 (Waitumbi et al. 2015). Erythrocyte 
deficiencies of CR1 and CD55 in children with SMA result in reduced immune complex 
(IC) binding capacity and are associated with increased deposition of C3b on 
erythrocytes during malaria infection (Odhiambo et al. 2008; Owuor et al. 2008).  
 
Complement activation has also been implicated in placental malaria (Alim et al. 2015; 
McDonald et al. 2015; Khattab et al. 2013). Levels of maternal plasma C5a and 
placental messenger RNA (mRNA) encoding the C5a receptor, C5aR, are increased 
in placental malaria infection (Conroy et al. 2009). Equally, the levels of C5a have been 
shown to be significantly higher in women with preeclampsia than in normal pregnant 
women. In contrast, the median maternal plasma concentration of C4a has been 
shown to be  lower in women with preeclampsia than that of those with normal 
pregnancy with no changes in complement C3a observed (Soto et al. 2010). In 
summary, there is evidence to suggest that, 1) complement activation occurs during 
malaria infection, and 2) complement activation may be linked to the pathogenesis of 
malaria. However, little attention has been paid specifically to the role of plasma FH 
levels and polymorphisms in FH and whether they influence malaria outcomes. 
 
Common polymorphisms in the CFH gene can be classified into three groups: (1) 
polymorphisms affecting the ability of FH to bind to either host or pathogens surfaces; 
(2) polymorphisms affecting how FH regulates alternative pathway activation; and (3) 
polymorphisms affecting FH expression and hence circulating levels (De Córdoba and 
De Jorge 2007; Harris et al. 2012; Van Der Maten et al. 2016). One of the FH variant 
that has been shown to be associated with circulating FH levels and affect disease 
susceptibility is the Y402H variant (Haralambous et al. 2006; Sharma et al. 2013). 
Therefore, I tested whether the Y402H variant influences FH circulating levels in a 
cohort of children and whether it relates to the risk of developing clinical malaria. 
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5.3 Specific aims 
i. Determine whether variation in FH levels within the population is associated 
with the development of clinical episodes of malaria 
ii. Test for correlation between FH levels and antibodies to merozoite FH receptor 
proteins 
iii. Determine whether complement factor H levels differ in children with severe 
malaria compared to uncomplicated malaria controls  
iv. Investigate whether the Y402H allele is a risk factor for clinical malaria 
v. Explore whether there is a relationship between FH genotype and plasma FH 
levels  
 
5.4 Methods 
5.4.1 Study design 
The current study used archived heparinized plasma samples that are part of larger 
malaria immunological studies that are conducted at the KEMRI Wellcome Trust 
Research Programme started in 2005 (for the Junju longitudinal cohort of children) and 
2000 (for the hospital case-control cohort) and are on-going to date (see methods 
section 2.4 and 2.5 for more details). Baseline characteristics for the longitudinal 
cohort and the case-control are described in chapter 4 Table 4.1 and Table 4.4 
respectively. For the Junju cohort, only 276 children had complete antibody and FH 
level measurements. Hence, only they were analyzed in the current chapter. 
 
5.4.2 Laboratory procedures 
Inappropriate sample handling after collection can influence the evaluation of 
complement biomarkers (Yang et al. 2015). EDTA-plasma is recommended for the 
determinations of complement proteins levels. EDTA blocks both classical and 
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alternative pathways by chelating Ca2+ and Mg2+ ions (Ca2+ is needed for the 
assembly of C1 complex and Mg2+ for the formation of the alternative pathway C3 
convertase). This prevents artificial complement consumption during sample transport 
and handling, which may lead to false results (Roumenina et al. 2011). Although EDTA 
for reasons stated above is more efficient than say citrate and heparin in inhibiting in 
vitro activation, minimum activation has also been observed in all preparations (citrate 
and heparin) when samples are kept at 4°C for up to ten days. It has also been noted 
that a rapid increase in activation products can occur even in EDTA plasma when 
temperatures are elevated (Mollnes et al. 1988). Up to four freeze /thaw cycles on ice 
or room temperatures (RT) are known not to substantially increase the levels of C3a, 
factor Bb, C5a, and C5b-9 but can significantly affect C4d. Long term storage of 
plasma at -80°C has no significant effect on levels of complement factors (Yang et al. 
2015). It is recommended that if using serum strict handling should be followed as 
stated by Lachmann (Lachmann 2010). The current study used heparinized archived 
plasma samples collected and stored at -80°C. 
5.4.3 Sample preparation for complement proteins measurement 
Venous blood was collected from all of the subjects into heparin tubes (BD 
Diagnostics, Oxford, England) and was transported from the hospital to the laboratory 
at 4°C in cooler boxes. Blood samples were centrifuged at 440g for 5 minutes at 4°C, 
and the plasma was aliquoted and stored at −80°C within an hour of collection and 
then thawed to room temperatures on ice when required by individual study 
investigators. The plasma FH levels and TCC levels were quantified by commercial 
MicroVue Factor H EIA (Quidel, USA) and MicroVue sC5b-9 Plus Enzyme 
Immunoassay kit (Quidel, USA) respectively. The FH ELISA kit determines the amount 
of free FH molecules in human serum (Simon et al. 2018).  
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5.4.4 Genotyping for the Y402H variant of FH 
Genotyping of the Y402H variant was done using i) Sanger sequencing with published 
primers (Lau et al. 2006) and ii) using Factor H, 402H/Y variant detection, Human, 
ELISA kit (HycultBiotech) for a subset of samples. After sequencing, chromatograms 
were individually inspected using Ugene chromatogram viewer  
https://ugene.net/wiki/display/UUOUM15/Chromatogram+Viewer. To narrow down to 
the risk allele position, I used the nucleotide sequence; AAAATCATGGA (Dr. Ayman 
Khattab, personal communication) to search each sequence whereby the C in red 
denotes the presence of the variant nucleotide. 
 
5.4.5 Statistical analysis 
The correlation between FH levels and antibody MFI levels to merozoite FH receptor 
antigens were assessed using Spearman’s rho. Kruskal-Wallis test was used to 
compare the median FH levels across the three age groups (0-2 yrs, 3-5yrs and >6 
yrs). FH levels for all the children were grouped into ranked three tertiles from highest 
to the lowest as high, medium and low. Association between tertile and time to a first 
clinical episode of malaria (fever and > 2500 p/μl) was assessed using Cox 
proportional hazard model. The observation time was six months from the sampling 
time. Age as a categorical (0-2yrs, 3-5 yrs and 6+ yrs) variable was fitted into the model 
to account for its confounding effect on malaria. The Kruskal-Wallis test was also used 
to compared median FH levels in children with severe malaria anaemia (SMA), severe 
malaria without anaemia (SM) and uncomplicated malaria. A logistic regression model 
was used to test for the association between FH levels and risk of having severe 
malaria. 
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5.5 Results 
5.5.1 Variation in FH levels as measured in a longitudinal cohort of children 
Human complement FH is a 155kDa glycoprotein, composed of 1213 amino acid 
residues (Ripoche et al. 1988). It is the central fluid phase regulator of the alternative 
pathway (Pangburn 2002; Ferreira et al. 2010). It is mainly synthesized by the liver 
(Fagerberg et al. 2014) and is found in human plasma at highly variable concentrations 
(Esparza-Gordillo et al. 2004; Scholl et al. 2008). Similarly, in this cohort of young 
children (n=276) Figure 5.1 A, mean age 5.5 yrs, FH levels were observed to have a 
5-fold range (117 - 699 ug/ml). In those children who had parasites at the time of 
sampling (n=79) the median FH levels was 245 ug/ml 95% CI (238-270 ug/ml) 
compared to 263 ug/ml 95% CI (251-275ug/ml) for the children who did not have 
parasites (n=197) Appendices Figure 5.1. Median FH levels did not vary across the 
age categories Figure 5.1 B. I observed a very weak negative correlation between FH 
levels and parasite density (r= -0.072, P = 0.523 Appendices Figure 5.2). 
 
 
Figure 5.1 Distribution of FH levels (A) and comparison with age (B) in the malaria 
longitudinal cohort. 
Children were divided into three age groups, 0-2yrs n=48, 3-5 yrs n=106 and >6 yrs n=122. Box 
plots show the medians with 25% and 75% percentiles and the total range of FH levels across the 
age groups. 
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5.5.2 FH levels and association with protection from malaria 
Next, I tested whether the levels of FH measured during the cross-sectional survey 
would prospectively influence an individual’s risk for the development of a clinical 
episode of malaria during the ensuing six months follow-up period. Individuals were 
grouped into three tertiles of high, medium, and low. I observed that FH levels (high, 
medium or low) were not associated with age Figure 5.2 A. Children who had high FH 
levels tended to have more clinical episodes Figure 5.2 B. The same trend was 
observed when children were stratified to whether they were parasite negative or 
parasite positive at the time of sampling Appendices Figure 5.3. Additionally, cox 
regression output shows that having high FH levels increases the risk of clinical 
malaria, but this is not statistically Figure 5.2 C. Similarly, it has been observed that 
high plasma levels of FH increase susceptibility to Neisseria meningitidis 
(Haralambous et al. 2006). 
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Figure 5.2 Risk of developing a clinical episode of malaria based on FH levels. 
A) Frequency distribution of FH levels based on either low, medium or high based on rank, 
categorized by age B) Kaplan-Meier survival curves showing the risk of malaria stratified by 
whether the children had low (blue), medium (red) or high (green) FH levels, Statistical 
significance was determined by the log rank test for the differences between all three groups 
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C) Hazard ratio calculated using Cox proportional hazard model based while accounting for 
multiple clinical episodes of malaria during the six months follow up period. Unadjusted 
hazard ratio (uHR), adjusted HR (age adjusted) and interaction between age and FH were 
calculated. PH is the proportional hazard assumption test 
 
5.5.3 Correlation between FH levels and antibodies to merozoite FH receptor 
antigens 
Pathogenic proteins or antigens that bind complement regulatory protein FH are mostly 
surface exposed and have been shown to be targets of protective opsonophagocytic 
antibodies (Meri et al. 2008; Serruto et al. 2010). Specifically for Neisseria meningitidis, 
it has been shown that there is competition between FH and antibodies for binding to 
FH binding protein (fHbp) (Caesar et al. 2014; Biagini et al. 2016). It has been reported 
that there is an inverse correlation between FH in circulation and serum bactericidal 
antibody responses (Beernink et al. 2011). Here, I tested for correlation between 
circulating FH levels and protective antibody responses. I found no correlation between 
FH and antibody responses to merozoite FH receptor antigens Figure 5.3. The results 
obtained here suggest that the two could be acting independently of each other and 
highlight the complexity of malaria parasite-complement interactions.   
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Figure 5.3 Correlation between FH levels and antibody responses 
Antibody MFI measurements from all children in the Junju longitudinal cohort of children n=276 were 
correlated with FH levels. From the top A) P12 B) PF3D7_0206200 C) PF3D7_0629500_SEG1 D) 
PF3D7_0629500_SEG2 E) PF3D7_1105800 G) PF3D7_1252300 G) Pf92 and H) RH5 on the Y 
axis and FH levels on the X axis. Correlations were calculated using the Spearman’s rho. Statistical 
significance is indicated as p-value for each comparison. 
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5.5.4 Complement activation occurs during malaria infection 
There is evidence to suggest that complement activation occurs during malaria 
infection (Silver et al. 2010). I sought to determine whether there was differing 
complement activation in children with SMA, SM, and UM. Due to limited reagent 
availability, randomly selected samples of 29, 27, and 28 from UM, SMA and UM 
respectively were assessed. The median parasite density was significantly different 
among them (Kruskal Wallis test, P=0.025). The mean age was 2.3 yrs, 1.5 yrs and 
1.8 yrs for UM, SMA and SM respectively. Children with SMA had markedly raised 
plasma levels of soluble terminal complement complex (TCC), compared with 
uncomplicated malaria (P=0.049). Children with SM also had raised complement 
activation compared with those with UM, although this was not significant (P=0.078). 
However, there was no significant difference between SMA and SM Figure 5.4. 
Overall there was increased complement activation in severe malaria compared to 
uncomplicated malaria. 
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Figure 5.4 Complement activation in UM, SMA and SM. 
Randomly selected samples of 29, 27, and 28 from children with UM, SMA and UM respectively 
were assessed for TCC activation levels. The Mann-Whitney test was used for comparison 
between groups. For comparison among groups Kruskal-Wallis test was used 
 
5.5.5 Circulating levels of FH in severe and uncomplicated malaria 
After observing that complement activation occurs in children with malaria Figure 5.4, 
next I tested whether there were differential FH levels in children with severe malaria 
without anaemia (SM, n=85), severe malaria anaemia (SMA, n=129) and 
uncomplicated malaria (UM, n=96). The median FH levels in SM was 316.29 ug/ml 
(range 252.65-366.87 ug/ml), for SMA it was 247.70 ug/ml (range (93.52-315.30 ug/ml) 
while UM children had median of 381.58 ug/ml (range 316.58- 450.46 ug/ml). The 
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difference in levels of FH among the groups was statistically significant (P= <0.0001) 
Figure 5.5. 
 
 
 
Figure 5.5 Factor H serum levels in children with severe malaria, SMA and SM compared to 
controls, UM 
FH levels were measured in children presenting at the hospital with uncomplicated malaria (UM, 
n=96), severe malaria anaemia (SMA, n=129) and severe malaria without anaemia (SM, n=85). 
Mann-Whitney test was performed for the comparison between groups. For comparison among 
groups Kruskal-Wallis test was used. 
 
Additionally, the median parasite density for children with SM was 214480 parasites/ 
μL range (16848- 470400 parasites/ μL), for those with SMA it was 241780 range 
(74925-364885 parasites/ μL) while children with UM had median parasite density of 
18360 parasites/ μL (range 8280-170000 parasites/ μL). The median parasite density 
was significantly different among the groups (P= <0.0001). All the children were under 
the age of 5 years. Next, I used ordered logistic regression model to test for the 
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association between FH levels and the odds of having severe malaria. FH levels was 
used as the outcome variable and malaria severity, parasitaemia and age as 
covariates Table 5.1. The results indicate that children with severe malaria have a low 
probability of having high FH levels Table 5.1.  
 
 
Table 5.1 Relationship between FH levels and severe malaria 
Covariates Total Low  
(n %) 
Medium 
(n %) 
High 
(n %) 
Crude 
odds 
ratio 
P 
value 
Adjusted 
odds 
ratio 
P 
value 
Malaria severity 
UM 96 9 (9.38) 28 (29.17) 59 (61.46) 1.00   1.00   
SMA/SM 
214 95 (44.39) 75 (35.05) 44 (20.56) 
0.15 
(0.09-
0.25) <0.001 
0.13 
(0.08-
0.24) <0.001 
Age         
 <2 yrs 144 47 (32.64) 48 (33.33) 49 (34.03) 1.00       
2-5 yrs 166 57 (34.34) 55 (33.13) 54 (32.53) 
0.93 
(0.62-
1.40) 0.731 
0.95 
(0.62-
1.46) 0.813 
Parasitemia mean (SD) 
Parasitemia  310 
 239278.4 
(213284.9) 
249278.5 
(266606.8) 
156733.2 
(207942.8) 
0.99 
(0.98-
1.00) 0.015 
1 (0.99-
1.00) 0.967 
Total number of children included in the analysis is N=310 with children having severe malaria 
being 214 and those with uncomplicated malaria being 96 
 
 
To further investigate the role of FH in with malaria, I assessed the relationship 
between FH and markers of malaria severity including parasite density and 
hemoglobin levels. There was a trend towards lower parasite density with increase in 
FH levels Figure 5.6 A. On the contrary there was a trend towards higher Hb as FH 
levels increased Figure 5.6 B. While there was a weak negative statistically significant 
correlation between parasite density and FH levels (r= -0.208, P=<0.001), there was a 
positive correlation between hemoglobin levels and FH (r=0.295) P=<0.001), which 
was also statistically significant.  
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Figure 5.6 Relationship between FH levels and Parasite density (A) and Hemoglobin levels 
(B). 
A total of N=310 children with either SMA, SM and UM were used for the comparison, with FH 
levels split into low, medium and high based on rank. Although all the children had complete 
parasite density data, only 161 had Hb data available. Kruskal-Wallis test was used for 
comparison among the groups. 
 
I also investigated whether complement activation that leads to TCC formation as 
observed in Figure 5.4 relates to complement regulation, in terms of FH levels. I found 
evidence of negative correlation between TCC and FH levels (r= -0.196 P=0.035). In 
addition, children with high FH levels tended to have less complement activation 
Figure 5.7. 
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Figure 5.7 Relationship between complement activation and regulation 
Only children with complete TCC and FH measurement were included in the analysis n=84, with 
FH split into low, medium and high based on rank. Kruskal-Wallis test was used for comparison 
among the three groups while Mann-Whitney test was performed for the comparison between 
groups 
 
5.5.6 The Y402H variant of FH and risk of malaria 
5.5.6.1 Genotyping for the Y402H variant in the malaria case control study using 
Sanger sequencing  
The Y402H variant results in a histidine residue replacing a tyrosine residue at position 
402 (using the pro-protein sequence numbering) of FH. Structurally, the Y402H 
polymorphism occurs in the seventh of FH’s twenty complement control protein (CCP) 
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domains (Schramm et al. 2014). After Sanger sequencing was performed for all 
samples, chromatogram for each sample sequenced was individually inspected to 
check for the presence of the risk alleles (C) and the genotypes; TT, TC, and CC. 
Normal individuals have TT genotype at position 402, CT is heterozygous while the 
CC is homozygous for the AMD risk genotype. A total of 250 samples were sequenced, 
out of which 11 failed sequencing and 16 of them were undetermined, i.e. the 
chromatogram could not resolve the identity of the genotypes. Due to time limitations 
and reagent depletion, the failed, and undetermined samples were not repeated. Only 
173 (101 with severe malaria and 71 with uncomplicated malaria) children who had 
complete genotype and FH level data were analyzed Figure 5.8. 
 
5.5.6.2 Confirmation of the Sanger sequencing genotyping using Factor H 402H/Y 
variant ELISA kit 
To confirm the genotyping done using Sanger sequencing a subset of samples were 
tested using Factor H, 402H/Y variant, Human ELISA kit. This ELISA kit uses a set of 
monoclonal antibodies to identify the Y402H allelic variant in plasma (Hakobyan et al. 
2008). A total of 141 samples were run using the ELISA kit, three of which failed 
detection even after being repeated and varying dilution tested. Excluding the plasma 
samples that did not have paired EDTA blood and those that failed to sequence, only 
120 samples had complete sequencing and ELISA genotyping results Figure 5.8. Due 
to time limitations, samples that did not sequence successfully were not repeated. 
There was a 94% agreement between the sequencing and ELISA genotyping data, 
I.e. 113/120 samples had the same genotypes identified through sequencing as the 
ELISA kit genotyping suggesting that either method can be used. However, due to the 
high cost of ELISA genotyping kit, studies with high throughput can consider relying 
on the relatively cheaper Sanger sequencing method. 
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Figure 5.8 Flow chat of samples analyzed by Sanger sequencing and the ELISA 402H/Y 
variant for genotyping of the Y402H variant of FH 
 
 
5.5.6.3 Association between the Y402H allele and genotype with severe malaria 
There is evidence to suggest that the Y404H variants predispose individuals to age-
related macular degeneration (AMD). A meta-analysis of 26 separate studies showed 
that individuals who are 402H heterozygous have a 2.3-fold increased risk of 
developing AMD, and the homozygotes have a 5.2-fold increased risk (Sofat et al. 
2012) but these studies have been limited to populations of the Caucasian origin. 
Evidence for the association of the Y402H variant and infectious diseases is limited 
and thus far has only been investigated with regards to group A streptococcal 
infections (Haapasalo et al. 2008) and meningococcal disease (Haralambous et al. 
2006) still in Caucasian population. Using a carefully designed case-control study of 
severe malaria and uncomplicated malaria, I observed that children with the CC 
genotype had an 8% increased risk of having severe malaria compared with the normal 
TT individuals, while those who were heterozygous had reduced odds of having 
malaria Table 5.2. Additionally, children with the risk allele, C, had a 19% increased 
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risk of having severe malaria if compared to the T allele. However, none of the odds 
ratios was statistically significant Table 5.2 below.  
 
Table 5.2 Genotype and allele frequency of Y402H by logistic regression analysis 
 Severe 
malaria 
Uncomplicated 
malaria 
Unadjusted  Adjusted for age and 
parasite density 
 N (%) N (%) OR 95% CI P OR 95% CI P 
Y402H genotypes 
TT 32 
(31.37) 
18 (25.35 1 - - 1 - - 
CT 43 
(43.16) 
39 (54.93 0.62 0.30-1.28 0.195 0.65 0.29-
1.42 
0.277 
CC 27 
(26.47) 
14 (19.72) 1.08 0.46-2.58 0.854 1.04 0.41-
2.61 
0.941 
Y402H alleles 
T 43 
(42.16) 
33 (46.48) 1 - - 1 - - 
C 59 
(57.84) 
38 (53.52) 1.19 0.65-2.19 0.573 1.05 0.54-
2.05 
0.885 
 
 
5.5.6.4 Relationship between genotypes and plasma FH levels 
It has been shown that the CFH SNP [rs1061170 encoding Y402H), affects plasma 
circulating FH levels, which in return relates to susceptibility to AMD (Ansari et al. 
2013). Here I tested whether there was variation in FH levels based on the Y402H 
genotypes. I found that overall, there were statistically significant differences in FH 
levels with regards to the genotype (P =0.019) Figure 5.9. Children with the AMD risk 
genotype CC had a statistically significant lower median FH levels compared to the 
normal individuals Figure 5.9. Based on the allele distribution, children who had the T 
allele had median FH levels of 330.37 ug/ml (range 121.48-832.80 ug/ml) while those 
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with the C allele had median FH levels of 308.39 ug/ml with a range of (123.38-706.22 
ug/ml). 
 
 
Figure 5.9 Levels of FH based on the genotypes of children with severe malaria and 
uncomplicated malaria with CC (n= 41), CT (n=82) and TT (n=50).  
A total of 173 children from the cohort of SMA, SM and UM who had complete genotype and FH 
level measurements were included in the analysis. Mann-Whitney test was performed for the 
comparison between groups while Kruskal-Wallis test was used for comparison among the three 
groups. 
 
As results from Figure 5.9 provides relationship between FH levels and genotypes, the 
analysis has one main limitation, it does not take into account malaria severity. Next I 
used the ordered logistic regression model so as to be able to control for the possible 
confounding effects of malaria severity Table 5.3. Being either homozygous (CC) or 
heterozygous (TC) increased the likelihood of having high FH levels even after 
accounting for parasitaemia but this was not statistically significant.  
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Table 5.3 Relationship between FH levels and the Y402H genotype 
Covariates 
Total 
Lower  
(n %) 
Medium  
(n %) 
High  
(n %) 
Crude 
Odds 
ratio 
(95% CI) 
p 
value 
Adjusted 
for severity 
p 
value 
Genotypes 
TT 50 
12 
(24.000 
17 
(34.00) 
21 
(42.00) 1   1   
TC 82 
22 
(26.83) 
27 
(32.93) 
33 
(40.24) 
2.01 
(1.00-
4.06) 0.051 
1.61 (0.77-
3.35) 0.203 
CC 41 
18 
(43.90) 
12 
(29.27) 
11 
(26.83) 
2.22 
(1.03-
4.81) 0.043 
2.10 (0.94-
4.70) 0.071 
Malaria severity 
Um 71 
8 
(11.27) 
20 
(28.17) 
43 
(60.56) 1    N/A  N/A 
sma/sm 102 
44 
(43.14) 
36 
(35.29) 
22 
(21.57) 
0.18 
(0.09-
0.33) <0.001 N/A N/A 
 
 
Literature on the genetic model relating Y402H genotypes and FH levels is sparse. Of 
the few studies that have explored this area, the relationship had only been between 
the genotypes and disease outcomes. Zarewparsi et at., concluded that the additive 
model best accounted for  the association with age macular degeneration (Zareparsi 
et al. 2005) while Kristel et al., concluded on the recessive genetic model for 
cardiovascular disease  (Koeijvoets et al. 2009). The ordered logistic regression model 
in Table 5.3 above used the additive model while in Table 5.4 below I have explored 
the recessive model. The results indicate compared to normal either having CT or CC 
increased the likelihood of having high FH levels, and is significant but the statistical 
significance is lost once malaria severity is adjusted for in the model.  
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Table 5.4 Association between FH levels and genotypes using recessive model 
Covariates Total 
(N) 
Low 
(n %) 
Medium 
(n %) 
High 
(n %) 
Crude 
odds 
ratio 
P 
value 
Adjusted 
for 
severity 
P value 
TT 41 
18 
(43.90) 
12 
(29.27) 
11 
(26.83) 1   1   
TC/CC 132 
34 
(25.76) 
44 
(33.33) 
54 
(40.91) 
2.09 
(1.08-
4.04) 0.028 
1.78 
(0.90 -
3.54) 0.099 
 
 
5.6 Discussion 
The complement system plays an essential role in the host response to infectious 
processes (Walport, 2001). However, complement activation is tightly regulated, and 
the loss of this control can contribute to the pathogenesis of multiple diseases (Ricklin 
and Lambris 2013). Indeed complement activation has been implicated in the 
pathogenesis of malaria including, cerebral malaria (Patel et al. 2008), severe malaria 
anaemia (Nyakoe et al. 2009), and placental malaria (Silver et al. 2010). Although 
previous studies have looked at activation of complement pathways and the up-
regulation or down-regulation of various complement pathways proteins, so far only 
one study has assessed the role of FH in the pathogenesis of malaria (van Beek et al. 
2018). I have tested the effects of Y402H variant of FH, for the first time to the best of 
my knowledge, in carefully selected malaria cases and controls in addition to plasma 
FH levels. Homozygous, CC, children had increased odds of having malaria while 
those who were heterozygous, CT. had reduced odds of having severe malaria if 
compared to individuals with TT. Besides, the homozygous individuals had reduced 
FH levels compared to the normal. Since the children with severe malaria had 
markedly reduced FH levels compared to the uncomplicated malaria controls, it can 
be postulated that the reduced FH in children with severe malaria would be partly due 
to the Y402H polymorphism. Alternatively, the low FH levels could be malaria disease-
driven. 
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Complement activation has been observed both during malaria challenge 
(Roestenberg et al. 2007) and during clinical infections (Silver et al. 2010). In line with 
these observations, there was an increased TCC level in children with severe forms of 
malaria (SM and SMA) compared to controls (UM). The increased complement 
activation could at least in part be due to the lower level of complement regulation 
because in the same case-control study, children with severe malaria anaemia (SMA) 
and severe malaria without anaemia (SM) had significantly lower FH levels compared 
to children with uncomplicated malaria (UM). Besides, children who had either medium 
or high FH levels had reduced odds of having severe malaria compared to those who 
had low FH levels Table 5.1. This essentially means that the higher complement 
activation in SMA and SM could, in some way, be related to lower FH levels. 
 
The pathogenesis of malaria is complicated with parasite sequestering in tissues such 
as the brain for cerebral malaria and the loss of uninfected red blood cells during 
severe malaria anaemia (Perkins et al. 2011; Cowman et al. 2016). Specifically, during 
severe malaria anaemia, there is the formation of immune complexes (ICs) that get 
attached via the CR1 molecules to the red blood cells which can then be removed from 
the RBCs surfaces by macrophages in the liver and spleen. Continuous removal of the 
deposited ICs leads to a reduction in complement regulatory proteins on the RBCs and 
therefore the indiscriminate deposition of IC leads to their removal (Biryukov and 
Stoute 2014).  In support of this argument is the observation that RBCs in patients with 
SMA have reduced CR1 and CD55 compared to their malaria controls (Waitumbi et al. 
2004). Complement FH is important in the protection of host cells from unnecessary 
bystander complement attack (Parente et al. 2017b) and has been observed to be 
localized on the red blood cells (Rosa et al. 2015b). Therefore, it is possible that during 
SMA as there is an increased loss of both infected and uninfected red blood cells, the 
FH localized on these cells could also be lost leading to a reduction in FH levels. Factor 
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H could also be sequestered out of plasma by binding to malaria parasites or to cells 
infected or otherwise affected by malaria parasites. 
 
Numerous reports have demonstrated the association of factor H deficiencies with 
chronic renal and infectious diseases, and that variation in plasma concentrations 
might influence disease susceptibility (Esparza-Gordillo et al. 2004). Within the 
longitudinal cohort, I observed a five-fold range in FH levels (117 - 699 ug/ml). This 
range remained the same, even after excluding children who had parasites at the time 
of sampling. The previously reported FH levels in individuals were about 350-700ug/ml 
(Oppermann et al. 1990); 350-750 ug/ml (Caprioli et al. 2003); 235-810 ug/ml 
(Neumann et al. 2003); 350-590 ug/ml (Venables et al. 2006; Moore et al. 2010); and 
135-349 ug/ml (Hakobyan et al. 2008). Most of these studies were done on patients 
presenting with atypical haemolytic uraemic syndrome with controls using both 
children and adults. None of these measurements were done in an African population, 
and there are reports of genetic differences between African and Caucasian 
populations (Gurdasani et al. 2015). Therefore, the results on the wide range of FH 
concentrations obtained herein are comparable to other published data. 
 
FH levels in the longitudinal cohort of children were divided into three equal tertiles, 
high, medium or low based on rank. The tertiles were used to determine whether 
starting FH levels influence susceptibility to clinical malaria. Overall there was no 
difference on whether a child had high, medium, or low FH levels and their prospective 
risk of developing malaria. However, children who had high FH levels tended to get 
more clinical episodes of malaria. There was an 80% increase in the number of 
episodes of malaria in children who had high FH levels compared to the low Figure 
5.2. One possible explanation for these results in that high FH levels could imply the 
parasites has a higher chance to acquire FH hence protecting itself and surviving to 
establish an infection.  
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Plasmodium falciparum merozoite proteins that bind FH can be considered as 
attractive vaccine candidates because blocking the interaction between FH and these 
antigens can prevent the parasite from establishing an infection. Alternatively, these 
antigens would be targets for protective antibodies. Since the protective antibodies and 
FH are targeting the same antigens on the parasites, I reasoned that there would be 
some correlation between the two as has been observed elsewhere (Beernink et al. 
2011; Caesar et al. 2014; Biagini et al. 2016). The finding of no correlation between 
FH and antibody to merozoite FH receptor antigens Figure 5.3 could imply that the 
two act independent of each other. Alternatively, the close relatedness between FH 
and FH related proteins could mean that they compete for binding to the same antigens 
(Caesar et al. 2014) and may not be related to how the antibodies interaction with 
these antigens. 
 
In a previous study where FH levels were measured in children with different forms of 
malaria, children with severe forms of malaria had increased levels of FH compare to 
children with uncomplicated malaria (van Beek et al. 2018). This is contrary to what I 
observed in the current study. However, in the Van Beek et al. study, they measured 
FH levels in convalescent samples which were obtained 28 days after presentation 
with severe malaria. This may not reflect what could be happening during an active 
malaria infection. This is supported by the previous observation that complement 
regulatory proteins, specifically CR1 and CD55, are reduced during presentation with 
severe malaria but at convalescence following treatment, the expression of these 
molecules increased to levels comparable to those of matched control subjects 
(Waitumbi et al. 2004). However, it is not known whether the same happens to FH 
levels as they were only measured at enrollment in the current study. Nevertheless, 
the observation of lower FH in severe malaria in the current study could also simply 
mean that FH is also being consumed or being driven by malaria disease status. This 
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argument can be tested in future studies by measuring FH levels in children presenting 
at the hospital with severe malaria and same children tested at convalescence. It is 
also very much possible that the children with lower FH levels are genetically 
predisposed to having lower levels and perhaps also to severe malaria. 
 
The Y402H variant of FH has a strong association with AMD (Sofat et al. 2012). The 
region of FH (402) containing this amino acid has also been shown to bind to heparin, 
CRP and the streptococcal M6 protein (Giannakis et al. 2003; Schmidt et al. 2008). In 
vitro work involving group A streptococcus showed reduced growth of GAS in human 
blood taken from 402H homozygous individuals. This observation leads to the thinking 
that the 402H variant individuals could have reduced binding to GAS, more 
complement activation and attack and hence be protected (Haapasalo et al. 2008). I, 
therefore, hypothesized that individuals homozygous for the AMD risk genotype, CC, 
could have less FH parasite interaction and therefore be protected from malaria. 
Contrary to this hypothesis, I observed that individuals with CC genotype had a 
modestly increased risk of having malaria compared to those individuals with the 
wildtype, TT, genotype. In addition, being either homozygous (CC) or heterozygous 
(TC) increased the likelihood of having high FH although this was not statistically 
significant. One possibility accounting for these results is that GAS might not 
necessarily behave the same way as malaria parasites. The current study did not also 
test for the interaction between the 402H variant and its binding to malaria parasites. 
Therefore, I was not able to systematically interrogate whether there is reduced binding 
between the two.  Future studies with a bigger sample sizes will be helpful to robustly 
interrogate the relationship between Y402H genotypes and malaria severity. 
 
In conclusion, I provide evidence that natural variation in FH levels is associated with 
malaria susceptibility and severity. I also show for the first time, to the best of my 
knowledge, that this variation could partly be explained by the genetic variation 
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occurring within FH. Future studies conducted in differing malaria transmission settings 
will be necessary for assessing the role of Y402H polymorphism and its interaction 
with malaria. Nevertheless, interrupting the malaria parasite FH interaction offers an 
alternative approach to limiting parasite growth and may contribute to the pool of tools 
required to fight malaria. 
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CHAPTER SIX 
6 Concluding remarks and recommendations 
 
6.1 Summary of findings 
The complement system forms the first line of defense against invading pathogens 
(Walport, 2001). However, numerous microbes have evolved mechanisms to avoid 
complement-mediated destruction. They can achieve this through recruitment of 
complement regulatory proteins such as factor H (Zipfel et al. 2007; Blom et al. 2009). 
Although the mechanisms for complement immune evasion have been well described 
for pathogens such as bacteria (Serruto et al. 2010), evidence of the same for 
Plasmodium falciparum has only been shown recently (Simon et al. 2013; Rosa et al. 
2015; Kennedy et al. 2015). The experiments and analysis presented in this thesis 
were aimed at: characterizing merozoite proteins important for interaction with FH and 
in part explain how the parasites escape complement attack; whether antibody 
responses to these merozoite FH receptor antigens are associated with protection; 
and finally whether host variation in FH levels and Y402H variant of FH influence 
malaria susceptibility and severity. Below is a summary of my findings. 
 
First, I provide evidence, for the first time, to the best of my knowledge, that many 
merozoite proteins are involved in the interaction with complement regulator protein 
FH. This is contrary to what was reported previously that only one merozoite protein, 
Pf92, interacts with FH (Kennedy et al. 2015). The proteins identified in this thesis 
project and referred to as merozoite FH receptor proteins include, PF3D7_1105800, 
PF3D7_0206200, RH5, Pf12, PF3D7_1252300, PF3D7_0629500 (SEG), and P12p. 
In the Kennedy et al study, whole parasite materials obtained after saponin treatment 
in a co-immunoprecipitation assay to identified Pf92 as the only merozoite antigen 
binding to FH. However, in a growth inhibition assay, a parasite knockout of Pf92 only 
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showed a modest reduction in growth compared to the wildtype parasite. This could 
imply two possibilities, that the parasite either uses other merozoite proteins or that it 
could evade complement activation using other strategies that involving other 
complement pathways (Kennedy et al. 2016). It is not clear why the whole parasite 
approach identified only one protein. My approach of using individually expressed 
merozoite antigens in a simple ELISA binding assay allowed each antigen to be tested 
for binding to FH. Besides, the binding in ELISA binding assay was confirmed using 
surface plasmon resonance, which is the gold standard for protein-protein interaction. 
 
Second, I used a longitudinal malaria cohort of young children and showed that the 
merozoite FH receptor proteins are targets of naturally acquired immunity to malaria. 
Although there was no evidence to suggest that antibody responses to these merozoite 
FH receptor antigens were individually associated with protection, some combinations 
of these responses were found to be associated with protective immunity. In the case-
control study, antibody responses to some of these merozoite FH receptor proteins 
were associated with reduced odds of having severe malaria. Although antibodies to 
these merozoite FH receptor proteins are potential targets of protective antibodies, the 
mechanism by which they mediate their protection was not defined. Antigen-specific 
functional responses would provide valuable information required for the selection of 
vaccine candidates. 
 
Lastly, I tested whether complement activation and regulation could in part, explain 
malaria susceptibility and severity. Children with severe malaria had increased 
complement activation compared to uncomplicated malaria controls. In the same set 
of severe malaria children, complement FH levels were statistically lower compared to 
uncomplicated malaria controls, supporting the idea of excessive complement 
consumption during severe malaria infection.  
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Malaria parasites have co-evolved together with the human host for many years 
(Jongwutiwes et al. 2005; Kwiatkowski 2005) exerting substantial evolutionary 
pressure on the human host. Thus far, the focus has been on changes on the red blood 
cell surface as the main determinant of malaria susceptibility and severity. For the 
complement system, the focus has been on the CR1 (Rowe et al. 1997) and the MBL 
protein (Lipscombe et al. 1995). I genotyped, for the first time to the best of my 
knowledge, the Y402H variant of FH, and showed that homozygous, CC, children, had 
increased odds of having malaria while those who were heterozygous, CT, had 
reduced odds of having severe malaria when compared to individuals, expressing the 
wild type  (TT) alleles. Understanding the mechanism of how these variants confer 
protection may inform new approaches for the prevention and treatment of malaria. 
 
6.2 Recommendation for future studies 
The work described in this thesis can be improved or extended in future studies in 
three main ways; i) overcoming the challenges of ELISA binding assay, ii) systematic 
screening of Plasmodium falciparum parasite stage-specific antigens to determine 
which ones interact with FH and iii) clearly demonstrating the essence of this 
interaction in a functional assay in order to elucidate its importance to parasite survival. 
 
6.2.1 Overcoming the challenges of ELISA binding assay 
I used an ELISA binding assay to screen over 100 merozoite proteins to narrow down 
to antigens that interact with FH. The interaction was then confirmed using the surface 
plasmon resonance (SPR) platform. One major limitation of the ELISA binding assay 
is that it could not detect low-affinity binding, especially for interactions that are 
characterized by low/weak interaction strengths. Additionally, it is clear from the data 
presented in this thesis project that the choice of antibody in the ELISA binding assay 
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matters. I used a polyclonal anti-FH antibody from previous publications (Kennedy et 
al. 2015; Rosa et al. 2015a) that had been used in western blotting. Transferring this 
to the ELISA binding assay showed that this antibody could recognize the antigen in 
the presence or absence of FH. This background noise was corrected by using a 
monoclonal anti-FH antibody (Fontaine et al. 1989; Jokiranta et al. 1996; Rosa et al. 
2015b). While using the ELISA binding assay as the first screening tool could mean 
that I might have missed other antigens involved in the interaction with FH, I was able 
to confirm a good proportion of these antigens for binding using SPR which is a gold 
standard for protein-protein interaction. These data are robust and showed that indeed 
many additional merozoite proteins bind to complement regulatory protein FH. 
 
Additional methods that could be used in future include the yeast two-hybrid system 
and Avidity-based Extracellular Interaction Screen (AVEXIS) (Mehla et al. 2015; 
Galaway et al. 2017) which are not only highly sensitive but also allow for high 
throughput testing. However, these two methods demand that the proteins are tagged 
or labeled in one way or another. The yeast two-hybrid system requires that the protein 
of interest is fused to the DNA binding domain (BD) of a transcription factor (the ‘bait’), 
while the target protein is fused to a transcriptional activation (AD) domain (the ‘prey’). 
Interaction of the prey and bait occurs when the two reconstitutes a functional 
transcription factor and is detected via the expression of reporter genes controlled by 
a promoter bearing the DNA binding site (Mehla et al. 2015). On the other hand, 
AVEXIS assay needs recombinant proteins to be produced in two forms; as a 
biotinylated bait and a pentamerized enzyme-tagged prey (Kerr and Wright 2012).  
 
One of the main advantages of the SPR platform is that it provides real-time label-free 
analysis of protein-protein interactions. Although the older platform of SPR allowed up 
to analysis of up to 24 samples, which can run for 8 hrs, advancement in technology 
has led to higher versions of SPR machines such as the Sierra SPR 32 
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https://www.bruker.com/products/surface-plasmon-resonance/sierra-spr-
32/technical-details.html  that can now analyze up to thousands of samples per day. 
In summary, future studies can benefit from using high throughput SPR platform, which 
can be used for both screening and a confirmatory test at the same time if many 
proteins are involved. It also offers the advantage of analyzing the kinetics of the 
interactions in terms of quantifying the strength of binding. 
 
6.2.2 Screening of Plasmodium falciparum parasite stage specific antigens for 
interaction with FH 
The work presented in this thesis looked at merozoite proteins that interact with FH 
and hence just to this stage of the parasite. This does not rule out that there are other 
antigens, possibly in the other developmental stages of the parasites that interact with 
FH. Indeed, it has been shown that during the mosquito stage of development, 
Plasmodium falciparum gametes recruit factor H (from the human blood ingested 
during a blood meal) to their surface to evade human complement attack within the 
mosquito midgut. Gamete surface protein GAP50 binds factor H (FH) and uses bound 
FH to inactivate the complement protein C3b (Simon et al. 2013). Within the human 
host, there is also evidence to suggest that other than the merozoites, trophozoites, 
and rings (Simon et al. 2018) also bind to FH. Together, there is evidence to suggest 
recruitment of FH by Plasmodium falciparum at different stages is crucial for parasite 
survival and therefore comprehensively identifying antigens involved will not only 
advance our understanding of parasite biology but will enable us to know how to 
interrupt the complex life cycle. 
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6.2.3 Demonstrating the consequences of the parasite-complement interaction 
What is the implication of parasite recruitment of FH? To answer this question, I used 
a modified growth inhibition assay and showed that in serum depleted of FH there is 
reduced parasite growth compared to serum containing FH. However, this approach 
has some limitations. For instance, if the serum is depleted of FH, that means that 
there will be uncontrolled alternative pathway activation and formation of C3b, and 
therefore this serum is not stable (Dr Ayman Khattab, personal communication). 
Furthermore, it is difficult to measure how much of the complement activity is reduced 
per se if FH is removed and how this affects the other pathways. For these reasons, 
using serum depleted of FH might not be the appropriate way of assessing the effect 
of FH parasite interaction. A more rigorous way could be to use the growth inhibition 
assay where FH interaction with the parasite is blocked by using either antibodies to 
these merozoite FH receptor proteins or using parasite knockout of these genes. A 
comprehensive library of essential and non-essential genes for parasite growth has 
been recently described (Zhang et al. 2018) allowing future studies to obtain parasite 
knockout of most genes and assessing directly the effect parasite FH interaction on 
parasite growth in the presence or absence of these genes.  
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APPENDICES 
 
Appendices 3.1 C3b deposition by schizonts 
Merozoites were incubated with normal human serum (NHS), heat inactivated serum (HIS) or NHS 
inactivated using EDTA (NHS-E 500mM or NHS-E 125mM) at 37oC for 1 hr. The proteins from the 
pellet were separated on SDS-PAGE under reducing conditions, transferred to an activated 
nitrocellulose membrane and probed for C3b using anti-C3b antibody and HRP detection antibody. 
Merozoite incubation with PBS was used as a negative control. 
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Appendices 3.2 Checkerboard titration for FH dilutions  
A starting concentration of 16ug/ml for each of Pf92 (A) and Cd4 tag (B) was immobilized on 
microtitrate plate and varying concentration of FH tested for each duplication dilution of the coating 
antigen. Interaction was detected using polyclonal anti-FH and HRP conjugated antibody. 
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Appendices 3.3 Sensorgram for the second independent experiment to test for FH 
interactions with merozoite proteins using SPR 
Merozoite proteins were injected over immobilized FH on the flow cell. 
 
 
 
Appendices 3.4 Correlation between Helsinki ELISA binding assay and SPR (A) using SPR 
response 1 and (B) using SPR response 2 
The same antigens were tested using Helsinki ELISA binding assay and SPR and correlation 
tested using Spearman’s rho.  
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Appendices 3.5 Dose dependent interaction between FH and (A) PF_3D7_0206200 and (B) 
PF_3D7_1105800 
Merozoite antigens (A) PF_3D7_0206200 and (B) PF3_D7_1105800 at a starting concentration of 
2uM and 1uM respectively in tow fold dilution on FH immobilized on the flow cell. 
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Appendices 3.6 Immobilization of FH fragments on the activated flow cell using amine 
coupling chemistry.  
Different FH fragments were immobilized on the flow cell (A) Blank, (B) FH CCP 1-5, (C) FH CCP 
5-7 and (D) FH CCP 19-20. Striking lines indicate presence of air bubbles during the injection of the 
ligand which has no effect on the immobilization 
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Appendices Error! Reference source not found. Scatter plot of the response unit  
The same merozoite proteins were run on the same flow cell but different days on immobilized FH 
CCP 5-7 fragment 
 
 
Appendices 3.6 Absence of FH in albumax and serum depleted of FH. 
Two microliters of NHS, HIS, Albumax, serum depleted of FH, recombinant FH were blotted unto a 
nitrocellulose membrane and allowed to air dry for at least 30 minutes. Blocking was done using 
4% Blotto and polyclonal anti-FH added. After washing, an HRP antibody was added and 
detection done using ECL (Invitrogen) 
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Appendices 4.1 Parasite density by age 
Analysis is on parasite positive (by microscopy) in individuals in the Junju 2008 cohort by age 
 
Appendices Table 4.1 Antibody responses and association with risk of clinical 
malaria 
Antigen No adjustment Age adjusted 
 IRR (95% CI) P IRR (95% CI) P 
Parasite negative children 
PF3D7_1252300 0.85 (0.61-1.17) 
0.32 0.86 (0.62-
1.19) 0.35 
Pf92 0.95 (0.68-1.34) 
0.79 1.04 (0.74-
1.46) 0.83 
PF3D7_0629500_SEG1 0.91 (0.67-1.24) 
0.57 0.86 (0.64-
1.17) 0.34 
RH5 1.01 (0.71-1.44) 
0.95 1.04 (0.73-
1.47) 0.85 
PF3D7_0629500_SEG2 1.11 (0.81-1.54) 
0.52 1.17 (0.86-
1.60) 0.32 
P12 1.12 (0.81-1.54) 
0.50 1.10 (0.80-
1.51) 0.57 
PF3D7_0206200 1.27 (0.95-1.71) 
0.11 1.26 (0.95-
1.69) 0.11 
PF3D7_1105800 1.47 (1.09-1.97) 
0.01 1.42 (1.07-
1.90) 0.02 
Parasite positive children 
PF3D7_1252300 
1.30 (0.54-3.12) 0.55 1.22 (0.50-
2.95) 
0.66 
Pf92 
0.96 (0.43-2.14) 0.93 1.17 (0.54-
2.54) 
0.69 
0-4 yrs > 5 yrs
0
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PF3D7_0629500_SEG1 
0.90 (0.40-2.05) 0.81 0.88 (0.38-
2.05) 
0.77 
RH5 
1.00 (0.43-2.33) 0.99 0.92 (0.41-
2.04) 
0.83 
PF3D7_0629500_SEG2 
0.64 (0.29-1.43) 0.28 0.76 (0.35-
1.66) 
0.49 
P12 
0.67 (0.30-1.50) 0.34 0.85 (0.40-
1.78) 0.66 
PF3D7_0206200 
1.25 (0.57-2.76) 0.57 1.08 (0.51-
2.30) 0.84 
PF3D7_1105800 
1.36 (0.60-3.11) 0.46 1.30 (0.59-
2.86) 0.52 
All children irrespective of parasite status 
PF3D7_1252300 
0.97 (0.71-1.32) 0.85 0.95 (0.70-
1.29) 0.75 
Pf92 
0.88 (0.64-1.22) 0.45 1.02 (0.74-
1.40) 0.92 
PF3D7_0629500_SEG1 
0.92 (0.68-1.24) 0.59 0.87 (0.65-
1.16) 0.33 
RH5 
0.96 (0.69-1.34) 0.82 0.96 (0.70-
1.33) 0.83 
PF3D7_0629500_SEG2 
0.87 (0.64-1.20) 0.40 0.97 (0.71-
1.33) 0.85 
P12 
0.90 (0.66-1.23) 0.49 0.96 (0.70-
1.31) 0.80 
PF3D7_0206200 
1.32 (0.92-1.64) 0.16 1.21 (0.92-
1.60) 0.18 
PF3D7_1105800 
1.22 (0.91-1.63) 0.19 1.22 (0.92-
1.62) 0.17 
Age categories used 0-2 yrs, 3-5yrs and >6 yrs 
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Appendices 5.1 Differences in FH levels in a group of children  
The differences are between those children who did not have parasite (Parasite Neg) and those 
who had parasites (Parasite Pos) at the time of sampling from the Junju longitudinal cohort of 
children. 
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Appendices 5.2 Correlation between FH levels and parasite density  
Parasite density and FH levels in parasite positive children at the time of the cross-sectional 
survey for the Junju longitudinal cohort of children 
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Appendices 5.3 Kaplan-Meier survival showing risk of clinical malaria for A) parasite 
negative and B) parasite positive children at time of sampling 
Kaplan-Meier survival curves showing the risk of malaria stratified by whether the children had low 
(blue), medium (red) or high (green) FH levels, Statistical significance was determined by the log 
rank test for the differences between all three groups 
